



King's Research Portal

DOI: 10.1016/j.biopsych.2019.02.022

Document Version Peer reviewed version

Link to publication record in King's Research Portal

Citation for published version (APA):

Zhang, X., Abdellaoui, A., Rucker, J., de Jong, S., Potash, J. B., Weissman, M. M., Shi, J., Knowles, J. A., Pato, C., Pato, M., Sobell, J., Smit, J. H., Hottenga, J. J., de Geus, E. J. C., Lewis, C. M., Buttenschøn, H. N., Craddock, N., Jones, I., Jones, L., ... Levinson, D. F. (2019). Genome-wide burden of rare short deletions is enriched in Major Depressive Disorder in four cohorts. *Biological psychiatry*, *85*(12), 1065-1073. https://doi.org/10.1016/j.biopsych.2019.02.022

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
You may not further distribute the material or use it for any profit-making activity or commercial gain
You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Accepted Manuscript

Genome-wide burden of rare short deletions is enriched in Major Depressive Disorder in four cohorts

Xianglong Zhang, Abdel Abdellaoui, James Rucker, Simone de Jong, James B. Potash, Myrna M. Weissman, Jianxin Shi, James A. Knowles, Carlos Pato, Michele Pato, Janet Sobell, Johannes H. Smit, Jouke-Jan Hottenga, Eco J.C. de Geus, Cathryn M. Lewis, Henriette N. Buttenschøn, Nick Craddock, Ian Jones, Lisa Jones, Peter McGuffin, Ole Mors, Michael J. Owen, Martin Preisig, Marcella Rietschel, John P. Rice, Margarita Rivera, Rudolf Uher, Pablo V. Gejman, Alan R. Sanders, Dorret Boomsma, Brenda W.J. H. Penninx, Gerome Breen, Douglas F. Levinson



PII: S0006-3223(19)30150-7

DOI: https://doi.org/10.1016/j.biopsych.2019.02.022

Reference: BPS 13781

To appear in: Biological Psychiatry

Received Date: 17 September 2018

Revised Date: 29 January 2019

Accepted Date: 19 February 2019

Please cite this article as: Zhang X., Abdellaoui A., Rucker J., de Jong S., Potash J.B., Weissman M.M., Shi J., Knowles J.A., Pato C., Pato M., Sobell J., Smit J.H., Hottenga J.-J., de Geus E.J.C., Lewis C.M, Buttenschøn H.N, Craddock N., Jones I., Jones L., McGuffin P., Mors O., Owen M.J, Preisig M., Rietschel M., Rice J.P, Rivera M., Uher R., Gejman P.V., Sanders A.R., Boomsma D., Penninx B.W.J.H., Breen G. & Levinson D.F., Genome-wide burden of rare short deletions is enriched in Major Depressive Disorder in four cohorts, *Biological Psychiatry* (2019), doi: https://doi.org/10.1016/j.biopsych.2019.02.022.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Genome-wide burden of rare short deletions is enriched

in Major Depressive Disorder in four cohorts

Short title: Rare deletions in major depression

Xianglong Zhang^{1,2}, Abdel Abdellaoui^{3,4}, James Rucker⁵, Simone de Jong⁵, James B. Potash⁶, Myrna M. Weissman⁷, Jianxin Shi⁸, James A. Knowles⁹, Carlos Pato¹⁰, Michele Pato¹¹, Janet Sobell¹², Johannes H. Smit¹³, Jouke-Jan Hottenga³, Eco J.C. de Geus³, Cathryn M Lewis^{14,15}, Henriette N Buttenschøn^{16,17}, Nick Craddock¹⁸, Ian Jones¹⁸, Lisa Jones¹⁹, Peter McGuffin¹⁴, Ole Mors²⁰, Michael J Owen²¹, Martin Preisig²², Marcella Rietschel²³, John P Rice²⁴, Margarita Rivera^{14,25}, Rudolf Uher²⁶, Pablo V. Gejman^{27,28}, Alan R. Sanders^{27,28}, Dorret Boomsma³, Brenda W. J. H. Penninx¹³, Gerome Breen^{14,29}, Douglas F. Levinson¹

¹Department of Psychiatry and Behavioral Sciences, and ²Department of Genetics, Stanford University School of Medicine, USA. ³Department of Biological Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, the Netherlands. ⁴Department of Psychiatry, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. ⁵The Institute of Psychiatry, King's College London, UK. ⁶Department of Psychiatry, Johns Hopkins University School of Medicine, USA. ⁷Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, USA. ⁸Division of Cancer Epidemiology and Genetics, Biostatistics Branch, National Cancer Institute, USA. ⁹Department of Cell Biology, Downstate Medical Center College of Medicine, USA. ¹⁰Downstate Medical Center College of Medicine, USA. ¹¹Department of Psychiatry, Downstate Medical Center College of Medicine, USA. ¹²Department of Psychiatry and Behavioral Sciences, University of Southern California, USA. ¹³Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Psychiatry, Amsterdam Public Health and GGz inGeest, Amsterdam, the Netherlands. ¹⁴MRC Social Genetic and Developmental Psychiatry Centre, King's College London, London, UK.¹⁵Department of Medical & Molecular Genetics, King's College London, London, UK. ¹⁶Department of Clinical Medicine, Translational Neuropsychiatry Unit, Aarhus University, Aarhus, DK. ¹⁷iSEQ, Centre for Integrative Sequencing, Aarhus University, Aarhus, DK.¹⁸Department of Psychological Medicine, Cardiff University, Cardiff, UK.¹⁹Institute of Health and Society, University of Worcester, Worcester, UK. ²⁰Psychosis Research Unit, Aarhus University Hospital, Risskov, Aarhus, DK. ²¹MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.²²Department of Psychiatry, University Hospital of Lausanne, Prilly, Switzerland.²³Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Mannheim, Germany.²⁴Department of Psychiatry, Washington University in Saint Louis School of Medicine, Saint Louis, USA.²⁵Department of Biochemistry and Molecular Biology II, Institute of Neurosciences, Center for Biomedical Research, University of Granada, Granada.²⁶Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.²⁷Center for Psychiatric Genetics, NorthShore University HealthSystem, Chicago, USA.²⁸Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, USA.²⁹NIHR BRC for Mental Health, King's College London, London, UK.

Corresponding Author

Douglas F. Levinson, M.D. 401 Quarry Rd., Stanford, CA 94305-5797, USA. Email: <u>dflev@stanford.edu</u>

Word count

Abstract: 240; Text: 3,776 Number of tables: 3 Supplementary file: 1 (includes 5 figures and 25 tables)

ABSTRACT

Background: Major Depressive Disorder (MDD) is moderately heritable, with high prevalence and presumed high heterogeneity. Copy number variants (CNVs) could contribute to the heritable component of risk, but the two previous genome-wide studies of rare CNVs did not report significant findings. **Methods:** In this meta-analysis of four cohorts (5,780 case and 6,626 control subjects), we analyzed association of MDD to (i) genome-wide burden of rare deletions and duplications, partitioned by length (<100 kb or >100kb) and other characteristics; and (ii) individual rare exonic CNVs and CNV regions. **Results:** Cases carried significantly more short deletions (P=0.0059), but not long deletions or short or long duplications. The confidence interval for long deletions overlapped with that for short deletions, but the former were 70% less frequent genome-wide, reducing power to detect increased burden. The increased burden of short deletions was primarily in intergenic regions. Short deletions in cases were also modestly enriched for high-confidence enhancer regions. No individual CNV achieved thresholds for suggestive or significant association after genome-wide correction. P-values <0.01 were observed for 15q11.2 duplications (*TUBGCP5*, *CYFIP1*, *NIPA1*, *NIPA2*), deletions in or near *PRKN* or *MSR1*, and exonic duplications of *ATG5*.

Conclusions: The increased burden of short deletions in cases suggests that rare CNVs increase MDD risk by disrupting regulatory regions. Results for longer deletions were less clear, but no large effects were observed for long multigenic CNVs (as seen in schizophrenia and autism). Further studies with larger sample sizes are warranted.

Keywords: major depressive disorder, copy number variation, genome-wide association study, metaanalysis, genetics, neuroscience

Introduction

Major depressive disorder (MDD) is a common psychiatric disorder with a lifetime prevalence of 10-20% (1). It was the third leading cause of global disability in 2015 (2). Heritability is approximately 37%, lower than that of several other psychiatric disorders (3). The genome-wide contribution of common single nucleotide polymorphisms (SNPs) to MDD risk is approximately 20% (4). Consistent with the moderate heritability and high population prevalence, it has required greater than 100,000 MDD cases to detect large numbers of genome-wide significant SNP associations, e.g., 15 loci in 121,380 cases plus 338,101 controls (5), and 44 loci in a partially-overlapping sample (135,458 cases plus 344,901 controls) (6).

Rare copy number variants (CNVs) could be contributing to the unexplained portion of genetic risk and provide information about disease mechanisms. Two previous MDD studies of longer CNVs reported no significant genome-wide burden in cases (7, 8). Here, to achieve a larger sample size, we performed a meta-analysis of the association of MDD to rare CNVs in 5,780 case and 6,626 control subjects from four cohorts. A significant increase of rare, shorter deletions (<100,000 bp) was observed in MDD cases, driven by CNVs in intergenic regions.

Methods and Materials

Samples. We studied four European-ancestry cohorts (*Table 1*). All participants gave signed informed consent under protocols approved by the relevant Institutional Review Boards.

(A) The *RADIANT* cohort (7) included cases from three studies of recurrent MDD and two control cohorts (458 controls who were screened for lifetime absence of psychiatric disorder; and 2,699 controls from phase 2 of the National Blood Service (NBS) WTCCC subcohort). Cases were interviewed with the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) (9) and diagnosed with ICD-10 or DSM-IV criteria. Exclusion criteria were: any history or family history of schizophrenia or bipolar disorder, or history of mood disorder secondary to alcohol/substance misuse or of mood-incongruent psychosis (7).

(B) *NESDA/NTR*. Cases and controls were drawn from the Netherlands Twin Register (NTR) (10) and the Netherlands Study of Depression and Anxiety (NESDA) (11). Cases had DSM-IV MDD diagnoses by the Composite Interview Diagnostic Instrument (CIDI) (12).

(C) *GenRED*. Cases and controls were from the Genetics of Recurrent Early-Onset Depression (GenRED) cohort (13, 14). Cases had a consensus DSM-IV MDD diagnosis based on Diagnostic Interview for Genetic Studies (DIGS) interview and other information, with recurrence or chronicity (an episode lasting \geq 3 years), onset <age 31, \geq 1 sibling or parent with recurrent MDD and onset <41, MDD independent of substance dependence, no bipolar, schizoaffective disorder or schizophrenia diagnosis, and no suspected bipolar-I parent or sibling. The controls (N=1,345) from the Molecular Genetics of Schizophrenia (MGS) cohort (15) denied (by online screen) ever meeting DSM-IV MDD gate criteria (no two-week period of depressed mood or anhedonia most of the day, nearly every day) – whereas the published GenRED GWAS (13) included controls who never met full MDD criteria by online screen (16).

(D) *GenRED-II*. Cases were from the second GenRED GWAS wave (same criteria as GenRED). Controls were drawn from the Genomic Psychiatry Cohort (17), Depression Genes and Networks (18), and the Mayo Clinic (19). The control cohorts were screened for lifetime depression with a questionnaire, SCID interview or medical records, respectively.

Genotyping. The RADIANT cases and screened controls were genotyped with the HumanHap 610-Quad Beadchip (Illumina, Inc., San Diego, CA, USA), and the unscreened NBS samples with Illumina Infinium 1M beadchips (hg18 for both) (7). The NTR/NESDA (20) and GenRED cohorts were genotyped with the Affymetrix Human Genome-Wide SNP 6.0 Array (Affymetrix, Santa Clara, CA, USA) (hg18) (14); and GenRED II cases and controls with the Illumina Omni1-Quad beadchip (hg19) (21).

Selection of CNV calling algorithms. CNVs had been called with PennCNV (22), QuantiSNP (23) and iPattern (24) in the RADIANT dataset (using 562,329 probes common to the two platforms); with Birdsuite (25) and PennCNV (22) in NTR/NESDA; with Birdsuite (25) in GenRED; and with QuantiSNP (23) and PennCNV (22) in GenRED II. There is no consensus "optimal" calling algorithm for each

platform. Various authors use a single calling method (8, 26), agreement between two methods (20, 27), or more complex approaches (28, 29).

Here we conducted a preliminary analysis of CNV call concordance for duplicate genotypes for 115 Affymetrix 6.0 samples and 20 Illumina Human610-Quad samples. For Affymetrix we compared CNVision (28), QuantiSNP (23), PennCNV (22) and Birdsuite (25) and each pair of algorithms, plus the addition of CNVision's pCNV parameter (estimating the probability of a true CNV, based on per-SNP variability of Log R Ratio [LRR] and the number of SNPs consistent with a CNV based on B Allele Frequency [BAF]). For Illumina we compared all algorithms (except Birdsuite) and pairs, and addition of pCNV. We also did the analyses for short (<100 kb) and long (>100 kb) CNVs separately.

For Affymetrix, Birdsuite had the highest concordance rate (deletions and duplications), whereas combining it with any other method slightly increased concordance but excluded >40% of calls (*Table S1*). Therefore we used Birdsuite alone for Affymetrix data. For Illumina data, QuantiSNP alone had the best concordance for deletions (*Table S2*). For duplications, concordance was highest for QuantiSNP alone; calls made by both PennCNV and QuantiSNP showed improved concordance but excluded >30% of calls. We used QuantiSNP for primary analyses, plus a secondary "narrow" QuantiSNP+PennCNV analysis. For both platforms, concordance was similar for shorter and longer CNVs (*Tables S3-S6*).

Quality control of samples and CNV calls. Exclusion criteria for samples were applied to each cohort separately. For NTR/NESDA (20) and GenRED (14), exclusions were applied to samples retained by the original studies, using the previous Birdsuite calls: (1) probe intensity variances >4 standard deviations (SDs) above cohort mean; (2) total number or length of deletions or duplications >3 SDs above the mean; (3) any chromosome with number or length of deletions or duplications >7 SDs above the mean; (4) only autosomal CNVs were called. For Illumina data (RADIANT and GenRED II), we re-called CNVs with QuantiSNP and PennCNV from raw LRR and BAF data. Exclusion criteria for unfiltered calls were: (1) genotype call rate <99%; (2) >5% of SNPs with LRR < -0.5 or > 0.5; (3) >1% of SNPs with LRR < -1; (4) BAF drift > 0.01; (5) LRR SD >0.28, (6) waviness factor <0.05 or >-0.05; (7) total CNV number or length >3 SDs above cohort mean (deletions or duplications).

For both platforms, we removed CNVs with <10 probes, and of Birdsuite calls with LOD score <10 (duplications) or <6 (deletions) and QuantiSNP calls with Maximum Log BF <10. We then merged adjacent deletions (copy numbers 0 or 1) or adjacent duplications (Cn 3 or 4) if the number of probes separating them was <30% of probes in the merged region (iterating through each chromosome until all eligible segments were merged, using an in-house script). We removed CNVs with \geq 50% overlap with centromeres, telomeres, segmental duplications, or immunoglobulin genes, or length <10 kb (too few probes to call reliably) or >4 Mb (in previous work (30), CNVs>4 Mb were disproportionately detected in DNA from lymphoblastic cell lines), or with frequency >1% in any of four large-sample cohorts included in the Database of Genomic Variants (DGV) (31-34), or with frequency >1% (based on 50% overlap) in any of our control cohorts.

Statistical analysis overview. All analyses were conducted for post-QC deletions and duplications using PLINK and R. Genomic locations with hg18 coordinates were converted to hg19 (UCSC liftOver tool). We first determined (as described below) that effects of cohort and sex had to be controlled appropriately. We chose primary analyses which directly compute an odds ratio and were equivalent to meta-analysis: logistic regression with sex and cohort covariates (for burden tests) or Cochrane-Mantel-Haenszel (CMH) tests stratified for sex and cohort (for single CNVs), plus meta-analysis and/or permutation tests to check results. We tested two main hypotheses, correcting for multiple tests within each hypothesis:

(1) *Global burden* of rare CNVs is greater in cases vs. controls. The four primary analyses were for deletions and duplications, each subdivided by size (<100kb, >100kb); thus the threshold of significance was P<0.0125 (0.05/4).

(2) Cases are more likely to carry *specific CNVs*. Primary analyses tested association by (i) *gene*(CNVs impacting exon(s) of the gene); and (ii) *CNV region* defined by pools of overlapping CNVs
(PLINK). We established thresholds for significant suggestive association as described below (30). Genic tests considered only exonic CNVs because of the stronger mechanistic hypothesis and because exonic

and "genic" CNVs were largely overlapping [*Table S7*] -- 93.2% (deletions) and 99.4% (duplications) of long genic CNVs, and 62.6% and 83.6% of short genic CNVs were exonic.

Effects of cohort and sex. We evaluated two potential confounding variables: cohort; and sex (the female proportion was higher in cases and variable across cohorts). Multiple linear regressions were performed for total rare deletions or duplications per subject or summed length (*Table S8*), with case/control status, cohort and sex as independent variables. There were significant effects for cohort (deletions and duplications) and sex (deletions).

Genome-wide burden analyses were performed for short and long deletions and duplications, using logistic regression with sex and cohort as covariates to test for case-control difference. Secondary analyses considered intergenic and genic CNVs; separate analyses of exonic and intronic-only CNVs; singletons; CNVs >500 kb and >1000 kb; short deletions by 10 kb length bins (10-20, 20-30, etc.). Results were checked against: logistic regression for each cohort (with sex as a covariate) followed by meta-analysis of the beta coefficients and standard errors (R function "metagen" (35)); and permutation tests stratified for cohort and sex (randomly swapping case-control status within the same sex and cohort 100,000 times using PLINK's "--within" option).

Down-sampled analysis. As a check on the effects of uneven numbers of cases/controls and males/females per cohort, we repeated burden analyses using a down-sampled dataset: 1,622 male and female cases and controls (6,488 total) drawn from each cohort proportional to its size (*Table S9*).

Analyses of single CNVs. We performed one-sided CMH tests (stratified by sex and cohort) of a case excess of exonic CNVs impacting each RefSeq gene, and of CNVs in each "CNV region"; and checked results with a stratified permutation tests (results were almost identical). To define regions, we used PLINK's "--segment-group" command to identify 994 CNV "pools" of overlapping post-QC CNVs (from all cohorts), and termed the union a *CNV region*.

For any CNV with nominally increased case frequency (CMH P<0.01), we carried out additional filtering because calling artifacts often produce "significant" results for rare events. We visualized regional LRR and BAF plots for all carriers and a threefold number of non-carriers, and superimposed on

LRR a plot of estimated probe-by-probe copy number using a different algorithm (36). We also plotted all CNVs in the region. We excluded CNVs for which the probewise algorithm showed no copy number change. After excluding genes/regions where most calls were considered artifacts, or were the edges of a common CNV region, we re-computed the CMH tests. We computed a proportion test across the four cohorts for each gene/region and excluded those with significant heterogeneity (P<3.53E-05 to correct for multiple tests, see below). *Table S10* lists the inspected regions and reasons for all exclusions.

Additional exploratory analyses (permutation tests) considered each transcript (<u>http://genome.ucsc.edu/</u>), ENCODE regulatory region, Roadmap Project putative enhancer, promoter and dyadic region, and in aggregate for lists of CNVs with reported associations to psychiatric disorders (29, 37) or developmental delay (32).

We used a previously-described method (30) to estimate thresholds for significant association (expected by chance once in 20 genome-wide studies) and suggestive association (expected once per study). For all 994 CNV regions, the 329 deletion regions intersected with 487 genes, and 665 duplication regions intersected with 1,475 genes (totaling 1,962 genic tests). However, tests of genes within a region are correlated, and each region contained 4.64 genes on average. Thus the 1,962 genic tests represented ~1962/4.64=423 independent tests. We corrected for 1,417 tests (994 regions and 423 genes), a conservative estimate because some regions were partially overlapping, and many genes were in more than one region, resulting in a P-value threshold for significant association of 0.05/1417=3.53E-05, and for suggestive association, 1.0/1417=7.06E-04.

Power analysis. Power analyses were conducted for detection of specific CNVs (*Figure S1*). For the ranges of allele frequencies and genotypic relative risks that were observed in this study, power was good-excellent to detect associations at P=0.01, but detection of suggestive or significant association would have required larger relative risks than were observed here.

Enrichment analysis of functional pathways. To detect gene sets associated with MDD, pathways from Kyoto Encyclopedia of Genes and Genomes (KEGG, http://rest.kegg.jp/list/pathway) and Gene Ontology (GO, http://geneontology.org/page/download-annotations) were downloaded. Geneset-

Xianglong Zhang et al.

-8-

enrichment methods (38) were used to test for enrichment of CNVs (separately for all or exonic CNVs) in all the genes of each pathway relative to all genic CNVs using '--cnv-enrichment-test' in PLINK. Permutation tests of enrichment in cases were also performed by adding '--mperm 10000' in PLINK, with batch and sex as covariates. A set of schizophrenia-associated genes (39) was also tested.

We also evaluated whether case CNVs were enriched in high-confidence DNaseI regions (log10(p)>= 10) from ENCODE (40)_or Roadmap Epigenomics Project (41) (downloaded from <u>https://personal.broadinstitute.org/meuleman/reg2map/HoneyBadger2_release/</u>). Separately for promoter, enhancer and dyadic regions, we analyzed all tissues together (i.e., whether more case short deletions intersected with at least one high-confidence regulatory sequence from any tissue), and then each tissue separately (counting high-confidence sequences for that tissue). For intergenic short deletions, averaged across tissues, the proportion of CNVs that overlap high-confidence regulatory regions was 1.3% for promoter regions, 2.0% (dyadic regions) and 14.9% (enhancer regions).

RESULTS

Of 14,429 samples, 12,406 passed QC (5,780 cases and 6,626 controls, *Table 1*). Total numbers of rare deletion and duplication calls are shown in *Table S11*.

Genome-wide burden. Cases had more CNVs per subject for rare, short (<100 kb) deletions (P=0.00592, odds ratio = 1.0483), driven by intergenic deletions (P=0.00714, OR=1.0716) (*Table 2*; and by cohort, *Table S12*). Similar results were observed by the primary logistic regression tests (*Table S13*), meta-analysis of cohort-specific logistic regressions (*Table S14*), stratified permutation tests (*Table S7*) and the downsampled dataset (*Table S9*). Short deletions across the 10-100kb range contributed to the case-control difference (*Table S15; Figures S2-S3*). No significant differences were observed for duplications or long deletions, but the OR for long deletions was positive (1.03), the confidence interval overlapped with that for short deletions (*Table 2*), and a secondary analysis of all rare deletions was significant (OR=1.044; CI=1.013-1.075; P=0.0046; *Table S16*). No significant effect was observed for singleton or very long (>500 kb, > 1000 kb) deletions or duplications. There was no evidence of strong heterogeneity by cohort for short deletions (Cochran's Q-test; P=0.31) or short intergenic deletions

(P=0.14) (*Table S14*; and *Table S12* and *Figure S4* for results by cohort). The excess of short deletions in cases became more significant when CNVs with frequency >1% in each cohort separately were excluded (rather than >1% in any cohort) (*Table S17*); or when QuantiSNP+PennCNV calls were required for Illumina data (*Table S18*). Burden results did not change after excluding nominally significant CNV regions that failed manual checks (*Table S19*).

We considered two possible within-cohort confounding factors: DNA source and genotyping platforms. In GenRED II, there were two DNA sources: blood (137 cases and all controls) or lymphoblastic cell lines (674 cases) (*Table S20*). CNV burden did not significantly differ between blood vs. LCL case DNAs for any category, with a trend for more *long* deletions in LCL DNA (*Table S21*). RADIANT CNV calls used probes common to Illumina 610-Quad (assayed in cases and screened controls) and Illumina 1M (unscreened controls). Burden results were similar for cases vs. screened or unscreened controls, except that cases had more short deletions than *screened* controls (assayed with the same array) (*Table S22*). Thus, neither factor accounted for the main finding.

Exonic CNVs and CNV regions. After all QC, no gene or region met criteria for significant or suggestive association (*Table S10*). Results with P<0.01 are shown in *Table 3*. These represent four independent loci. Duplications in 15q11.2 achieved P=0.00076 (OR=3.88). These duplications are reciprocal to a well-known deletion region (see Discussion), consistently impacting four genes. Less consistent results are observed in surrounding genes in segmental duplication regions (*Table S10*). Exonic deletions in *MSR1* achieve P=0.0019 (OR=1.96); the region test includes several intronic deletions, with a similar result (P=0.00075, OR=2.05). A CNV region containing exonic and intronic deletions in *PRKN* (formerly *PARK2*) produced P=0.00097 (OR=1.92); the exonic test for *PRKN* had P>0.01. Finally, there were 6 duplications, all in cases, in 6q21 (P=0.0059, OR= ∞), including 5 exonic duplications in *ATG5* that overlapped with one upstream duplication. LRR/BAF plots of CNVs shown in *Table 3* are provided in *Figure S5*.

Pathway enrichment analysis. After correction for multiple testing, no KEGG or GO pathway was enriched with short deletions in cases.

Xianglong Zhang et al. -10-

Regulatory regions. Enhancer regions were modestly enriched in cases for all tissues combined as defined above (P=0.024), and in 5 of 127 specific tissues (P<0.05) (*Table S23*).

Known loci associated with psychiatric disorders or developmental delay. Permutation tests did not demonstrate case enrichment of CNVs in loci associated with psychiatric disorders (*Table S24*) or developmental delay (*Table S25*). There was no overlap between the CNVs reported in *Table 3* and significant MDD GWAS loci (6, 42).

Discussion

This is the largest genome-wide study to date of the association of MDD with rare CNVs. An excess of long CNVs (>100 kb) was initially reported in an analysis of the RADIANT cohort that included additional controls with DNA from buccal swabs (43), but a subsequent re-analysis (without the extra controls and with stricter QC, producing a substantial reduction in number of CNVs per subject similar to that reported here) detected no significant excess (7). Another study of longer CNVs in 452 treatment-resistant depression cases and 811 controls also reported no significant differences (8). For schizophrenia, evidence for association of several long CNVs with large effects on risk could be detected with samples comparable in size to RADIANT (44). There were no such findings for single CNVs in the present, larger study. Thus it appears that very long, multigenic CNVs are less likely to have large effects on the risk of MDD.

Global burden of short deletions. We observed enrichment of short deletions (<100 kb) in cases, and particularly intergenic deletions. This suggests that the effect on MDD risk is due to deletion of regulatory elements, consistent with the (modest) enrichment of high-confidence enhancer regions in short deletions in cases. This is consistent with the extensive analyses of the Psychiatric Genomics Consortium's meta-analysis of depression GWAS data (6) which detected 44 significant associations primarily in non-exonic SNPs, including several in genes that are involved with extensive regulatory networks (*RBFOX1, RBFOX2, RBFOX3, CELF4*), as well as genome-wide enrichment of highly conserved regions, open chromatin in human brain and an epigenetic mark of active enhancers (H3K4me1).

One might expect an increased burden of longer CNVs as well, because they contain more genes and regulatory elements. We analyzed short and long deletions separately because longer CNVs have been more frequently implicated in disease risk. Similar ORs were observed for burden of short and of long deletions in cases, and their confidence intervals overlapped, but we had less power to detect an excess of long deletions because they were 70% less frequent than short deletions. Thus, an increased burden of longer deletions might be observed in larger meta-analyses. We also suspect that the ascertainment methods of most MDD studies are biased against individuals with long multigenic CNVs, whose carriers are at higher risk of disorders such as schizophrenia, autism and intellectual disability. Individuals with these phenotypes are at increased risk of depression (45, 46), but they are often excluded from MDD cohorts, and are often not specifically diagnosed with, or treated for, depression (resulting in exclusion even from registry-based cohorts). Thus, both short and long rare deletions could impact on risk of MDD, but the current results are significant only for shorter deletions (10-100kb), and larger cohorts will be needed to resolve the issue.

Individual genes and regions. No significant or suggestive associations were detected for individual exonic CNVs or for CNV regions, after conservative correction for genome-wide testing. Larger datasets will be needed to identify true positive findings. Nominal association was observed in several regions (P<0.01 but not achieving suggestive or significant thresholds): (i) 15q11.2 duplications encompassing the small, non-imprinted BP1-BP2 segment of the Prader-Willi/Angelman region. Deletions of this segment are weakly associated with risk of schizophrenia (29, 37), and have been reported to be associated with dyslexia and dyscalculia (with deletions and duplications associated with reductions or increases, respectively, in size and activity of the left fusiform gyrus) (47). (ii) Deletions in exons of *MSR1* (Macrophage Scavenger Receptor 1) (or all deletions in that region), implicated in atherosclerosis, Alzheimer's disease and host defense. (iii) Deletions in 6q26 impacting introns or exons of *PRKN* (Parkin RBR E3 Ubiquitin Protein Ligase), where recessive mutations cause early-onset Parkinson's disease (PD) (type 2) but heterozygous variants are not associated with PD (48), although PD is associated with increased depressive symptoms (49). (iii) Duplications in exons of, or upstream sequence near, *ATG5*

Xianglong Zhang et al.

-12-

(Autophagy Related 5). *ATG5* has multiple immune functions including negative regulation of the type I interferon production pathway, which is of note because reduced white blood cell expression of interferon I response genes was reported (18), but not replicated (50) in studies of MDD.

Limitations. The sample size is larger than previous CNV studies of MDD, but remains underpowered. Combining CNV cohorts presents challenges including differences in clinical methods (inclusion criteria, ascertainment, assessments) and genotyping (platforms which differ in genome coverage and signal:noise ratio). Also, the present cohorts are not ideal for testing whether the long, multigenic "neuropsychiatric" CNVs are also predisposing for depression: the psychiatric and neurological features of these CNVs may be considered exclusion criteria from MDD studies; and the associated cognitive impairments reduce the probability of being recruited into MDD cohorts because individual carriers are less likely to volunteer or to be treated in the targeted clinical settings. On the other hand, the cohorts are broadly representative of the current concept of clinically significant MDD.

Conclusion. In MDD cases from four cohorts, we found significant evidence for an increased global burden of shorter rare deletions, which was mainly driven by intergenic deletions. The evidence regarding longer deletions was inconclusive: they were not significantly increased in cases, but the confidence intervals overlapped with the case-control ORs for shorter and longer deletions, and there was less power to detect a difference because longer deletions are less frequent. Overall, the results suggest that the effects of CNVs on regulatory elements, primarily in intergenic regions, play a role in predisposition to MDD.

ACKNOWLEDGMENTS

GenRED and GenRED II: These projects were supported by NIMH R01 Grants MH061686 (DF Levinson), MH059542 (WH Coryell), MH075131 (WB Lawson), MH059552 (JB Potash), MH059541 (WA Scheftner) and MH060912 (MM Weissman). The NIMH Cell Repository at Rutgers University and the NIMH Center for Collaborative Genetic Studies on Mental Disorders made essential contributions to this project. Genotyping was carried out by the Broad Institute Center for Genotyping and Analysis with

support from Grant U54 RR020278 (which partially subsidized the genotyping of the GenRED cases). Collection and quality control analyses of the control data set were supported by grants from NIMH and the National Alliance for Research on Schizophrenia and Depression.

For the Molecular Genetics of Schizophrenia (MGS) control cohort from which GenRED-I controls were drawn: This work was supported primarily by the National Institutes of Health (R01MH067257 to NG Buccola, R01MH 059588 to BJ Mowry, R01MH059571 to PV Gejman, R01MH059565 to R Freedman, R01MH059587 to F Amin, R01MH060870 to WF Byerley., R01M H059566 to DW Black, R01MH059586 to JM Silverman, R01MH061675 to DF Levinson, R01MH060879 to CR Cloninger, R01MH081800 to PV Gejman, U01MH046276 to CR Cloninger, U01MH046289 to C Kaufmann, U01MH046318 to MT Tsuang, U01MH079469 to PV Gejman and U01MH079470 to DF Levinson), the Genetic Association Information Network (GAIN, for genotyping of half of the EA sample), and The Paul Michael Donovan Charitable Foundation. Genotyping was carried out by the Center for Genotyping and Analysis at the Broad Institute of Harvard and MIT (S Gabriel and DB Mirel), supported by NIH grant U54RR020278. We are grateful to Knowledge Networks (Menlo Park, CA, USA) for assistance in collecting the control data set.

NESDA/NTR: The Netherlands Study of Depression and Anxiety (NESDA) and the Netherlands Twin Register (NTR) contributed to GAIN-MDD and to MDD2000. Funding was from: the Netherlands Organization for Scientific Research (MagW/ZonMW Grants 904-61-090, 985-10002, 904-61-193, 480-04-004, 400-05-717, 912-100-20; Spinozapremie 56-464-14192; Geestkracht program Grant 10-000-1002); the Center for Medical Systems Biology (NWO Genomics), Biobanking and Biomolecular Resources Research Infrastructure, VU University's Institutes for Health and Care Research and Neuroscience Campus Amsterdam, NBIC/BioAssist/ RK (2008.024); the European Science Foundation (EU/QLRT-2001-01254); the European Community's Seventh Framework Program (FP7/2007-2013); ENGAGE (HEALTH-F4-2007-201413); and the European Science Council (ERC, 230374). Genotyping was funded in part by the Genetic Association Information Network (GAIN) of the Foundation for the US National Institutes of Health, and analysis was supported by grants from GAIN and the NIMH

(MH081802). CM Middeldorp was supported by the Netherlands Organization for Scientific Research (NOW-VENI grant 916-76-125).

RADIANT: This work was supported by a joint grant from the United Kingdom Medical Research Council and GlaxoSmithKline (Grant No. G0701420) and the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley National Health Service (NHS) Foundation Trust and Institute of Psychiatry, King's College London. This work presents independent research in part funded by the NIHR. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. This work was also supported by the Wellcome Trust Grant No. 086635 (JJHR); NIHR Specialist Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, King's College London (SC-W); a Marie Curie Intra-European Fellowship within the 7th European Community Framework Programme; European Commission Grant Agreement No. 115008); and Canada Research Chairs program (http://www.chairs-chaires.gc.ca/). The Genome Based Therapeutic Drugs for Depression study was funded by a European Commission Framework 6 grant, European Commission Contract Reference LSHB-CT-2 003-503428, and GlaxoSmithKline. Genotyping was performed at the Centre Nationale De Genotypage, Evry, Paris. We acknowledge the contribution of phase 2 of the Wellcome Trust Case Control Consortium in providing access to control datasets from the 1958 British birth cohort and the National Blood Service cohort.

The authors express their appreciation to Dr. Stephan Sanders, University of California at San Francisco, for his assistance with using CNVision. We also express our profound appreciation to the individuals who participated in these projects, and to the many clinicians who facilitated or contributed to them.

Financial Disclosures

The authors report no biomedical financial interests or potential conflicts of interest.

Availability of data and biomaterials

Biomaterials and clinical data are available from the NIMH repository (<u>https://nimhgenetics.org</u>) for the GenRED cases (the GenRED1 cohort includes the family-based linkage cohort and part of the subsequent case collection; the GenRED2 cohort includes the remainder of the case collection); for the MGS controls; and for Genomic Psychiatry Cohort controls, including the Mayo Clinic controls.

REFERENCES

- Kessler RC, Bromet EJ (2013): The epidemiology of depression across cultures. *Annu Rev Public Health*. 34:119-138.
- Collaborators GDaIIaP (2016): Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 388:1545-1602.
- 3. Sullivan PF, Daly MJ, O'Donovan M (2012): Genetic architectures of psychiatric disorders: the emerging picture and its implications. *Nat Rev Genet*. 13:537-551.
- 4. Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, et al. (2013): Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nat Genet*. 45:984-994.
- Hyde CL, Nagle MW, Tian C, Chen X, Paciga SA, Wendland JR, et al. (2016): Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. *Nat Genet*. 48:1031-1036.
- Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. (2018): Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet.* 50:668-681.
- Rucker JJ, Tansey KE, Rivera M, Pinto D, Cohen-Woods S, Uher R, et al. (2016): Phenotypic Association Analyses With Copy Number Variation in Recurrent Depressive Disorder. *Biol Psychiatry*. 79:329-336.
- 8. O'Dushlaine C, Ripke S, Ruderfer DM, Hamilton SP, Fava M, Iosifescu DV, et al. (2014): Rare copy number variation in treatment-resistant major depressive disorder. *Biol Psychiatry*. 76:536-541.

Xianglong Zhang et al. -16-

- 9. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, et al. (1990): SCAN. Schedules for Clinical Assessment in Neuropsychiatry. *Arch Gen Psychiatry*. 47:589-593.
- Willemsen G, Vink JM, Abdellaoui A, den Braber A, van Beek JH, Draisma HH, et al. (2013): The Adult Netherlands Twin Register: twenty-five years of survey and biological data collection. *Twin Res Hum Genet*. 16:271-281.
- Penninx BW, Beekman AT, Smit JH, Zitman FG, Nolen WA, Spinhoven P, et al. (2008): The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. *Int J Methods Psychiatr Res.* 17:121-140.
- Boomsma DI, Willemsen G, Sullivan PF, Heutink P, Meijer P, Sondervan D, et al. (2008): Genomewide association of major depression: description of samples for the GAIN Major Depressive Disorder Study: NTR and NESDA biobank projects. *Eur J Hum Genet*. 16:335-342.
- Levinson DF, Zubenko GS, Crowe RR, DePaulo RJ, Scheftner WS, Weissman MM, et al. (2003): Genetics of recurrent early-onset depression (GenRED): design and preliminary clinical characteristics of a repository sample for genetic linkage studies. *Am J Med Genet B Neuropsychiatr Genet*. 119B:118-130.
- Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, Scheftner WA, et al. (2011): Genomewide association study of recurrent early-onset major depressive disorder. *Mol Psychiatry*. 16:193-201.
- Sanders AR, Duan J, Levinson DF, Shi J, He D, Hou C, et al. (2008): No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. *Am J Psychiatry*. 165:497-506.
- Sanders AR, Levinson DF, Duan J, Dennis JM, Li R, Kendler KS, et al. (2010): The Internet-based MGS2 control sample: self report of mental illness. *Am J Psychiatry*. 167:854-865.
- 17. Pato MT, Sobell JL, Medeiros H, Abbott C, Sklar BM, Buckley PF, et al. (2013): The genomic psychiatry cohort: partners in discovery. *Am J Med Genet B Neuropsychiatr Genet*. 162B:306-312.

- Mostafavi S, Battle A, Zhu X, Potash JB, Weissman MM, Shi J, et al. (2014): Type I interferon signaling genes in recurrent major depression: increased expression detected by whole-blood RNA sequencing. *Mol Psychiatry*. 19:1267-1274.
- Sobell JL, Heston LL, Sommer SS (1993): Novel association approach for determining the genetic predisposition to schizophrenia: case-control resource and testing of a candidate gene. Am J Med Genet. 48:28-35.
- 20. Abdellaoui A, Ehli EA, Hottenga JJ, Weber Z, Mbarek H, Willemsen G, et al. (2015): CNV Concordance in 1,097 MZ Twin Pairs. *Twin Res Hum Genet*. 18:1-12.
- Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, Breen G, et al. (2013): A megaanalysis of genome-wide association studies for major depressive disorder. *Mol Psychiatry*. 18:497-511.
- 22. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, et al. (2007): PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. *Genome Res.* 17:1665-1674.
- Colella S, Yau C, Taylor JM, Mirza G, Butler H, Clouston P, et al. (2007): QuantiSNP: an Objective Bayes Hidden-Markov Model to detect and accurately map copy number variation using SNP genotyping data. *Nucleic Acids Res.* 35:2013-2025.
- 24. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, et al. (2010): Functional impact of global rare copy number variation in autism spectrum disorders. *Nature*. 466:368-372.
- 25. Korn JM, Kuruvilla FG, McCarroll SA, Wysoker A, Nemesh J, Cawley S, et al. (2008): Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. *Nat Genet.* 40:1253-1260.
- 26. Szatkiewicz JP, O'Dushlaine C, Chen G, Chambert K, Moran JL, Neale BM, et al. (2014): Copy number variation in schizophrenia in Sweden. *Mol Psychiatry*. 19:762-773.

- Buizer-Voskamp JE, Muntjewerff JW, Strengman E, Sabatti C, Stefansson H, Vorstman JA, et al. (2011): Genome-wide analysis shows increased frequency of copy number variation deletions in Dutch schizophrenia patients. *Biol Psychiatry*. 70:655-662.
- Sanders SJ, Ercan-Sencicek AG, Hus V, Luo R, Murtha MT, Moreno-De-Luca D, et al. (2011): Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. *Neuron*. 70:863-885.
- 29. Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS, et al. (2017): Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat Genet.* 49:27-35.
- Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J, et al. (2011): Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. *Am J Psychiatry*. 168:302-316.
- Coe BP, Witherspoon K, Rosenfeld JA, van Bon BW, Vulto-van Silfhout AT, Bosco P, et al. (2014): Refining analyses of copy number variation identifies specific genes associated with developmental delay. *Nat Genet.* 46:1063-1071.
- 32. Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C, et al. (2011): A copy number variation morbidity map of developmental delay. *Nat Genet*. 43:838-846.
- Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. (2012): An integrated map of genetic variation from 1,092 human genomes. *Nature*. 491:56-65.
- 34. Mills RE, Walter K, Stewart C, Handsaker RE, Chen K, Alkan C, et al. (2011): Mapping copy number variation by population-scale genome sequencing. *Nature*. 470:59-65.
- 35. Schwarzer G, Carpenter JR, Rücker G (2015): *Meta-Analysis with R*. Springer International Publishing, Switzerland.
- 36. Lai TL, Xing H, Zhang N (2008): Stochastic segmentation models for array-based comparative genomic hybridization data analysis. *Biostatistics*. 9:290-307.

- 37. Rees E, Walters JT, Georgieva L, Isles AR, Chambert KD, Richards AL, et al. (2014): Analysis of copy number variations at 15 schizophrenia-associated loci. *Br J Psychiatry*. 204:108-114.
- 38. Raychaudhuri S, Korn JM, McCarroll SA, Altshuler D, Sklar P, Purcell S, et al. (2010): Accurately assessing the risk of schizophrenia conferred by rare copy-number variation affecting genes with brain function. *PLoS Genet.* 6:e1001097.
- 39. Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014): Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 511:421-427.
- 40. Consortium EP (2012): An integrated encyclopedia of DNA elements in the human genome. *Nature*.
 489:57-74.
- 41. Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, et al. (2015): Integrative analysis of 111 reference human epigenomes. *Nature*. 518:317-330.
- 42. Hafferty J, Gibson J, Shirali M, Coleman J, Hagenaars S, Ward J, et al. (2018): Genome-wide metaanalysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. bioRxiv.
- Rucker JJ, Breen G, Pinto D, Pedroso I, Lewis CM, Cohen-Woods S, et al. (2013): Genome-wide association analysis of copy number variation in recurrent depressive disorder. *Mol Psychiatry*. 18:183-189.
- 44. Stefansson H, Rujescu D, Cichon S, Pietiläinen OP, Ingason A, Steinberg S, et al. (2008): Large recurrent microdeletions associated with schizophrenia. *Nature*. 455:232-236.
- 45. Upthegrove R, Marwaha S, Birchwood M (2017): Depression and Schizophrenia: Cause, Consequence, or Trans-diagnostic Issue? *Schizophr Bull*. 43:240-244.
- 46. Baudewijns L, Ronsse E, Verstraete V, Sabbe B, Morrens M, Bertelli MO (2018): Problem behaviours and Major Depressive Disorder in adults with intellectual disability and autism. *Psychiatry Res.* 270:769-774.

- 47. Ulfarsson MO, Walters GB, Gustafsson O, Steinberg S, Silva A, Doyle OM, et al. (2017): 15q11.2
 CNV affects cognitive, structural and functional correlates of dyslexia and dyscalculia. *Transl Psychiatry*. 7:e1109.
- 48. Hattori N, Mizuno Y (2017): Twenty years since the discovery of the parkin gene. *J Neural Transm* (*Vienna*). 124:1037-1054.
- 49. Larsen JP, Dalen I, Pedersen KF, Tysnes OB (2017): The natural history of depressive symptoms in patients with incident Parkinson's disease: a prospective cohort study. *J Neurol*. 264:2401-2408.
- 50. Jansen R, Penninx BW, Madar V, Xia K, Milaneschi Y, Hottenga JJ, et al. (2016): Gene expression in major depressive disorder. *Mol Psychiatry*. 21:339-347.

Cohort	Pre-QC Sa	mple Size	Post-QC Sample Size					
	Cases	Controls	Cases	Controls				
	(Male/Female)	(Male/Female)	(Male/Female)	(Male/Female)				
RADIANT	3,087 (908/2,179)	3,157 (1,522/1,635)	2,460 (724/1,736)	2,587 (1,240/1,347)				
NESDA/NTR	1,637 (509/1,128)	2,030 (765/1,265)	1,568 (488/1,080)	1,913 (719/1,194)				
GenRED I	1,089 (319/770)	1,345 (784/561)	941 (271/670)	1,264 (743/521)				
GenRED II	831 (144/687)	944 (418/526)	811 (139/672)	862 (384/478)				
Total	6,644 (1,880/4,764)	7,476 (3,489/3,987)	5,780 (1,622/4,158)	6,626 (3,086/3,540)				

Table 1. Cohorts and sample sizes before and after QC filtering

CNIV type	CNVs/s	subject	OP	050/ CI	n valua
Civit type	Cases	Cont	UK	95% CI	p value
]	Deletions		
>100kb — All	0.324	0.318	1.0296	0.9658-1.0975	3.71E-01
Intergenic	0.134	0.138	0.9881	0.8956-1.0899	8.11E-01
Genic	0.191	0.181	1.0606	0.9754-1.1531	1.68E-01
Exonic	0.175	0.168	1.0521	0.9646-1.1475	2.51E-01
Intronic	0.015	0.012	1.1672	0.8591-1.5876	3.23E-01
<100kb — All	1.015	0.978	1.0483	1.0139-1.0843	5.92E-03
Intergenic	0.506	0.483	1.0716	1.0190-1.1270	7.14E-03
Genic	0.509	0.495	1.0343	0.9877-1.0842	1.56E-01
Exonic	0.330	0.310	1.0552	0.9965-1.1192	6.95E-02
Intronic	0.179	0.185	0.9952	0.9149-1.0825	9.11E-01
		Dı	plication	s)
>100kb — All	0.496	0.476	1.0268	0.9837-1.0725	2.29E-01
Intergenic	0.087	0.079	1.0912	0.9654-1.2333	1.62E-01
Genic	0.409	0.397	1.0187	0.9723-1.0677	4.37E-01
Exonic	0.406	0.395	1.0166	0.9702-1.0657	4.89E-01
Intronic	0.004	0.002	1.5254	0.7880-3.0095	2.13E-01
<100kb — All	0.670	0.702	0.9850	0.9512-1.0194	3.90E-01
Intergenic	0.252	0.266	0.9788	0.9166-1.0449	5.21E-01
Genic	0.418	0.436	0.9845	0.9410-1.0296	4.96E-01
Exonic	0.345	0.365	0.9730	0.9253-1.0225	2.83E-01
Intronic	0.073	0.072	1.0586	0.9285-1.2066	3.94E-01

Table 2. Genome-wide burden analyses of long and short deletions and duplications (CNVs/subject)

For rare CNVs (carried by <1% of controls in each cohort), we defined four primary case-control tests of CNV subsets: deletions and duplications, and within each type, long (>100kb) and short (<100kb). For each subset, case-control difference in CNVs per subject was tested by logistic regression, stratified for cohort and sex (Bonferroni-corrected threshold of significance p=0.05/4=0.0125 (significant result shown in *bold italics*). Further exploration then considered genomic location: only intergenic, genic (exonic and/or intronic impact), exonic (subset of genic), and only intronic (subset of genic). See Table S8 for complete results.

Gene or				ALL CMH test RAD GR2 GR1 Neth												
region	Chr	Start	End	Case	Cont	OR	р	Ca	Co	Ca	Co	Ca	Со	Ca	Co	Annotation
							Genes	(exo	nic)							
Del																
MSR1	8	15,965,386	16,050,300	55	32	1.96	1.9E-03	23	10	6	3	15	10	11	9	
Dup																
TUBGCP5	15	22,833,394	22,873,891											X	1	
CYFIP1	15	22,892,648	23,003,603	24	7	2 00	7 65 04	7	2	11	Δ	2	1		2	15q11.2 (reciprocal to well-known
NIPA2	15	23,004,683	23,034,427	24	/	5.00	7.0E-04	/	3	11	0	2		4	3	deletion region)
NIPA1	15	23,043,278	23,086,843								(
					R	egions	s (genic a	nd/	or ir	nterg	geni	c)	7			
Del																
6q26	6	162,136,159	163,489,668	65	40	1.92	9.7E-04	33	17	10	11	9	5	13	7	PRKN
8p22	8	15,817,196	16,092,656	59	33	2.05	7.5E-04	24	10	18	11	6	3	11	9	MSR1
Dup																
6q21	6	106,549,398	107,026,323	6	0	Inf	5.9E-03	2	0	1	0	0	0	3	0	ATG5
15q11.2	15	22,652,330	23,309,294	24	7	3.88	7.6E-04	7	3	2	1	11	0	4	3	TUBGCP5, CYFIP1, NIPA1, NIPA2

Table 3. CNV genes and regions (p<0.01 case-control difference)</th>

Shown are the numbers of cases (out of 5,780) and of controls (out of 6,626) carrying each CNV with post-QC P<0.01. Del=deletions; Dup=duplications; Chr=chromosome; Start and End are genomic positions in base pairs (build HG19) either for the gene for which one or more exons was impacted by each CNV, or for the region within which CNVs were counted. Cont=control; CMH=Cochrane-Mantel-Haenszel; OR = CMH odds ratio; Ca=case; Co=controls; GR2=GenRED2 (Illumina); GR1=GenRED1 (Affymetrix); Neth=NESDA/NTR (Affymetrix); RAD = RADIANT cohort (Illumina platform).

Genome-wide Burden of Rare Short Deletions Is Enriched in Major Depressive Disorder in Four Cohorts

Supplementary Information

Table of Contents

Supplementary text: Comparative analyses of multiple CNV calling algorithms	2
Table S1. Concordance rate of CNV calls between duplicate samples genotyped with Affymetrix array	3
Table S2. Concordance rate of CNV calls between duplicate samples genotyped with Illumina array	6
Table S3. Concordance rate of short CNV calls between duplicate samples genotyped with Affymetrix array	7
Table S4. Concordance rate of long CNV calls between duplicate samples genotyped with Affymetrix array	10
Table S5. Concordance rate of short CNV calls between duplicate samples genotyped with Illumina array	13
Table S6. Concordance rate of long CNV calls between duplicate samples genotyped with Illumina array	14
Table S7. Global CNV burden analyses by permutation tests	15
Table S8. Results of multiple linear regressions	17
Table S9. Global burden analyses of CNVs in down-sampled dataset	19
Table S10. Manually checked genes and regions with stratified permutation test and stratified CMH test P <	21
0.01	
Table S11. Summary of number of CNV calls	25
Table S12. Logistic regression analyses of global burden of CNVs for each cohort	26
Table S13. Logistic regression analyses of global burden of CNVs	27
Table S14. Meta-analysis of global CNV burden	29
Table S15. Logistic regression analyses of global burden of short deletions with various sizes	30
Table S16. Logistic regression analyses of global burden of all rare deletions and duplications	30
Table S17. Global burden analyses of rare CNVs after filtering common CNVs within each cohort separately	31
rather than in all cohorts	
Table S18. Global burden analyses of CNVs called by both QuantiSNP and PennCNV for Illumina data	33
and by Birdsuite for Affymetrix data	
Table S19. Global burden analyses of CNVs after excluding nominally significant CNV regions that failed	35
manual checks	
Table S20. DNA sample sources of the subjects included in this dataset	36
Table S21. CNV burden comparison between blood vs. LCL case DNAs in cohort GenRED II	36
Table S22. Logistic regression analyses of global burden of CNVs for RADIANT cases vs. screened controls	37
and for RADIANT cases vs. unscreened NBS samples	
Table S23. CNV burden in regulatory regions	38
Table S24. Regional tests on known regions associated with psychiatric disorders	39
Table S25. Regional tests on known regions associated with developmental delay	40
Figure S1. Statistical power to detect single CNV loci associated with MDD	42
Figure S2. Average number of short deletions of various sizes per subject	43
Figure S3. Odds ratios and 95% confidence intervals of short deletions of various sizes	44
Figure S4. The forest plot of odds ratio (OR) estimates and 95% confidence intervals for each burden test by	45
cohort	
Figure S5. Plots of 15q11.2 dups, 6q21 dups, 8p22 dels, and 6q26 dels	46
Supplementary text - Codes for the analysis pipeline: PLINK command and R scripts used in the analyses	57

Comparative analyses of multiple CNV calling algorithms

Concordance analyses were restricted to calls after quality control. But when considering whether a call in specimen 1 was concordant with specimen 2, we used CNV calls of Specimen 2 before quality control as even a sub-threshold call could provide some evidence for the existence of a CNV. A CNV call was considered to be concordant if 50% length of the call in specimen 1 is overlapped by the call in specimen

2.

2

Zhang et al.

Table S1. Concordance rate of CNV calls between duplicate samples genotyped with Affymetrix array.

	115					Affymeti	rix Deletions				
CNVision cutoff	duplicate pairs	CNVision	PennCNV	PennCNV + QuantiSNP	PennCNV + Birdsuite	QuantiSNP	QuantiSNP + PennCNV	QuantiSNP + Birdsuite	Birdsuite	Birdsuite + QuantiSNP	Birdsuite + PennCNV
	# S1	12.56	11.36	10.78	10.41	11.12	10.40	10.18	20.10	11.12	10.41
No filtering	# S2	12.44	11.44	10.89	10.56	11.00	10.35	10.17	20.46	11.17	10.42
No Intering	% S1 by S2	0.77	0.79	0.82	0.82	0.84	0.86	0.86	0.92	0.95	0.95
	% S2 by S1	0.80	0.82	0.84	0.85	0.86	0.88	0.88	0.91	0.95	0.97
	# S1	10.47	9.73	9.45	9.06	9.83	9.43	9.16	9.28	8.90	8.68
	# S2	10.18	9.55	9.30	8.98	9.65	9.32	9.07	8.93	8.69	8.50
pcivv<0.05	% S1 by S2	0.83	0.84	0.85	0.86	0.86	0.87	0.88	0.95	0.96	0.96
	% S2 by S1	0.85	0.87	0.88	0.88	0.89	0.90	0.90	0.97	0.97	0.98
	# S1	11.68	10.72	10.26	9.88	10.48	9.98	9.68	10.54	9.85	9.50
nCNIV/ler (0.0E	# S2	11.57	10.85	10.47	10.11	10.47	10.03	9.77	10.75	9.90	9.57
	% S1 by S2	0.79	0.80	0.82	0.83	0.84	0.86	0.86	0.94	0.96	0.96
	% S2 by S1	0.82	0.84	0.85	0.86	0.87	0.88	0.88	0.96	0.97	0.97
	# S1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.01	0.01
	# S2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
penvual<0.05	% S1 by S2	NA	NA	NA	NA	NA	NA	NA	0.50	1.00	1.00
	% S2 by S1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	# S1	11.68	10.72	10.26	9.88	10.48	9.98	9.68	10.54	9.85	9.50
pCNV<0.05 or	# S2	11.57	10.85	10.47	10.11	10.47	10.03	9.77	10.75	9.90	9.57
pCNVIrr<0.05	% S1 by S2	0.79	0.80	0.82	0.83	0.84	0.86	0.86	0.94	0.96	0.96
	% S2 by S1	0.82	0.84	0.85	0.86	0.87	0.88	0.88	0.96	0.97	0.97
	# S1	10.47	9.73	9.45	9.06	9.83	9.43	9.16	9.29	8.91	8.69
pCNV<0.05 or	# S2	10.18	9.55	9.30	8.98	9.65	9.32	9.07	8.93	8.69	8.50
pCNVbaf<0.05	% S1 by S2	0.83	0.84	0.85	0.86	0.86	0.87	0.88	0.95	0.96	0.96
	% S2 by S1	0.85	0.87	0.88	0.88	0.89	0.90	0.90	0.97	0.97	0.98
	# S1	11.68	10.72	10.26	9.88	10.48	9.98	9.68	10.55	9.86	9.50
pCNVIrr<0.05 or	# S2	11.57	10.85	10.47	10.11	10.47	10.03	9.77	10.75	9.90	9.57
pCNVbaf<0.05	% S1 by S2	0.79	0.80	0.82	0.83	0.84	0.86	0.86	0.94	0.96	0.96
	% S2 by S1	0.82	0.84	0.85	0.86	0.87	0.88	0.88	0.96	0.97	0.97
	# S1	11.68	10.72	10.26	9.88	10.48	9.98	9.68	10.55	9.86	9.50
pCNV<0.05 or	# S2	11.57	10.85	10.47	10.11	10.47	10.03	9.77	10.75	9.90	9.57
pCNVIrr<0.05 or	% S1 by S2	0.79	0.80	0.82	0.83	0.84	0.86	0.86	0.94	0.96	0.96
pCNVbat<0.05	% S2 by S1	0.82	0.84	0.85	0.86	0.87	0.88	0.88	0.96	0.97	0.97

(continues on next page)

Zhang et al.

	115					Affymetrix	Duplications				
CNVision cutoff	duplicate pairs	CNVision	PennCNV	PennCNV + QuantiSNP	PennCNV + Birdsuite	QuantiSNP	QuantiSNP + PennCNV	QuantiSNP + Birdsuite	Birdsuite	Birdsuite + QuantiSNP	Birdsuite + PennCNV
	# S1	9.34	8.27	7.42	4.15	8.39	7.27	4.04	5.68	3.00	2.97
No filtoring	# S2	9.72	8.57	7.88	4.36	8.76	7.51	4.45	5.80	3.13	3.02
No filtering	% S1 by S2	0.70	0.72	0.74	0.80	0.76	0.79	0.83	0.81	0.92	0.92
	% S2 by S1	0.68	0.70	0.73	0.74	0.73	0.76	0.79	0.79	0.94	0.94
	# S1	1.76	1.64	1.59	1.47	1.71	1.66	1.50	1.43	1.37	1.36
	# S2	1.58	1.63	1.58	1.42	1.63	1.58	1.43	1.27	1.25	1.25
pcivv<0.03	% S1 by S2	0.85	0.88	0.88	0.90	0.87	0.89	0.89	0.95	0.97	0.97
	% S2 by S1	0.90	0.89	0.90	0.91	0.95	0.95	0.97	0.97	0.97	0.97
	# S1	6.61	6.18	5.76	3.01	6.38	5.80	2.97	2.46	2.28	2.28
nCNV/rr<0.05	# S2	6.47	6.07	5.87	2.97	6.50	5.88	3.18	2.36	2.26	2.18
pon m < 0.00	% S1 by S2	0.73	0.75	0.76	0.82	0.78	0.80	0.82	0.93	0.95	0.95
	% S2 by S1	0.72	0.75	0.76	0.78	0.77	0.80	0.82	0.94	0.95	0.95
	# S1	0.99	0.97	0.94	0.90	0.97	0.94	0.90	0.90	0.85	0.85
nCNIVbaf<0.05	# S2	0.90	0.94	0.90	0.88	0.89	0.87	0.85	0.85	0.83	0.83
	% S1 by S2	0.91	0.91	0.91	0.93	0.91	0.92	0.91	0.96	0.97	0.97
	% S2 by S1	0.94	0.90	0.91	0.90	0.97	0.97	0.97	0.99	0.99	0.99
	# S1	6.85	6.38	5.92	3.18	6.58	5.97	3.16	2.67	2.47	2.45
pCNV<0.05 or	# S2	6.67	6.30	6.10	3.19	6.71	6.09	3.39	2.56	2.46	2.37
pCNVIrr<0.05	% S1 by S2	0.74	0.76	0.77	0.83	0.79	0.81	0.83	0.94	0.95	0.95
	% S2 by S1	0.74	0.75	0.76	0.79	0.78	0.81	0.83	0.95	0.95	0.96
	# S1	1.81	1.69	1.63	1.50	1.75	1.70	1.53	1.44	1.38	1.37
pCNV<0.05 or	# S2	1.62	1.66	1.60	1.43	1.64	1.58	1.44	1.29	1.26	1.27
pCNVbaf<0.05	% S1 by S2	0.84	0.88	0.89	0.90	0.87	0.89	0.89	0.95	0.97	0.97
	% S2 by S1	0.90	0.90	0.90	0.91	0.95	0.95	0.97	0.97	0.97	0.97
	# S1	6.87	6.41	5.96	3.21	6.60	5.99	3.17	2.67	2.46	2.45
pCNVIrr<0.05 or	# S2	6.71	6.32	6.10	3.19	6.71	6.08	3.39	2.57	2.46	2.38
pCNVbaf<0.05	% S1 by S2	0.74	0.76	0.77	0.83	0.79	0.81	0.84	0.94	0.95	0.95
	% S2 by S1	0.74	0.75	0.77	0.79	0.78	0.80	0.83	0.95	0.95	0.96
nCNV < 0.05 or	# S1	6.89	6.43	5.96	3.22	6.62	6.01	3.18	2.69	2.48	2.47
nCNV/rr < 0.05 or	# S2	6.71	6.34	6.11	3.21	6.72	6.09	3.40	2.57	2.47	2.39
nCNIVhaf<0.0501	% S1 by S2	0.74	0.76	0.77	0.83	0.79	0.81	0.84	0.94	0.95	0.95
	% S2 by S1	0.74	0.75	0.77	0.79	0.78	0.81	0.83	0.95	0.95	0.96

(continues on next page)

Zhang et al.

	115					Affymetr	rix All CNVs				
CNVision cutoff	duplicate pairs	CNVision	PennCNV	PennCNV + QuantiSNP	PennCNV + Birdsuite	QuantiSNP	QuantiSNP + PennCNV	QuantiSNP + Birdsuite	Birdsuite	Birdsuite + QuantiSNP	Birdsuite + PennCNV
	# S1	21.90	19.63	18.20	14.56	19.51	17.67	14.23	25.78	14.12	13.38
No filtoring	# S2	22.16	20.01	18.77	14.91	19.76	17.86	14.62	26.26	14.30	13.43
No filtering	% S1 by S2	0.74	0.76	0.78	0.81	0.81	0.83	0.85	0.90	0.95	0.95
	% S2 by S1	0.74	0.76	0.78	0.81	0.80	0.82	0.85	0.89	0.95	0.96
	# S1	12.24	11.37	11.04	10.53	11.55	11.10	10.66	10.70	10.28	10.03
	# S2	11.76	11.17	10.88	10.40	11.29	10.90	10.50	10.20	9.94	9.75
pcivv<0.05	% S1 by S2	0.83	0.85	0.86	0.86	0.86	0.88	0.88	0.95	0.96	0.96
	% S2 by S1	0.85	0.87	0.88	0.89	0.89	0.91	0.91	0.97	0.97	0.97
	# S1	18.29	16.90	16.02	12.89	16.86	15.78	12.65	13.00	12.13	11.77
pCNV/rr <0.0E	# S2	18.04	16.92	16.34	13.09	16.97	15.91	12.95	13.10	12.16	11.75
pcivii1<0.05	% S1 by S2	0.77	0.78	0.80	0.83	0.82	0.83	0.85	0.94	0.96	0.96
	% S2 by S1	0.78	0.80	0.81	0.84	0.82	0.84	0.86	0.95	0.96	0.96
	# S1	0.99	0.97	0.94	0.90	0.97	0.94	0.90	0.91	0.86	0.86
	# S2	0.90	0.94	0.90	0.88	0.89	0.87	0.85	0.85	0.83	0.83
pcivbal<0.05	% S1 by S2	0.91	0.91	0.91	0.93	0.91	0.92	0.91	0.95	0.97	0.97
	% S2 by S1	0.94	0.90	0.91	0.90	0.97	0.97	0.97	0.99	0.99	0.99
	# S1	18.53	17.10	16.18	13.06	17.06	15.96	12.83	13.21	12.32	11.95
pCNV<0.05 or	# S2	18.24	17.16	16.57	13.30	17.18	16.12	13.16	13.30	12.36	11.94
pCNVIrr<0.05	% S1 by S2	0.77	0.78	0.80	0.83	0.82	0.84	0.85	0.94	0.96	0.96
	% S2 by S1	0.78	0.80	0.81	0.84	0.82	0.84	0.86	0.95	0.96	0.96
	# S1	12.28	11.42	11.08	10.57	11.58	11.13	10.69	10.73	10.30	10.06
pCNV<0.05 or	# S2	11.80	11.21	10.90	10.42	11.30	10.90	10.51	10.22	9.95	9.77
pCNVbaf<0.05	% S1 by S2	0.83	0.85	0.86	0.87	0.86	0.88	0.88	0.95	0.96	0.96
	% S2 by S1	0.86	0.87	0.88	0.89	0.89	0.91	0.91	0.97	0.97	0.97
	# S1	18.55	17.13	16.22	13.09	17.08	15.97	12.84	13.22	12.32	11.96
pCNVIrr<0.05 or	# S2	18.28	17.17	16.57	13.30	17.18	16.11	13.16	13.31	12.36	11.95
pCNVbaf<0.05	% S1 by S2	0.77	0.78	0.80	0.83	0.82	0.84	0.85	0.94	0.96	0.96
	% S2 by S1	0.78	0.80	0.81	0.84	0.82	0.84	0.86	0.95	0.96	0.96
	# S1	18.57	17.15	16.22	13.10	17.10	15.99	12.86	13.23	12.34	11.97
$p_{ONV} < 0.00 \text{ OI}$	# S2	18.29	17.19	16.58	13.32	17.19	16.12	13.17	13.32	12.37	11.96
pCNVbaf<0.05	% S1 by S2	0.77	0.78	0.80	0.83	0.82	0.84	0.85	0.94	0.96	0.96
P0111001 (0.00	% S2 by S1	0.78	0.80	0.81	0.84	0.82	0.84	0.86	0.95	0.96	0.96

S1,2 = N(CNVs) detected in sample 1 or 2 of each pair of duplicates.
% S1 by S2 = proportion of S1 CNVs detected (50% overlap) in S2 - with no filtering of S2.
Method1+Method2 = results when CNVs detected by Method1 were restricted to those also detected by Method2.

Zhang et al.

Table S2. Concordance rate of CNV calls between duplicate samples genotyped with Illumina array.

			IIIu	umina All C	NVs			Illu	mina Delet	tions			Illumi	na Duplica	tions	
CNVision cutoff	20 duplicate pairs	CNVision	PennCNV	QuantiSNP	QuantiSNP + PennCNV	PennCNV + QuantiSNP	CNVision	PennCNV	QuantiSNP	QuantiSNP + PennCNV	PennCNV + QuantiSNP	CNVision	PennCNV	QuantiSNP	QuantiSNP + PennCNV	PennCNV + QuantiSNP
No filtering	# S1	8.95	7.70	8.10	6.15	6.70	6.40	5.00	4.60	3.80	4.60	2.55	2.70	3.50	2.35	2.10
	# S2	8.70	7.60	7.80	6.00	6.75	6.35	5.25	4.55	3.95	4.75	2.35	2.35	3.25	2.05	2.00
	% S1 by S2	0.86	0.87	0.89	0.97	0.93	0.94	0.96	1.00	1.00	0.98	0.59	0.65	0.74	0.88	0.73
	% S2 by S1	0.86	0.87	0.91	0.96	0.92	0.93	0.86	0.94	0.95	0.89	0.69	0.81	0.89	0.99	0.92
pCNV < 0.05	# S1	6.15	5.50	5.60	4.95	5.35	4.50	3.85	3.65	3.15	3.75	1.65	1.65	1.95	1.80	1.60
	# S2	6.05	5.40	5.50	4.95	5.35	4.35	3.60	3.45	3.10	3.55	1.70	1.80	2.05	1.85	1.80
	% S1 by S2	0.94	0.94	0.98	0.98	0.95	0.98	0.96	1.00	1.00	0.97	0.82	0.87	0.92	0.93	0.87
	% S2 by S1	0.96	0.94	0.98	0.99	0.94	1.00	0.92	0.98	0.99	0.91	0.85	0.99	0.99	0.99	0.99
pCNVIrr < 0.05	# S1	7.15	6.20	6.35	5.10	5.65	5.05	4.20	4.05	3.40	4.10	2.10	2.00	2.30	1.70	1.55
	# S2	6.80	5.85	6.30	4.90	5.55	4.90	4.15	3.95	3.40	4.05	1.90	1.70	2.35	1.50	1.50
	% S1 by S2	0.88	0.88	0.92	0.96	0.92	0.98	0.97	1.00	1.00	0.97	0.62	0.66	0.79	0.84	0.75
	% S2 by S1	0.90	0.88	0.95	0.99	0.91	0.96	0.87	0.98	0.99	0.88	0.73	0.87	0.91	0.99	0.99
pCNVbaf < 0.05	# S1	1.30	1.35	1.65	1.50	1.35	0.00	0.00	0.00	0.00	0.00	1.30	1.35	1.65	1.50	1.35
	# S2	1.50	1.60	1.80	1.60	1.60	0.00	0.00	0.00	0.00	0.00	1.50	1.60	1.80	1.60	1.60
	% S1 by S2	0.93	0.96	0.98	1.00	0.96	NA	NA	NA	NA	NA	0.93	0.96	0.98	1.00	0.96
	% S2 by S1	0.87	1.00	1.00	1.00	1.00	NA	NA	NA	NA	NA	0.87	1.00	1.00	1.00	1.00
pCNV < 0.05 or pCNVIrr < 0.05	# S1 # S2 % S1 by S2 % S2 by S1	7.35 7.10 0.89 0.89	6.50 6.20 0.88 0.89	6.80 6.80 0.92 0.95	5.45 5.35 0.96 0.99	5.95 5.90 0.93 0.92	5.05 4.90 0.98 0.96	4.20 4.15 0.97 0.87	4.05 3.95 1.00 0.98	3.40 3.40 1.00 0.99	4.10 4.05 0.97 0.88	2.30 2.20 0.62 0.71	2.30 2.05 0.67 0.89	2.75 2.85 0.80 0.92	2.05 1.95 0.88 0.99	1.85 1.85 0.77 0.99
pCNV < 0.05 or pCNVbaf < 0.05	# S1 # S2 % S1 by S2 % S2 by S1	6.15 6.05 0.94 0.96	5.50 5.40 0.94 0.94	5.60 5.55 0.98 0.98	4.95 4.95 0.98 0.99	5.35 5.35 0.95 0.94	4.50 4.35 0.98 1.00	3.85 3.60 0.96 0.92	3.65 3.45 1.00 0.98	3.15 3.10 1.00 0.99	3.75 3.55 0.97 0.91	1.65 1.70 0.82 0.85	1.65 1.80 0.87 0.99	1.95 2.10 0.92 0.99	1.80 1.85 0.93 0.99	1.60 1.80 0.87 0.99
pCNVIrr < 0.05 or pCNVbaf < 0.05	# S1 # S2 % S1 by S2 % S2 by S1	7.35 7.10 0.89 0.89	6.50 6.20 0.88 0.89	6.80 6.85 0.92 0.95	5.45 5.35 0.96 0.99	5.95 5.90 0.93 0.92	5.05 4.90 0.98 0.96	4.20 4.15 0.97 0.87	4.05 3.95 1.00 0.98	3.40 3.40 1.00 0.99	4.10 4.05 0.97 0.88	2.30 2.20 0.62 0.71	2.30 2.05 0.67 0.89	2.75 2.90 0.80 0.92	2.05 1.95 0.88 0.99	1.85 1.85 0.77 0.99
pCNV < 0.05 or	# S1	7.35	6.50	6.80	5.45	5.95	5.05	4.20	4.05	3.40	4.10	2.30	2.30	2.75	2.05	1.85
pCNVIrr < 0.05	# S2	7.10	6.20	6.85	5.35	5.90	4.90	4.15	3.95	3.40	4.05	2.20	2.05	2.90	1.95	1.85
or pCNVbaf <	% S1 by S2	0.89	0.88	0.92	0.96	0.93	0.98	0.97	1.00	1.00	0.97	0.62	0.67	0.80	0.88	0.77
0.05	% S2 by S1	0.89	0.89	0.95	0.99	0.92	0.96	0.87	0.98	0.99	0.88	0.71	0.89	0.92	0.99	0.99

Table S3. Concordance rate of short CNV calls between duplicate samples genotyped with Affymetrix array.

	115				Af	fymetrix Short	Deletions (<10	0 kb)			
CNVision cutoff	duplicate pairs	CNVision	PennCNV	PennCNV + QuantiSNP	PennCNV + Birdsuite	QuantiSNP	QuantiSNP + PennCNV	QuantiSNP + Birdsuite	Birdsuite	Birdsuite + QuantiSNP	Birdsuite + PennCNV
	# S1	10.35	9.29	8.83	8.57	9.27	8.59	8.51	16.52	9.32	8.56
No filtering	# S2	10.25	9.37	8.93	8.73	9.09	8.45	8.49	16.81	9.36	8.57
No menng	% S1 by S2	0.77	0.78	0.80	0.81	0.83	0.85	0.86	0.92	0.95	0.95
	% S2 by S1	0.80	0.82	0.84	0.84	0.85	0.88	0.87	0.92	0.96	0.97
	# S1	8.84	8.13	7.90	7.58	8.31	7.92	7.77	7.91	7.58	7.32
	# S2	8.57	8.01	7.80	7.57	8.12	7.79	7.67	7.50	7.29	7.06
pciv < 0.05	% S1 by S2	0.81	0.82	0.83	0.84	0.85	0.86	0.87	0.95	0.96	0.96
	% S2 by S1	0.84	0.86	0.87	0.87	0.87	0.89	0.89	0.97	0.97	0.97
	# S1	9.75	8.90	8.52	8.21	8.82	8.33	8.16	8.93	8.33	7.93
nCNIV/Irr<0.05	# S2	9.64	8.97	8.66	8.41	8.70	8.27	8.17	9.01	8.29	7.90
	% S1 by S2	0.78	0.78	0.80	0.81	0.83	0.85	0.85	0.94	0.95	0.95
	% S2 by S1	0.81	0.83	0.84	0.85	0.86	0.88	0.87	0.95	0.96	0.97
	# S1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.01	0.01
	# S2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
penvuar<0.05	% S1 by S2	NA	NA	NA	NA	NA	NA	NA	0.50	1.00	1.00
	% S2 by S1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	# S1	9.75	8.90	8.52	8.21	8.82	8.33	8.16	8.93	8.33	7.93
pCNV<0.05 or	# S2	9.64	8.97	8.66	8.41	8.70	8.27	8.17	9.01	8.29	7.90
pCNVIrr<0.05	% S1 by S2	0.78	0.78	0.80	0.81	0.83	0.85	0.85	0.94	0.95	0.95
	% S2 by S1	0.81	0.83	0.84	0.85	0.86	0.88	0.87	0.95	0.96	0.97
	# S1	8.84	8.13	7.90	7.58	8.31	7.92	7.77	7.92	7.59	7.33
pCNV<0.05 or	# S2	8.57	8.01	7.80	7.57	8.12	7.79	7.67	7.50	7.29	7.06
pCNVbaf<0.05	% S1 by S2	0.81	0.82	0.83	0.84	0.85	0.86	0.87	0.95	0.96	0.96
	% S2 by S1	0.84	0.86	0.87	0.87	0.87	0.89	0.89	0.97	0.97	0.97
	# S1	9.75	8.90	8.52	8.21	8.82	8.33	8.16	8.94	8.34	7.94
pCNVIrr<0.05 or	# S2	9.64	8.97	8.66	8.41	8.70	8.27	8.17	9.01	8.29	7.90
pCNVbaf<0.05	% S1 by S2	0.78	0.78	0.80	0.81	0.83	0.85	0.85	0.94	0.95	0.95
	% S2 by S1	0.81	0.83	0.84	0.85	0.86	0.88	0.87	0.95	0.96	0.97
011/ 0.05	# S1	9.75	8.90	8.52	8.21	8.82	8.33	8.16	8.94	8.34	7.94
pCNV<0.05 or	# S2	9.64	8.97	8.66	8.41	8.70	8.27	8.17	9.01	8.29	7.90
pUNVIrr<0.05 or	% S1 by S2	0.78	0.78	0.80	0.81	0.83	0.85	0.85	0.94	0.95	0.95
punvbar<0.05	% S2 by S1	0.81	0.83	0.84	0.85	0.86	0.88	0.87	0.95	0.96	0.97

(continues on next page)

Zhang et al.

	115				Affy	ymetrix Short D	Ouplications (<1	00 kb)			
CNVision cutoff	duplicate pairs	CNVision	PennCNV	PennCNV + QuantiSNP	PennCNV + Birdsuite	QuantiSNP	QuantiSNP + PennCNV	QuantiSNP + Birdsuite	Birdsuite	Birdsuite + QuantiSNP	Birdsuite + PennCNV
	# S1	6.20	5.10	4.68	2.22	5.69	4.65	2.34	2.69	1.54	1.39
No filtoring	# S2	6.42	5.01	4.70	2.17	5.77	4.66	2.63	2.70	1.51	1.30
No filtering	% S1 by S2	0.69	0.65	0.67	0.71	0.73	0.77	0.79	0.80	0.90	0.91
	% S2 by S1	0.66	0.68	0.70	0.72	0.71	0.73	0.75	0.77	0.95	0.97
	# S1	1.01	0.90	0.85	0.78	0.97	0.91	0.82	0.79	0.74	0.72
	# S2	0.90	0.88	0.83	0.77	0.89	0.83	0.77	0.65	0.63	0.63
pcivv<0.05	% S1 by S2	0.76	0.80	0.81	0.84	0.80	0.82	0.84	0.89	0.91	0.93
	% S2 by S1	0.85	0.82	0.82	0.80	0.90	0.90	0.92	0.93	0.93	0.93
	# S1	4.53	3.93	3.70	1.63	4.37	3.79	1.70	1.31	1.19	1.16
nCNIVIrr>0.05	# S2	4.53	3.81	3.67	1.60	4.33	3.75	1.85	1.23	1.14	1.06
	% S1 by S2	0.69	0.67	0.67	0.73	0.73	0.76	0.78	0.89	0.91	0.91
	% S2 by S1	0.66	0.68	0.69	0.68	0.72	0.75	0.73	0.93	0.94	0.95
	# S1	0.57	0.52	0.50	0.45	0.52	0.49	0.45	0.47	0.43	0.43
	# S2	0.50	0.50	0.47	0.45	0.47	0.45	0.44	0.44	0.43	0.43
	% S1 by S2	0.88	0.84	0.83	0.89	0.87	0.88	0.88	0.91	0.92	0.94
	% S2 by S1	0.91	0.81	0.81	0.81	0.94	0.94	0.94	0.96	0.96	0.96
	# S1	4.70	4.06	3.79	1.74	4.50	3.90	1.81	1.45	1.31	1.26
pCNV<0.05 or	# S2	4.67	3.95	3.80	1.72	4.46	3.87	1.97	1.34	1.24	1.16
pCNVIrr<0.05	% S1 by S2	0.70	0.67	0.68	0.74	0.74	0.76	0.79	0.89	0.91	0.92
	% S2 by S1	0.68	0.68	0.69	0.69	0.74	0.76	0.75	0.94	0.95	0.96
	# S1	1.03	0.92	0.87	0.79	0.98	0.93	0.83	0.79	0.74	0.72
pCNV<0.05 or	# S2	0.93	0.90	0.84	0.77	0.90	0.83	0.78	0.65	0.63	0.63
pCNVbaf<0.05	% S1 by S2	0.75	0.80	0.81	0.84	0.80	0.82	0.84	0.89	0.91	0.93
	% S2 by S1	0.85	0.82	0.82	0.80	0.90	0.90	0.92	0.93	0.93	0.93
	# S1	4.70	4.06	3.81	1.74	4.50	3.90	1.80	1.43	1.30	1.24
pCNVIrr<0.05 or	# S2	4.69	3.96	3.80	1.71	4.46	3.86	1.97	1.33	1.23	1.15
pCNVbaf<0.05	% S1 by S2	0.70	0.68	0.68	0.75	0.74	0.77	0.79	0.89	0.91	0.92
	% S2 by S1	0.67	0.68	0.69	0.69	0.73	0.76	0.75	0.93	0.95	0.96
p(N)/20.05 or	# S1	4.73	4.08	3.81	1.75	4.51	3.91	1.82	1.45	1.31	1.26
μ Ω V V Λ Ω Ω Ω Ω Ω	# S2	4.70	3.97	3.81	1.72	4.47	3.87	1.98	1.34	1.24	1.16
nCNIVhaf<0.00 01	% S1 by S2	0.70	0.67	0.68	0.74	0.74	0.77	0.79	0.89	0.91	0.92
	% S2 by S1	0.68	0.68	0.69	0.69	0.74	0.76	0.75	0.94	0.95	0.96

(continues on next page)

	115				At	ffymetrix All Sh	ort CNVs (<100	kb)			
CNVision cutoff	duplicate pairs	CNVision	PennCNV	PennCNV + QuantiSNP	PennCNV + Birdsuite	QuantiSNP	QuantiSNP + PennCNV	QuantiSNP + Birdsuite	Birdsuite	Birdsuite + QuantiSNP	Birdsuite + PennCNV
	# S1	16.55	14.38	13.50	10.78	14.96	13.24	10.85	19.21	10.86	9.95
No filtoring	# S2	16.67	14.37	13.63	10.90	14.86	13.11	11.11	19.50	10.87	9.87
No filtering	% S1 by S2	0.74	0.73	0.75	0.78	0.79	0.82	0.84	0.90	0.95	0.95
	% S2 by S1	0.74	0.76	0.78	0.81	0.79	0.82	0.84	0.90	0.95	0.96
	# S1	9.85	9.03	8.75	8.37	9.28	8.83	8.58	8.70	8.32	8.04
	# S2	9.47	8.89	8.63	8.33	9.01	8.63	8.44	8.15	7.92	7.70
pcivv<0.05	% S1 by S2	0.81	0.82	0.83	0.84	0.84	0.86	0.86	0.94	0.96	0.96
	% S2 by S1	0.84	0.85	0.86	0.87	0.88	0.89	0.89	0.96	0.96	0.97
	# S1	14.28	12.83	12.22	9.84	13.18	12.12	9.85	10.24	9.52	9.09
pCNV/rr>0.05	# S2	14.17	12.77	12.33	10.01	13.03	12.02	10.03	10.24	9.43	8.96
pcivii1<0.05	% S1 by S2	0.75	0.75	0.76	0.80	0.79	0.81	0.83	0.93	0.95	0.95
	% S2 by S1	0.76	0.78	0.79	0.83	0.81	0.83	0.85	0.95	0.96	0.96
	# S1	0.57	0.52	0.50	0.45	0.52	0.49	0.45	0.49	0.44	0.43
	# S2	0.50	0.50	0.47	0.45	0.47	0.45	0.44	0.44	0.43	0.43
	% S1 by S2	0.88	0.84	0.83	0.89	0.87	0.88	0.88	0.89	0.92	0.94
	% S2 by S1	0.91	0.81	0.81	0.81	0.94	0.94	0.94	0.96	0.96	0.96
	# S1	14.45	12.97	12.31	9.95	13.31	12.23	9.97	10.38	9.64	9.19
pCNV<0.05 or	# S2	14.31	12.91	12.46	10.13	13.16	12.14	10.15	10.35	9.53	9.05
pCNVIrr<0.05	% S1 by S2	0.75	0.75	0.76	0.80	0.80	0.82	0.84	0.94	0.95	0.95
	% S2 by S1	0.76	0.78	0.79	0.82	0.81	0.83	0.85	0.95	0.96	0.96
	# S1	9.88	9.05	8.77	8.37	9.30	8.85	8.59	8.71	8.33	8.05
pCNV<0.05 or	# S2	9.50	8.90	8.64	8.33	9.02	8.63	8.45	8.15	7.92	7.70
pCNVbaf<0.05	% S1 by S2	0.81	0.82	0.83	0.84	0.84	0.86	0.86	0.94	0.96	0.96
	% S2 by S1	0.84	0.85	0.86	0.87	0.88	0.89	0.89	0.96	0.96	0.97
	# S1	14.45	12.97	12.33	9.95	13.31	12.23	9.96	10.37	9.63	9.18
pCNVIrr<0.05 or	# S2	14.33	12.92	12.46	10.12	13.16	12.13	10.15	10.34	9.52	9.04
pCNVbaf<0.05	% S1 by S2	0.75	0.75	0.76	0.80	0.80	0.82	0.84	0.94	0.95	0.95
	% S2 by S1	0.76	0.78	0.79	0.82	0.81	0.83	0.85	0.95	0.96	0.96
nCNV < 0.05 or	# S1	14.48	12.98	12.33	9.96	13.33	12.24	9.97	10.39	9.65	9.20
pCNVIrr<0.05 or	# S2	14.34	12.93	12.47	10.13	13.17	12.14	10.16	10.35	9.53	9.05
pCNVbaf<0.05	% S1 by S2	0.75	0.75	0.76	0.80	0.80	0.82	0.84	0.94	0.95	0.95
	% S2 by S1	0.76	0.78	0.79	0.82	0.81	0.83	0.85	0.95	0.96	0.96

Table S4. Concordance rate of long CNV calls between duplicate samples genotyped with Affymetrix array.

	115				A	ffymetrix Long	Deletions (>100) kb)			
CNVision cutoff	duplicate pairs	CNVision	PennCNV	PennCNV + QuantiSNP	PennCNV + Birdsuite	QuantiSNP	QuantiSNP + PennCNV	QuantiSNP + Birdsuite	Birdsuite	Birdsuite + QuantiSNP	Birdsuite + PennCNV
	# S1	2.14	2.07	1.96	1.84	1.85	1.81	1.67	3.58	1.80	1.85
No filtering	# S2	2.12	2.08	1.96	1.83	1.91	1.90	1.68	3.65	1.82	1.85
No Intering	% S1 by S2	0.84	0.88	0.90	0.91	0.90	0.90	0.91	0.93	0.95	0.96
	% S2 by S1	0.85	0.87	0.89	0.90	0.90	0.89	0.91	0.90	0.94	0.95
	# S1	1.67	1.60	1.56	1.48	1.52	1.51	1.39	1.37	1.32	1.36
nCNV/<0.05	# S2	1.58	1.54	1.50	1.42	1.53	1.53	1.40	1.43	1.40	1.43
pcivv<0.05	% S1 by S2	0.92	0.97	0.97	0.98	0.93	0.93	0.94	0.99	0.99	0.99
	% S2 by S1	0.91	0.94	0.95	0.97	0.95	0.95	0.97	0.99	0.99	0.99
	# S1	1.92	1.82	1.74	1.67	1.66	1.65	1.52	1.61	1.52	1.57
nCNIVIrr>0.05	# S2	1.92	1.89	1.81	1.70	1.77	1.77	1.59	1.74	1.61	1.67
	% S1 by S2	0.87	0.92	0.93	0.94	0.91	0.91	0.92	0.97	0.99	0.98
	% S2 by S1	0.89	0.90	0.91	0.93	0.90	0.90	0.92	0.98	0.98	0.98
	# S1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
nCNIVbaf<0.05	# S2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	% S1 by S2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	% S2 by S1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	# S1	1.92	1.82	1.74	1.67	1.66	1.65	1.52	1.61	1.52	1.57
pCNV<0.05 or	# S2	1.92	1.89	1.81	1.70	1.77	1.77	1.59	1.74	1.61	1.67
pCNVIrr<0.05	% S1 by S2	0.87	0.92	0.93	0.94	0.91	0.91	0.92	0.97	0.99	0.98
	% S2 by S1	0.89	0.90	0.91	0.93	0.90	0.90	0.92	0.98	0.98	0.98
	# S1	1.67	1.60	1.56	1.48	1.52	1.51	1.39	1.37	1.32	1.36
pCNV<0.05 or	# S2	1.58	1.54	1.50	1.42	1.53	1.53	1.40	1.43	1.40	1.43
pCNVbaf<0.05	% S1 by S2	0.92	0.97	0.97	0.98	0.93	0.93	0.94	0.99	0.99	0.99
	% S2 by S1	0.91	0.94	0.95	0.97	0.95	0.95	0.97	0.99	0.99	0.99
	# S1	1.92	1.82	1.74	1.67	1.66	1.65	1.52	1.61	1.52	1.57
pCNVIrr<0.05 or	# S2	1.92	1.89	1.81	1.70	1.77	1.77	1.59	1.74	1.61	1.67
pCNVbaf<0.05	% S1 by S2	0.87	0.92	0.93	0.94	0.91	0.91	0.92	0.97	0.99	0.98
	% S2 by S1	0.89	0.90	0.91	0.93	0.90	0.90	0.92	0.98	0.98	0.98
	# S1	1.92	1.82	1.74	1.67	1.66	1.65	1.52	1.61	1.52	1.57
pCNV<0.05 or	# S2	1.92	1.89	1.81	1.70	1.77	1.77	1.59	1.74	1.61	1.67
pUNVIRCE 0.05 or	% S1 by S2	0.87	0.92	0.93	0.94	0.91	0.91	0.92	0.97	0.99	0.98
penvuai<0.05	% S2 by S1	0.89	0.90	0.91	0.93	0.90	0.90	0.92	0.98	0.98	0.98

(continues on next page)
Zhang et al.

Supplement

	115				Aff	ymetrix Long D	uplications (>1	00 kb)			
CNVision cutoff	duplicate pairs	CNVision	PennCNV	PennCNV + QuantiSNP	PennCNV + Birdsuite	QuantiSNP	QuantiSNP + PennCNV	QuantiSNP + Birdsuite	Birdsuite	Birdsuite + QuantiSNP	Birdsuite + PennCNV
	# S1	3.23	3.17	2.74	1.93	2.70	2.62	1.70	2.99	1.46	1.58
No filtoring	# S2	3.57	3.56	3.17	2.19	2.98	2.85	1.83	3.10	1.62	1.71
No Intering	% S1 by S2	0.75	0.81	0.86	0.87	0.83	0.84	0.88	0.83	0.93	0.93
	% S2 by S1	0.73	0.75	0.79	0.78	0.77	0.80	0.81	0.80	0.92	0.92
	# S1	0.76	0.74	0.74	0.69	0.75	0.75	0.69	0.63	0.63	0.63
	# S2	0.77	0.75	0.75	0.65	0.75	0.75	0.66	0.62	0.62	0.62
pcivv<0.03	% S1 by S2	0.95	0.97	0.97	0.97	0.98	0.98	0.97	1.00	1.00	1.00
	% S2 by S1	0.94	0.96	0.96	1.00	0.96	0.96	0.98	1.00	1.00	1.00
	# S1	2.16	2.25	2.06	1.37	2.02	2.01	1.28	1.15	1.09	1.12
nCNV/rr<0.05	# S2	2.25	2.26	2.20	1.37	2.17	2.13	1.33	1.12	1.12	1.12
pon m < 0.00	% S1 by S2	0.83	0.87	0.89	0.90	0.86	0.86	0.89	0.97	0.97	0.97
	% S2 by S1	0.83	0.86	0.87	0.87	0.82	0.84	0.86	0.92	0.92	0.92
	# S1	0.44	0.45	0.44	0.44	0.45	0.45	0.44	0.43	0.42	0.43
nCNIVbaf<0.05	# S2	0.44	0.43	0.43	0.43	0.42	0.42	0.41	0.41	0.40	0.41
	% S1 by S2	0.95	1.00	1.00	1.00	0.95	0.95	0.95	1.00	1.00	1.00
	% S2 by S1	0.96	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
	# S1	2.23	2.32	2.13	1.44	2.09	2.08	1.35	1.22	1.16	1.19
pCNV<0.05 or	# S2	2.35	2.36	2.30	1.47	2.25	2.22	1.42	1.22	1.22	1.22
pCNVIrr<0.05	% S1 by S2	0.83	0.87	0.90	0.91	0.86	0.86	0.89	0.97	0.98	0.98
	% S2 by S1	0.84	0.86	0.87	0.88	0.83	0.84	0.87	0.93	0.93	0.93
	# S1	0.77	0.77	0.76	0.71	0.77	0.77	0.70	0.65	0.64	0.65
pCNV<0.05 or	# S2	0.78	0.77	0.76	0.67	0.75	0.75	0.66	0.63	0.63	0.63
pCNVbaf<0.05	% S1 by S2	0.93	0.97	0.97	0.97	0.98	0.98	0.97	1.00	1.00	1.00
	% S2 by S1	0.94	0.96	0.96	1.00	0.96	0.96	0.98	1.00	1.00	1.00
	# S1	2.24	2.35	2.15	1.47	2.10	2.10	1.37	1.23	1.17	1.21
pCNVIrr<0.05 or	# S2	2.36	2.37	2.30	1.48	2.25	2.22	1.42	1.23	1.23	1.23
pCNVbaf<0.05	% S1 by S2	0.83	0.88	0.90	0.91	0.86	0.86	0.89	0.97	0.98	0.98
	% S2 by S1	0.84	0.86	0.87	0.88	0.83	0.84	0.87	0.93	0.93	0.93
nCNV < 0.05 or	# S1	2.24	2.35	2.15	1.47	2.10	2.10	1.37	1.23	1.17	1.21
pONV < 0.00 OI	# S2	2.37	2.37	2.30	1.49	2.25	2.22	1.42	1.23	1.23	1.23
nCNIVhaf<0.05	% S1 by S2	0.83	0.88	0.90	0.91	0.86	0.86	0.89	0.97	0.98	0.98
	% S2 by S1	0.84	0.86	0.87	0.88	0.83	0.84	0.87	0.93	0.93	0.93
			Y								

	115				A	ffymetrix All Lo	ng CNVs (>100 l	 b)			
CNVision cutoff	duplicate pairs	CNVision	PennCNV	PennCNV + QuantiSNP	PennCNV + Birdsuite	QuantiSNP	QuantiSNP + PennCNV	QuantiSNP + Birdsuite	Birdsuite	Birdsuite + QuantiSNP	Birdsuite + PennCNV
	# S1	5.37	5.24	4.70	3.77	4.56	4.43	3.37	6.57	3.26	3.43
No filtoring	# S2	5.69	5.63	5.13	4.02	4.90	4.75	3.50	6.76	3.43	3.57
No memby	% S1 by S2	0.79	0.83	0.87	0.89	0.86	0.87	0.90	0.88	0.93	0.94
	% S2 by S1	0.75	0.78	0.81	0.82	0.81	0.83	0.86	0.85	0.92	0.93
	# S1	2.43	2.34	2.30	2.17	2.27	2.26	2.08	2.00	1.96	1.99
	# S2	2.35	2.29	2.24	2.07	2.28	2.28	2.06	2.05	2.02	2.05
pcivv<0.05	% S1 by S2	0.92	0.97	0.97	0.97	0.94	0.94	0.95	0.99	0.99	0.99
	% S2 by S1	0.92	0.94	0.95	0.98	0.96	0.96	0.98	0.99	0.99	0.99
	# S1	4.08	4.07	3.80	3.04	3.68	3.66	2.80	2.76	2.61	2.69
pCNI/Irr < 0.05	# S2	4.17	4.15	4.01	3.08	3.94	3.90	2.92	2.86	2.73	2.79
	% S1 by S2	0.85	0.89	0.91	0.93	0.89	0.90	0.92	0.97	0.98	0.97
	% S2 by S1	0.85	0.86	0.86	0.89	0.84	0.85	0.89	0.96	0.96	0.96
	# S1	0.44	0.45	0.44	0.44	0.45	0.45	0.44	0.43	0.42	0.43
	# S2	0.44	0.43	0.43	0.43	0.42	0.42	0.41	0.41	0.40	0.41
pentrual<0.05	% S1 by S2	0.95	1.00	1.00	1.00	0.95	0.95	0.95	1.00	1.00	1.00
	% S2 by S1	0.96	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
	# S1	4.15	4.14	3.87	3.11	3.75	3.73	2.87	2.83	2.68	2.76
pCNV<0.05 or	# S2	4.27	4.24	4.10	3.17	4.03	3.98	3.01	2.96	2.83	2.89
pCNVIrr<0.05	% S1 by S2	0.85	0.89	0.91	0.93	0.90	0.90	0.92	0.97	0.98	0.97
	% S2 by S1	0.85	0.86	0.87	0.90	0.85	0.86	0.89	0.96	0.96	0.96
	# S1	2.44	2.37	2.31	2.19	2.29	2.28	2.10	2.02	1.97	2.01
pCNV<0.05 or	# S2	2.37	2.30	2.25	2.09	2.28	2.28	2.06	2.07	2.03	2.07
pCNVbaf<0.05	% S1 by S2	0.91	0.97	0.97	0.97	0.94	0.94	0.95	0.99	0.99	0.99
	% S2 by S1	0.92	0.94	0.95	0.98	0.96	0.96	0.98	0.99	0.99	0.99
	# S1	4.17	4.17	3.89	3.14	3.77	3.75	2.89	2.84	2.69	2.77
pCNVIrr<0.05 or	# S2	4.28	4.25	4.10	3.18	4.03	3.98	3.01	2.97	2.83	2.90
pCNVbaf<0.05	% S1 by S2	0.85	0.90	0.91	0.93	0.90	0.90	0.92	0.97	0.98	0.97
	% S2 by S1	0.85	0.86	0.87	0.90	0.85	0.86	0.89	0.96	0.96	0.96
pCNV $< 0.05 or$	# S1	4.17	4.17	3.89	3.14	3.77	3.75	2.89	2.84	2.69	2.77
pCNV r < 0.05 Or	# S2	4.29	4.26	4.11	3.19	4.03	3.98	3.01	2.97	2.83	2.90
pCNVbaf<0.05	% S1 by S2	0.85	0.90	0.91	0.93	0.90	0.90	0.92	0.97	0.98	0.97
	% S2 by S1	0.85	0.86	0.87	0.90	0.85	0.86	0.89	0.96	0.96	0.96

Zhang et al.

Table S5. Concordance rate of short CNV calls between duplicate samples genotyped with Illumina array.

			Illumina	a All CNVs	(<100 kb)			Illumina	Deletions	(<100 kb)			Illumina Du	uplications	(<100 kb)	
CNVision cutoff	20 duplicate pairs	CNVision	PennCNV	QuantiSNP	QuantiSNP + PennCNV	PennCNV + QuantiSNP	CNVision	PennCNV	QuantiSNP	QuantiSNP + PennCNV	PennCNV + QuantiSNP	CNVision	PennCNV	QuantiSNP	QuantiSNP + PennCNV	PennCNV + QuantiSNP
No filtering	# S1	6.30	5.70	4.90	4.05	4.85	4.95	4.10	3.40	2.90	3.75	1.35	1.60	1.50	1.15	1.10
	# S2	6.00	5.45	4.60	4.00	4.70	4.85	4.10	3.35	2.95	3.60	1.15	1.35	1.25	1.05	1.10
	% S1 by S2	0.87	0.89	0.94	0.98	0.95	0.95	0.95	1.00	1.00	0.97	0.57	0.67	0.79	0.90	0.83
	% S2 by S1	0.89	0.86	0.93	0.95	0.93	0.94	0.88	0.93	0.94	0.92	0.72	0.79	0.92	1.00	0.92
pCNV < 0.05	# S1	3.90	3.75	3.45	3.05	3.65	3.15	2.95	2.60	2.25	2.90	0.75	0.80	0.85	0.80	0.75
	# S2	3.90	3.60	3.50	3.10	3.55	3.10	2.65	2.45	2.15	2.60	0.80	0.95	1.05	0.95	0.95
	% S1 by S2	0.96	0.92	1.00	1.00	0.93	0.99	0.93	1.00	1.00	0.93	0.82	0.91	1.00	1.00	1.00
	% S2 by S1	0.97	0.95	0.98	0.99	0.95	1.00	0.94	0.97	0.99	0.94	0.86	1.00	1.00	1.00	1.00
pCNVIrr < 0.05	# S1	4.80	4.40	3.80	3.25	3.95	3.65	3.30	2.90	2.50	3.25	1.15	1.10	0.90	0.75	0.70
	# S2	4.65	4.15	3.75	3.20	3.85	3.60	3.15	2.85	2.45	3.05	1.05	1.00	0.90	0.75	0.80
	% S1 by S2	0.91	0.90	0.96	0.97	0.95	0.99	0.96	1.00	1.00	0.96	0.60	0.65	0.78	0.80	0.89
	% S2 by S1	0.90	0.87	0.97	0.99	0.92	0.95	0.88	0.97	0.99	0.91	0.80	0.85	0.91	1.00	1.00
pCNVbaf < 0.05	# S1	0.60	0.65	0.75	0.70	0.65	0.00	0.00	0.00	0.00	0.00	0.60	0.65	0.75	0.70	0.65
	# S2	0.70	0.85	0.95	0.85	0.85	0.00	0.00	0.00	0.00	0.00	0.70	0.85	0.95	0.85	0.85
	% S1 by S2	0.89	1.00	1.00	1.00	1.00	NA	NA	NA	NA	NA	0.89	1.00	1.00	1.00	1.00
	% S2 by S1	0.83	1.00	1.00	1.00	1.00	NA	NA	NA	NA	NA	0.83	1.00	1.00	1.00	1.00
pCNV < 0.05 or pCNVIrr < 0.05	# S1 # S2 % S1 by S2 % S2 by S1	4.90 4.70 0.91 0.90	4.60 4.30 0.90 0.88	4.05 4.00 0.96 0.97	3.45 3.40 0.97 0.99	4.15 4.00 0.95 0.93	3.65 3.60 0.99 0.95	3.30 3.15 0.96 0.88	2.90 2.85 1.00 0.97	2.50 2.45 1.00 0.99	3.25 3.05 0.96 0.91	1.25 1.10 0.63 0.74	1.30 1.15 0.72 0.87	1.15 1.15 0.83 0.92	0.95 0.95 0.86 1.00	0.90 0.95 0.91 1.00
pCNV < 0.05 or pCNVbaf < 0.05	# S1 # S2 % S1 by S2 % S2 by S1	3.90 3.90 0.96 0.97	3.75 3.60 0.92 0.95	3.45 3.50 1.00 0.98	3.05 3.10 1.00 0.99	3.65 3.55 0.93 0.95	3.15 3.10 0.99 1.00	2.95 2.65 0.93 0.94	2.60 2.45 1.00 0.97	2.25 2.15 1.00 0.99	2.90 2.60 0.93 0.94	0.75 0.80 0.82 0.86	0.80 0.95 0.91 1.00	0.85 1.05 1.00 1.00	0.80 0.95 1.00 1.00	0.75 0.95 1.00 1.00
pCNVIrr < 0.05 or pCNVbaf < 0.05	# S1 # S2 % S1 by S2 % S2 by S1	4.90 4.70 0.91 0.90	4.60 4.30 0.90 0.88	4.05 4.00 0.96 0.97	3.45 3.40 0.97 0.99	4.15 4.00 0.95 0.93	3.65 3.60 0.99 0.95	3.30 3.15 0.96 0.88	2.90 2.85 1.00 0.97	2.50 2.45 1.00 0.99	3.25 3.05 0.96 0.91	1.25 1.10 0.63 0.74	1.30 1.15 0.72 0.87	1.15 1.15 0.83 0.92	0.95 0.95 0.86 1.00	0.90 0.95 0.91 1.00
pCNV < 0.05 or	# S1	4.90	4.60	4.05	3.45	4.15	3.65	3.30	2.90	2.50	3.25	1.25	1.30	1.15	0.95	0.90
pCNVIrr < 0.05	# S2	4.70	4.30	4.00	3.40	4.00	3.60	3.15	2.85	2.45	3.05	1.10	1.15	1.15	0.95	0.95
or pCNVbaf <	% S1 by S2	0.90	0.91	0.96	0.97	0.95	0.99	0.96	1.00	1.00	0.96	0.63	0.69	0.83	0.86	0.91
0.05	% S2 by S1	0.89	0.87	0.97	0.99	0.92	0.95	0.88	0.97	0.99	0.92	0.74	0.86	0.92	1.00	1.00

Zhang et al.

Table S6. Concordance rate of long CNV calls between duplicate samples genotyped with Illumina array.

			Illumina	a All CNVs	(>100 kb)			Illumina	Deletions	(>100 kb)		I	llumina Du	uplications	(>100 kb)	
CNVision cutoff	20 duplicate pairs	CNVision	PennCNV	QuantiSNP	QuantiSNP + PennCNV	PennCNV + QuantiSNP	CNVision	PennCNV	QuantiSNP	QuantiSNP + PennCNV	PennCNV + QuantiSNP	CNVision	PennCNV	QuantiSNP	QuantiSNP + PennCNV	PennCNV + QuantiSNP
No filtering	# S1	2.65	2.00	3.20	2.10	1.85	1.45	0.90	1.20	0.90	0.85	1.20	1.10	2.00	1.20	1.00
	# S2	2.70	2.15	3.20	2.00	2.05	1.50	1.15	1.20	1.00	1.15	1.20	1.00	2.00	1.00	0.90
	% S1 by S2	0.83	0.79	0.81	0.93	0.83	0.95	0.92	1.00	1.00	1.00	0.68	0.68	0.69	0.89	0.73
	% S2 by S1	0.82	0.86	0.92	0.99	0.91	0.85	0.87	1.00	1.00	0.87	0.73	0.88	0.85	0.97	0.95
pCNV < 0.05	# S1	2.25	1.75	2.15	1.90	1.70	1.35	0.90	1.05	0.90	0.85	0.90	0.85	1.10	1.00	0.85
	# S2	2.15	1.80	2.00	1.85	1.80	1.25	0.95	1.00	0.95	0.95	0.90	0.85	1.00	0.90	0.85
	% S1 by S2	0.89	0.84	0.93	0.95	0.86	0.97	0.92	1.00	1.00	1.00	0.77	0.77	0.88	0.92	0.77
	% S2 by S1	0.92	0.92	0.99	0.99	0.92	1.00	0.86	1.00	1.00	0.86	0.83	0.95	0.97	0.97	0.95
pCNVIrr < 0.05	# S1	2.35	1.80	2.55	1.85	1.70	1.40	0.90	1.15	0.90	0.85	0.95	0.90	1.40	0.95	0.85
	# S2	2.15	1.70	2.55	1.70	1.70	1.30	1.00	1.10	0.95	1.00	0.85	0.70	1.45	0.75	0.70
	% S1 by S2	0.84	0.80	0.89	0.95	0.83	0.95	0.92	1.00	1.00	1.00	0.63	0.63	0.83	0.92	0.68
	% S2 by S1	0.93	0.90	0.94	0.98	0.90	0.98	0.86	1.00	1.00	0.86	0.75	0.94	0.87	0.96	0.94
pCNVbaf < 0.05	# S1	0.70	0.70	0.90	0.80	0.70	0.00	0.00	0.00	0.00	0.00	0.70	0.70	0.90	0.80	0.70
	# S2	0.80	0.75	0.85	0.75	0.75	0.00	0.00	0.00	0.00	0.00	0.80	0.75	0.85	0.75	0.75
	% S1 by S2	0.90	0.90	0.96	1.00	0.90	NA	NA	NA	NA	NA	0.90	0.90	0.96	1.00	0.90
	% S2 by S1	0.86	1.00	1.00	1.00	1.00	NA	NA	NA	NA	NA	0.86	1.00	1.00	1.00	1.00
pCNV < 0.05 or pCNVIrr < 0.05	# S1 # S2 % S1 by S2 % S2 by S1	2.45 2.40 0.84 0.88	1.90 1.90 0.80 0.91	2.75 2.80 0.87 0.94	2.00 1.95 0.95 0.99	1.80 1.90 0.83 0.91	1.40 1.30 0.95 0.98	0.90 1.00 0.92 0.86	1.15 1.10 1.00 1.00	0.90 0.95 1.00 1.00	0.85 1.00 1.00 0.86	1.05 1.10 0.67 0.73	1.00 0.90 0.67 0.95	1.60 1.70 0.82 0.89	1.10 1.00 0.93 0.97	0.95 0.90 0.71 0.95
pCNV < 0.05 or pCNVbaf < 0.05	# S1 # S2 % S1 by S2 % S2 by S1	2.25 2.15 0.89 0.92	1.75 1.80 0.84 0.92	2.15 2.05 0.93 0.99	1.90 1.85 0.95 0.99	1.70 1.80 0.86 0.92	1.35 1.25 0.97 1.00	0.90 0.95 0.92 0.86	1.05 1.00 1.00 1.00	0.90 0.95 1.00 1.00	0.85 0.95 1.00 0.86	0.90 0.90 0.77 0.83	0.85 0.85 0.77 0.95	1.10 1.05 0.88 0.97	1.00 0.90 0.92 0.97	0.85 0.85 0.77 0.95
pCNVIrr < 0.05 or pCNVbaf < 0.05	# S1 # S2 % S1 by S2 % S2 by S1	2.45 2.40 0.84 0.88	1.90 1.90 0.80 0.91	2.75 2.85 0.87 0.94	2.00 1.95 0.95 0.99	1.80 1.90 0.83 0.91	1.40 1.30 0.95 0.98	0.90 1.00 0.92 0.86	1.15 1.10 1.00 1.00	0.90 0.95 1.00 1.00	0.85 1.00 1.00 0.86	1.05 1.10 0.67 0.73	1.00 0.90 0.67 0.95	1.60 1.75 0.82 0.90	1.10 1.00 0.93 0.97	0.95 0.90 0.71 0.95
pCNV < 0.05 or	# S1	2.45	1.90	2.75	2.00	1.80	1.40	0.90	1.15	0.90	0.85	1.05	1.00	1.60	1.10	0.95
pCNVIrr < 0.05	# S2	2.40	1.90	2.85	1.95	1.90	1.30	1.00	1.10	0.95	1.00	1.10	0.90	1.75	1.00	0.90
or pCNVbaf <	% S1 by S2	0.83	0.82	0.87	0.94	0.88	0.95	0.91	1.00	1.00	1.00	0.64	0.64	0.82	0.92	0.77
0.05	% S2 by S1	0.88	0.91	0.94	0.99	0.91	0.98	0.85	1.00	1.00	0.86	0.71	0.95	0.90	0.97	0.95

Table S7. Global CNV burden analyses by permutation tests.

						A. De	letions							
Type of	Type of	- Tostad affact		All (<1%)		-	Singleton CN	IVs	-	> 500 kb CN	Vs		> 1 Mb CN\	ls
Del	CNV	Tested effect	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value
	ΔII	CNVs/subj	0.3242	0.3181	1.82E-01	0.0559	0.0501	8.10E-02	0.0216	0.0189	2.06E-01	0.0066	0.0044	9.41E-02
		Subjs w CNV	0.2818	0.2709	4.49E-02	0.0547	0.0485	6.59E-02	0.0215	0.0186	1.90E-01	0.0066	0.0044	9.41E-02
	Intergenic	CNVs/subj	0.1337	0.1376	6.31E-01	0.0206	0.0180	1.09E-01	0.0028	0.0020	3.97E-01	0.0010	0.0003	1.16E-01
	intergenie	Subjs w CNV	0.1247	0.1298	7.16E-01	0.0204	0.0178	1.15E-01	0.0028	0.0020	3.97E-01	0.0010	0.0003	1.16E-01
		CNVs/subj	0.1905	0.1805	7.12E-02	0.0420	0.0376	1.38E-01	0.0189	0.0169	2.39E-01	0.0055	0.0041	1.99E-01
Lona (>	Gene-	Subjs w CNV	0.1773	0.1628	1.05E-02	0.0412	0.0370	1.52E-01	0.0189	0.0166	2.00E-01	0.0055	0.0041	1.99E-01
100 kb or	containing	Genes/CNV	0.7183	0.7074	3.75E-01	0.1294	0.1420	7.78E-01	0.2097	0.1656	1.08E-01	0.0931	0.0457	4.65E-02
lonaer)		Genes/CNV kb	0.0099	0.0098	5.26E-01	0.0120	0.0131	8.92E-01	0.0113	0.0116	3.72E-01	0.0100	0.0079	1.66E-01
J . ,		CNVs/subj	0.1754	0.1683	1.04E-01	0.0410	0.0364	1.14E-01	0.0189	0.0169	2.42E-01	0.0055	0.0041	1.98E-01
	Exon-	Subjs w CNV	0.1635	0.1532	3.00E-02	0.0403	0.0358	1.20E-01	0.0189	0.0166	2.04E-01	0.0055	0.0041	1.98E-01
	containing	Genes/CNV	3.8760	3.6940	2.74E-01	0.6983	0.7495	7.04E-01	1.3940	1.0450	6.54E-02	0.6121	0.3052	5.56E-02
		Genes/CNV kb	0.0477	0.0468	4.62E-01	0.0586	0.0673	9.18E-01	0.0742	0.0727	2.58E-01	0.0639	0.0525	2.02E-01
	Intronic	CNVs/subj	0.0151	0.0122	2.07E-01	0.0036	0.0027	3.55E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
	intronio	Subjs w CNV	0.0151	0.0119	1.70E-01	0.0036	0.0027	3.55E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
	ΔII	CNVs/subj	1.0150	0.9777	2.20E-03	0.2154	0.2009	3.30E-02						
		Subjs w CNV	0.5798	0.5744	1.87E-02	0.1865	0.1719	5.35E-03						
	Intorgonic	CNVs/subj	0.5062	0.4831	4.03E-03	0.1048	0.0921	6.90E-03						
	intergenic	Subjs w CNV	0.3692	0.3651	5.31E-02	0.0972	0.0868	1.01E-02						
		CNVs/subj	0.5087	0.4946	6.21E-02	0.1176	0.1155	3.03E-01						
	Gene-	Subjs w CNV	0.3791	0.3684	2.07E-02	0.1059	0.1049	3.14E-01						
Short (<	containing	Genes/CNV	0.8919	0.8518	3.55E-02	0.2109	0.1947	1.50E-01						
100 kb)		Genes/CNV kb	0.0281	0.0286	6.02E-01	0.0329	0.0346	6.85E-01						
		CNVs/subj	0.3299	0.3097	2.99E-02	0.0893	0.0851	2.52E-01						
	Exon-	Subjs w CNV	0.2697	0.2522	5.55E-03	0.0808	0.0782	3.01E-01						
	containing	Genes/CNV	2.1270	1.9440	5.15E-02	0.5422	0.5066	3.49E-01						
		Genes/CNV kb	0.0558	0.0535	3.14E-01	0.0670	0.0685	7.92E-01						
	Intronio	CNVs/subj	0.1787	0.1849	4.91E-01	0.0351	0.0386	7.09E-01						
	intronic	Subjs w CNV	0.1616	0.1641	3.22E-01	0.0337	0.0377	7.47E-01						

						B. Duplic	ations							
Type of Dup	Type of	Tostad offect		All (< 1%)			Singleton CN	lVs		<mark>> 500 kb CN</mark>	Vs	-	> 1 Mb CN	/s
Type of Dup	CNV	Tested effect	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value
	A 11	CNVs/subj	0.4960	0.4763	1.18E-01	0.0863	0.0753	3.16E-02	0.0720	0.0712	6.49E-01	0.0161	0.0155	5.99E-01
		Subjs w CNV	0.3678	0.3630	4.09E-01	0.0779	0.0700	6.29E-02	0.0678	0.0684	7.35E-01	0.0157	0.0152	6.00E-01
	Intergonic	CNVs/subj	0.0867	0.0791	9.35E-02	0.0225	0.0184	7.17E-02	0.0076	0.0066	4.14E-01	0.0012	0.0005	1.74E-01
	intergenic	Subjs w CNV	0.0818	0.0747	1.06E-01	0.0218	0.0180	7.37E-02	0.0076	0.0066	4.14E-01	0.0012	0.0005	1.74E-01
		CNVs/subj	0.4093	0.3972	2.20E-01	0.0702	0.0651	2.11E-01	0.0644	0.0646	6.92E-01	0.0149	0.0151	7.04E-01
	Gene-	Subjs w CNV	0.3161	0.3129	4.32E-01	0.0633	0.0614	4.17E-01	0.0614	0.0620	7.15E-01	0.0145	0.0148	7.09E-01
Long (> 100	containing	Genes/CNV	2.4920	2.5020	5.27E-01	0.2901	0.2750	4.60E-01	0.7848	0.8495	7.81E-01	0.3318	0.3714	7.38E-01
kb or longer)		Genes/CNV kb	0.0172	0.0181	9.41E-01	0.0161	0.0171	8.48E-01	0.0122	0.0131	6.64E-01	0.0130	0.0137	5.28E-01
		CNVs/subj	0.4057	0.3948	2.47E-01	0.0694	0.0647	2.44E-01	0.0644	0.0646	6.91E-01	0.0149	0.0151	7.08E-01
	Exon-	Subjs w CNV	0.3135	0.3118	5.08E-01	0.0628	0.0611	4.32E-01	0.0614	0.0620	7.13E-01	0.0145	0.0148	7.13E-01
	containing	Genes/CNV	15.3200	15.0900	4.12E-01	1.6930	1.6330	5.53E-01	5.4280	5.9070	7.69E-01	2.3660	2.6810	7.37E-01
		Genes/CNV kb	0.0954	0.0961	5.93E-01	0.0889	0.0957	8.91E-01	0.0846	0.0889	5.62E-01	0.0922	0.0997	5.50E-01
	Intronic	CNVs/subj	0.0036	0.0024	1.02E-01	0.0017	0.0012	2.86E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
	Intronic	Subjs w CNV	0.0036	0.0024	1.02E-01	0.0017	0.0012	2.86E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
	A 11	CNVs/subj	0.6702	0.7015	7.80E-01	0.1715	0.1773	6.21E-01						
	All	Subjs w CNV	0.4616	0.4582	1.24E-01	0.1517	0.1471	1.17E-01						
	Intorgonio	CNVs/subj	0.2524	0.2655	7.32E-01	0.0706	0.0696	2.29E-01						
	intergenic	Subjs w CNV	0.2164	0.2199	3.59E-01	0.0677	0.0628	4.89E-02						
		CNVs/subj	0.4178	0.4360	7.22E-01	0.1069	0.1133	8.21E-01						
	Gene-	Subjs w CNV	0.3237	0.3189	1.48E-01	0.0965	0.0978	5.40E-01						
Short (< 100	containing	Genes/CNV	0.9334	0.9953	8.76E-01	0.2285	0.2372	6.74E-01						
kb)		Genes/CNV kb	0.0339	0.0334	4.64E-01	0.0326	0.0338	7.50E-01	_					
		CNVs/subj	0.3446	0.3645	8.29E-01	0.0898	0.0973	8.93E-01						
	Exon-	Subjs w CNV	0.2756	0.2748	3.36E-01	0.0815	0.0845	7.22E-01						
	containing	Genes/CNV	3.5150	3.6340	7.19E-01	0.8014	0.8504	7.56E-01						
		Genes/CNV kb	0.1089	0.1020	1.78E-01	0.0937	0.1027	9.13E-01						
	Intronic	CNVs/subj	0.0732	0.0715	2.28E-01	0.0192	0.0220	8.13E-01						
		Subjs w CNV	0.0701	0.0667	1.16E-01	0.0190	0.0217	8.09E-01						

Shown are results of global burden analyses of deletions and of duplications in cases vs. controls for all CNVs in each class (genic, exonic, intronic and intergenic CNVs) and then separately for CNVs < 100 kb and > 100 kb, with secondary analyses for singleton CNVs (occurring only once in this entire dataset), CNVs > 500 kb and CNVs > 1000 kb. All tests are one-sided permutations based on the assumption of increased CNV burden in cases. CNVs/subj, average number of CNVs per subject; Subjs w CNV, proportion of subjects with at least one CNV; Genes/CNV, number of genes spanned per CNV; Genes/CNV kb, number of genes per total CNV kb.

Table S8. Results of multiple linear regressions.

					A. Deletions	5				
Type of	Type of	Tostod offost	All (<	1%)	Singletor	n CNVs	>500kb	CNVs	>1Mb (CNVs
Deletion	CNV	Testeu effect	NSEG p value	KB p value						
		Sex	6.49E-01	5.86E-01	5.42E-01	4.95E-01	3.71E-01	2.04E-01	3.87E-01	1.56E-01
	All	Phenotype	4.84E-01	3.66E-01	1.92E-01	6.93E-01	3.55E-01	2.20E-01	1.26E-01	2.10E-01
		Batch	6.29E-07	4.66E-04	8.77E-07	3.74E-06	2.83E-01	3.92E-01	1.91E-01	1.67E-01
	Cama	Sex	6.76E-01	5.28E-01	2.36E-01	2.56E-01	6.91E-01	3.61E-01	5.20E-01	2.10E-01
	Gene-	Phenotype	2.17E-01	2.75E-01	2.97E-01	5.53E-01	4.52E-01	3.44E-01	2.81E-01	3.68E-01
	containing	Batch	4.69E-04	2.30E-02	1.88E-07	8.42E-08	1.44E-01	5.39E-01	2.73E-01	3.56E-01
المعم	Fyan	Sex	8.91E-01	6.78E-01	3.25E-01	2.58E-01	6.91E-01	3.61E-01	5.20E-01	2.10E-01
LONG	EXON-	Phenotype	3.15E-01	3.12E-01	2.50E-01	4.30E-01	4.52E-01	3.44E-01	2.81E-01	3.68E-01
(>100KD)	containing	Batch	2.90E-03	5.16E-02	1.48E-07	2.08E-07	1.44E-01	5.39E-01	2.73E-01	3.56E-01
		Sex	4.36E-02	6.38E-02	2.09E-01	1.79E-01	NA	NA	NA	NA
	Intronic	Phenotype	3.28E-01	4.58E-01	4.94E-01	9.14E-01	NA	NA	NA	NA
		Batch	7.73E-03	1.77E-03	2.19E-01	1.90E-01	NA	NA	NA	NA
		Sex	2.35E-01	9.63E-01	4.47E-01	6.55E-01	1.25E-01	1.85E-01	4.50E-01	4.52E-01
	Intergenic	Phenotype	7.10E-01	8.67E-01	2.21E-01	4.45E-01	5.17E-01	2.80E-01	1.35E-01	1.74E-01
		Batch	1.32E-04	5.79E-05	5.73E-02	4.51E-01	3.65E-02	3.84E-02	2.97E-02	5.32E-02
		Sex	2.27E-04	1.91E-02	1.21E-01	7.20E-01				
	All	Phenotype	2.28E-01	5.04E-02	2.25E-01	4.29E-02				
		Batch	0.00E+00	1.59E-161	3.81E-68	1.82E-22				
		Sex	5.15E-03	9.24E-03	4.41E-01	3.85E-01	•			
	Gene-	Phenotype	6.34E-01	1.64E-01	8.82E-01	2.97E-01				
	containing	Batch	1.11E-208	5.36E-69	6.77E-34	9.57E-10				
		Sex	1.19E-03	1.22E-03	3.38E-01	4.22E-01	•			
Short	Exon-	Phenotype	2 41F-01	7 38F-02	6 46F-01	2 88F-01				
(<100kb)	containing	Batch	6 30E-120	7 74F-44	4 24F-22	1 11E-06				
		Sov	7.66E-01	6 20E-01	7 17E-01	9.56E-01				
	Intropic	Phonotypo	2 02E 01	7 09E 01	2 415 01	0.00E 01				
	Intronic	Phenotype	3.03L-01	7.00L-01	3.4 IL-01	0.23L-01				
		Batch	3.4 IE-109	2.29E-31	4.80E-20	7.04E-00				
		Sex	9.42E-03	5.3/E-01	1.10E-01	6.51E-01				
	Intergenic	Phenotype	1.83E-01	1.39E-01	4.95E-02	3.70E-02				
		Batch	4.67E-316	1.52E-113	2.96E-49	6.21E-18				

					B. Duplication	15				
Type of	Type of	Tested	All (<	1%)	Singletor	n CNVs	>500kb	CNVs	>1Mb (NVs
Duplication	CNV	effect	NSEG p value	KB p value	NSEG p value	KB p value	NSEG p value	KB p value	NSEG p value	KB p value
		Sex	6.80E-01	3.61E-01	5.20E-01	1.77E-01	1.34E-01	1.11E-01	3.53E-01	3.10E-01
	All	Phenotype	2.11E-01	4.63E-01	5.80E-02	2.48E-01	8.91E-01	8.37E-01	9.50E-01	7.03E-01
		Batch	5.58E-04	9.13E-08	1.02E-03	7.19E-04	1.86E-07	1.45E-08	1.29E-04	4.34E-05
	Gene-	Sex	5.07E-01	4.16E-01	3.07E-01	6.86E-02	1.80E-01	2.10E-01	4.05E-01	4.58E-01
	containing	Phenotype	4.47E-01	8.51E-01	4.01E-01	9.17E-01	7.56E-01	7.83E-01	7.96E-01	8.16E-01
	containing	Batch	9.30E-04	6.35E-05	1.02E-02	2.52E-03	7.21E-07	1.24E-05	3.10E-03	2.18E-02
Long	Evon-	Sex	5.06E-01	4.26E-01	3.59E-01	1.20E-01	1.80E-01	2.10E-01	4.05E-01	4.58E-01
(>100kb)	containing	Phenotype	5.01E-01	8.67E-01	4.52E-01	9.67E-01	7.56E-01	7.83E-01	7.96E-01	8.16E-01
(>100kb)	containing	Batch	1.06E-03	6.87E-05	7.90E-03	4.11E-03	7.21E-07	1.24E-05	3.10E-03	2.18E-02
		Sex	9.89E-01	6.67E-01	6.86E-01	5.53E-01	NA	NA	NA	NA
	Intronic	Phenotype	2.07E-01	6.31E-01	4.85E-01	4.58E-01	NA	NA	NA	NA
		Batch	8.96E-01	7.82E-01	5.92E-01	5.93E-01	NA	NA	NA	NA
		Sex	5.70E-01	6.46E-01	7.38E-01	8.21E-01	4.54E-01	2.20E-01	6.04E-01	3.80E-01
	Intergenic	Phenotype	1.15E-01	1.09E-01	1.28E-01	2.44E-01	6.10E-01	1.90E-01	1.58E-01	1.06E-01
		Batch	1.70E-05	1.10E-08	1.43E-02	2.10E-02	5.38E-03	6.70E-07	1.51E-04	3.28E-07
		Sex	3.77E-01	1.78E-01	2.73E-01	3.59E-01				
	All	Phenotype	1.29E-01	2.66E-01	6.41E-01	9.75E-01				
		Batch	1.01E-160	1.31E-57	3.90E-31	2.94E-12				
	0	Sex	3.68E-01	2.64E-01	9.79E-01	9.75E-01				
	Gene-	Phenotype	2.70E-01	5.89E-01	3.27E-01	7.49E-01				
	containing	Batch	1.15E-89	2.44E-27	1.42E-20	5.05E-07				
. .	_	Sex	4.68E-01	3.38E-01	6.01E-01	7.24E-01				
Short	Exon-	Phenotype	1.61E-01	4.40E-01	1.80E-01	5.15E-01				
(<100kd)	containing	Batch	5.74E-77	1.72E-24	1.78E-18	2.98E-06				
-		Sex	4.76E-01	3.95E-01	1.41E-01	2.43E-01				
	Intronic	Phenotype	6.33E-01	4.40E-01	4.09E-01	5.49E-01				
		Batch	1.11E-26	1.47E-08	7.18E-03	3.04E-01				
		Sex	7.17E-01	3.89E-01	9.45E-02	1.15E-01				
	Intergenic	Phenotype	2.03E-01	1.72E-01	6.02E-01	5.31E-01				
	Ū	Batch	4.39E-110	4.36E-46	2.13E-16	1.62E-07				

Shown are results of multiple linear regressions to evaluate the potential confounding effect by using total CNV number or length as dependent variable and case/control status, batch, and sex as independent variables. Analyses were conducted separately for deletions and duplications, for longer and shorter (<100kb) CNVs, for all CNVs, and those overlapping with at least one gene, and those overlapping with at least one exon. Only rare CNVs were used. P values surviving FDR correction (< 0.05) are in red.

Table S9. Global burden analyses of CNVs in down-sampled dataset.

						A. I	Deletions							
Type of		- Tostad affast		All (< 1%)		- 9	Singleton CN	IVs		> 500 kb CN	Vs		> 1 Mb CNV	/s
Del	Type of Civi	lested effect	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value
	A.II.	CNVs/subj	0.3283	0.3101	1.00E-01	0.0829	0.0768	2.03E-01	0.0225	0.0210	3.68E-01	0.0062	0.0049	3.07E-01
	All	Subjs w CNV	0.2851	0.2626	2.27E-02	0.0798	0.0728	1.51E-01	0.0222	0.0207	3.67E-01	0.0062	0.0049	3.07E-01
	Internetie	CNVs/subj	0.1332	0.1338	5.42E-01	0.0324	0.0296	2.88E-01	0.0022	0.0025	6.96E-01	0.0012	0.0000	6.30E-02
	Intergenic	Subjs w CNV	0.1245	0.1270	6.34E-01	0.0321	0.0287	2.35E-01	0.0022	0.0025	6.96E-01	0.0012	0.0000	6.30E-02
		CNVs/subj	0.1951	0.1763	4.16E-02	0.0604	0.0536	1.38E-01	0.0204	0.0185	3.28E-01	0.0049	0.0049	5.69E-01
lona (>	Gene-	Subjs w CNV	0.1809	0.1600	1.37E-02	0.0586	0.0524	1.53E-01	0.0204	0.0182	2.93E-01	0.0049	0.0049	5.69E-01
100 kb	containing	Genes/CNV	0.7793	0.7226	2.38E-01	0.1637	0.1936	8.28E-01	0.2549	0.1899	1.54E-01	0.1174	0.0647	1.26E-01
or		Genes/CNV kb	0.0102	0.0097	2.14E-01	0.0103	0.0106	6.00E-01	0.0131	0.0119	3.33E-01	0.0131	0.0098	1.87E-01
longer)		CNVs/subj	0.1825	0.1649	4.75E-02	0.0583	0.0515	1.31E-01	0.0204	0.0185	3.25E-01	0.0049	0.0049	5.71E-01
	Exon-	Subjs w CNV	0.1699	0.1510	2.15E-02	0.0570	0.0506	1.35E-01	0.0204	0.0182	2.91E-01	0.0049	0.0049	5.71E-01
	containing	Genes/CNV	4.2240	3.7410	1.80E-01	0.9041	0.9439	5.91E-01	1.6740	1.1740	1.24E-01	0.7380	0.4405	1.82E-01
		Genes/CNV kb	0.0493	0.0453	1.78E-01	0.0519	0.0520	5.00E-01	0.0856	0.0711	2.25E-01	0.0797	0.0663	3.20E-01
	Induce a la	CNVs/subj	0.0126	0.0114	3.70E-01	0.0049	0.0052	6.34E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
	Intronic	Subjs w CNV	0.0126	0.0108	2.81E-01	0.0049	0.0052	6.34E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
	A 11	CNVs/subj	0.9846	0.9202	8.95E-03	0.2965	0.2700	6.13E-02						
	All	Subjs w CNV	0.5746	0.5524	2.81E-02	0.2432	0.2260	4.86E-02						
	Intergenic	CNVs/subj	0.4867	0.4562	3.77E-02	0.1430	0.1292	7.23E-02						
	Intergenie	Subjs w CNV	0.3634	0.3471	7.40E-02	0.1307	0.1190	7.92E-02						
		CNVs/subj	0.4978	0.4639	4.62E-02	0.1603	0.1470	1.74E-01						
	Gene-	Subjs w CNV	0.3739	0.3502	2.10E-02	0.1381	0.1344	3.42E-01						
Short (<	containing	Genes/CNV	0.8/11	0.7879	2.53E-02	0.2855	0.2401	6.11E-02						
100 KD)		Genes/CINV KD	0.0275	0.0272	4.05E-01	0.0315	0.0318	5.45E-01						
	Fuen	CNVS/SUDJ	0.3227	0.2925	3.24E-02	0.1190	0.1054	1.33E-01						
	EXON-		0.2030	0.2420	2.33E-02	0.1039	0.0990	2.99E-01 2.50E-02						
	containing	Genes/CNV kh	0.0549	0.0523	2 40F-01	0.7472	0.0500	2.09L-02 3.47F-01						
		CNVs/subi	0.1751	0.1714	3 72F-01	0.0487	0.0484	5.94E-01						
	Intronic	Subjs w CNV	0.1591	0.1535	2.76E-01	0.0466	0.0469	5.50E-01						

Zhang et al.

						B. Dup	lications							
Type of	Type of CNV	Tostod offect		All (< 1%)		S	ingleton CN	Vs		<mark>> 500 kb CN</mark>	Vs		> 1 Mb CN\	ls
Dup	Type of Civi	Testeu enect	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value
	A II	CNVs/subj	0.4790	0.5003	8.50E-01	0.1178	0.1264	8.29E-01	0.0678	0.0731	7.96E-01	0.0160	0.0179	7.48E-01
	All	Subjs w CNV	0.3607	0.3721	8.35E-01	0.1054	0.1134	8.60E-01	0.0638	0.0700	8.53E-01	0.0157	0.0176	7.54E-01
	Intergonic	CNVs/subj	0.0823	0.0839	6.00E-01	0.0299	0.0277	3.31E-01	0.0071	0.0068	4.98E-01	0.0009	0.0006	5.02E-01
	Intergenic	Subjs w CNV	0.0768	0.0792	6.61E-01	0.0290	0.0268	3.24E-01	0.0071	0.0068	4.98E-01	0.0009	0.0006	5.02E-01
		CNVs/subj	0.3967	0.4165	8.52E-01	0.0946	0.1067	9.23E-01	0.0607	0.0663	8.22E-01	0.0151	0.0173	7.82E-01
Long (>	Gene-	Subjs w CNV	0.3132	0.3187	6.92E-01	0.0848	0.0983	9.74E-01	0.0583	0.0632	8.11E-01	0.0148	0.0170	7.89E-01
100 kb	containing	Genes/CNV	2.5020	2.7340	8.34E-01	0.3995	0.5000	9.46E-01	0.8086	0.9695	8.65E-01	0.3708	0.4454	7.39E-01
or		Genes/CNV kb	0.0179	0.0178	4.16E-01	0.0153	0.0176	9.50E-01	0.0127	0.0141	8.25E-01	0.0140	0.0139	4.94E-01
longer)		CNVs/subj	0.3930	0.4137	8.64E-01	0.0928	0.1057	9.41E-01	0.0607	0.0663	8.23E-01	0.0151	0.0173	7.80E-01
	Exon-	Subjs w CNV	0.3110	0.3172	7.12E-01	0.0835	0.0977	9.79E-01	0.0583	0.0632	8.11E-01	0.0148	0.0170	7.86E-01
	containing	Genes/CNV	15.2500	16.7100	8.14E-01	2.2780	2.9420	9.56E-01	5.6890	6.8400	8.67E-01	2.6820	3.2410	7.49E-01
		Genes/CNV kb	0.0989	0.0955	2.41E-01	0.0809	0.0979	9.80E-01	0.0902	0.0978	7.61E-01	0.1015	0.1025	5.21E-01
	Intronic	CNVs/subj	0.0037	0.0028	3.29E-01	0.0022	0.0015	3.88E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
	Intronic	Subjs w CNV	0.0037	0.0028	3.29E-01	0.0022	0.0015	3.88E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
	All	CNVs/subj	0.6510	0.6609	6.63E-01	0.2263	0.2420	8.69E-01						
	All	Subjs w CNV	0.4553	0.4448	1.99E-01	0.1924	0.1961	6.59E-01						
	Intergenic	CNVs/subj	0.2478	0.2408	3.00E-01	0.0925	0.0863	2.27E-01						
	Intergenite	Subjs w CNV	0.2118	0.2065	3.10E-01	0.0863	0.0798	1.84E-01						
		CNVs/subj	0.4032	0.4202	8.17E-01	0.1384	0.1618	9.82E-01						
Ch+ /	Gene-	Subjs w CNV	0.3200	0.3113	2.32E-01	0.1224	0.1335	9.16E-01						
500rt (<	containing	Genes/CNV kb	0.9084	0.9701	8.63E-UI	0.3110	0.3419	8.55E-01						
100 KD)		CNVs/subi	0.0320	0.0325	4.10L-01	0.0332	0.1250	0.501-01						
	Exon-	Subis w CNV	0.3332	0.3499	3.07E-01	0.1101	0.1359	9.04L-01 8.82F-01						
	containing	Genes/CNV	3.5310	3.6040	6.07E-01	1.1200	1.1820	6.81E-01						
		Genes/CNV kb	0.1120	0.1001	2.89E-02	0.1018	0.1026	5.27E-01						
	Intronio	CNVs/subj	0.0700	0.0703	5.36E-01	0.0219	0.0290	9.66E-01						
	Intronic	Subjs w CNV	0.0681	0.0650	3.25E-01	0.0210	0.0284	9.77E-01						

Shown are results of global burden analysis on down-sampled dataset consisting of 6,488 subjects in which there were equal number of male cases, male controls, female cases and female controls within each cohort.

21

Supplement

Table S10. Manually checked genes and regions with stratified permutation test and CMH test P < 0.01.

• 、

Gene	Chr	Start	End	Comb_Case	Comb_Cont	EMP p-value	CMH OR	CMH p-value	RADIANT case	RADIANT Cont	GR Illum case	GR Illum Cont	GR Affy case	GR Affy Cont	Neth case	Neth Cont	Plot check	RADIANT cov	GR Illum cov	Affy cov	Rare region	Prop test p-value	VALID
							PASSED QC																
MSR1	8	15,965,386	16,050,300	55	32	2.05E-03	1.96	1.93E-03	23	10	6	3	15	10	11	9	+	Y	Y	Y	Y	5.68E-02	Y
								FA	ILED (2C		~											
NEU4	2	242,750,159	242,758,739	12	2	4.59E-03	6.53	4.89E-03	12	2	0	0	0	0	0	0	+	Y	Y	Y	Ν	1.38E-04	Ν
LOC93622	4	6,675,820	6,677,774	25	3	7.00E-05	7.60	6.96E-05	0	0	25	3	0	0	0	0	-	Y	Υ	Y	Y	8.65E-39	Ν
PRKN	6	161,768,589	163,148,834	29	16	1.63E-02	2.03	1.72E-02	15	9	3	3	4	2	7	2	+	Y	Υ	Y	Y	3.44E-01	Ν
LOC441242	7	64,600,748	65,235,797	7	0	4.55E-03	Inf	4.34E-03	1	0	0	0	3	0	3	0	+	Υ	Υ	Υ	Ν	1.60E-01	Ν
PEMT	17	17,408,876	17,495,017	16	0	2.00E-05	Inf	1.20E-05	16	0	0	0	0	0	0	0	-	Y	Υ	Y	Υ	3.40E-05	Ν

(continues on next page)

Zhang et al.

Zhang et al.

Supplement

B. Duplications in genes (exonic)

Gene	Chr	Start	End	Comb_Case	Comb_Cont	EMP p-value	CMH OR	CMH p-value	RADIANT case	RADIANT Cont	GR Illum case	GR Illum Cont	GR Affy case	GR Affy Cont	Neth case	Neth Cont	Plot check	RADIANT cov	GR Illum cov	GR Affy cov	Rare region	Prop test p-value	VALID
								PASSED QC	;						7								
TUBGCP5	15	22,833,394	22,873,891	24	7	7.80E-04	3.88	7.58E-04	7	3	11	0	2	1	4	3	+	Y	Υ	Y	Y	2.32E-03	Y
CYFIP1	15	22,892,648	23,003,603	24	7	7.80E-04	3.88	7.58E-04	7	3	11	0	2	1	4	3	+	Y	Y	Y	Y	4.28E-03	Y
NIPA2	15	23,004,683	23,034,427	24	7	8.60E-04	3.88	7.58E-04	7	3	11	0	2	1	4	3	+	Y	Y	Y	Y	4.28E-03	Y
NIPA1	15	23,043,278	23,086,843	24	7	6.70E-04	3.88	7.58E-04	7	3	11	0	2	1	4	3	+	Y	Y	Y	Y	4.28E-03	Y
								FAILED QC) (
NBPF1	1	16,888,921	16,940,100	54	40	9.07E-03	1.70	8.21E-03	0	0	5	1	11	15	38	24	+	Ν	Υ	Y	Ν	1.26E-20	Ν
CROCCP2	1	16,944,750	16,957,401	57	41	4.22E-03	1.77	4.17E-03	0	0	5	1	12	15	40	25	+	Ν	Y	Y	Ν	9.36E-22	Ν
TM4SF20	2	228,226,873	228,244,022	91	63	2.73E-03	1.67	2.68E-03	1	0	90	63	0	0	0	0	+	Low	Y	Low	Ν	2.59E-213	Ν
HLA-DQA1	6	32,605,182	32,611,429	25	10	7.30E-03	2.69	7.09E-03	0	1	25	9	0	0	0	0	-	Low	Y	Low	Ν	2.18E-45	Ν
PRH1-PRR4	12	10,998,447	11,324,224	31	13	4.72E-03	2.53	4.36E-03	0	0	31	12	0	0	0	1	?	Low	Y	Y	Ν	6.05E-58	Ν
PRH1	12	11,033,559	11,324,222	31	13	4.21E-03	2.53	4.36E-03	0	0	31	12	0	0	0	1	?	Low	Y	Y	Ν	6.05E-58	Ν
TAS2R46	12	11,213,963	11,214,893	31	12	2.58E-03	2.74	2.59E-03	0	0	31	12	0	0	0	0	?	Low	Y	Y	Ν	1.03E-59	Ν
TAS2R43	12	11,243,885	11,244,912	31	12	2.69E-03	2.74	2.59E-03	0	0	31	12	0	0	0	0	?	Low	Y	Y	Ν	1.03E-59	Ν
RASA3	13	114,747,193	114,898,095	30	9	2.00E-04	3.81	1.65E-04	26	8	1	1	3	0	0	0	-	Y	Y	Y	Y	7.37E-08	Ν
ZFYVE1	14	73,436,152	73,493,920	3	0	3.86E-02	Inf	3.98E-02	1	0	0	0	1	0	1	0	+	Y	Y	Y	Y	8.30E-01	Ν
ASPG	14	104,552,022	104,579,046	24	3	8.00E-05	7.63	5.24E-05	23	3	0	0	0	0	1	0	+	Y	Y	Low	Y	1.38E-07	Ν
MIR203A	14	104,583,741	104,583,851	24	3	8.00E-05	7.63	5.24E-05	23	3	0	0	0	0	1	0	+	Y	Y	Low	Y	1.38E-07	Ν
MIR203B	14	104,583,754	104,583,840	24	3	5.00E-05	7.63	5.24E-05	23	3	0	0	0	0	1	0	+	Y	Y	Low	Y	1.38E-07	Ν
KIF26A	14	104,605,059	104,647,235	23	3	1.20E-04	7.26	9.69E-05	23	3	0	0	0	0	0	0	+	Y	Y	Low	Y	2.84E-08	Ν
GOLGA8DP	15	22,702,284	22,715,728	9	1	8.34E-03	10.36	8.25E-03	0	0	6	0	2	0	1	1	+	Y	Y	Y	Y	1.41E-04	Ν
GOLGA6L1	15	22,736,245	22,746,002	9	1	8.80E-03	10.36	8.25E-03	0	0	6	0	2	0	1	1	+	Y	Y	Y	Y	1.41E-04	Ν
GOLGA6L22	15	22,736,267	22,746,002	9	1	8.04E-03	10.36	8.25E-03	0	0	6	0	2	0	1	1	+	Y	Y	Y	Y	1.41E-04	Ν
LOC283683	15	23,094,330	23,115,254	24	6	4.10E-04	4.49	3.56E-04	7	2	11	0	2	1	4	3	+	Y	Y	Y	Y	2.79E-03	Ν
WHAMMP3	15	23,187,728	23,208,357	20	5	8.70E-04	4.59	9.93E-04	4	1	11	0	2	1	3	3	+	Y	Y	Y	Y	1.31E-04	Ν
HERC2P2	15	23,282,264	23,378,259	13	3	4.80E-03	5.33	4.88E-03	0	0	9	0	2	1	2	2	+	Y	Y	Y	Y	3.13E-06	Ν
ERVV-1	19	53,517,343	53,519,833	85	66	5.71E-03	1.59	5.92E-03	4	3	80	61	0	1	1	1	+	Y	Y	Y	Ν	5.40E-181	Ν
LILRB3	19	54,720,146	54,746,711	77	47	4.70E-04	1.95	3.92E-04	20	7	48	33	6	3	3	4	+	Y	Y	Y	Ν	9.74E-63	Ν
TPTE	21	10,906,186	10,990,943	60	29	1.00E-05	3.30	2.46E-07	0	0	3	4	57	25	0	0	-	Ν	Y	Y	Ν	5.94E-74	Ν

(continues on next page)

Zhang et al.

Supplement

C. Deletions in CNV regions

Region	Comb Case	Comb cont	EMP p-value	CMH OR	CMH p-value	ADIANT case	ADIANT cont	GR Affy case	3R Affy cont	sR Illum case	SR Illum cont	Neth case	Neth cont	Plot check	RADIANT cov	Affy cov	GR Illum cov	Rare region	Prop test p-value	VALID
					0	≥ P∆9	SED C		<u> </u>	0	0			7	Ľ.		Ŭ			
chr6:162 136 159-163 489 668	65	40	8 90F-04	1 92	9 74F-04	33	17	10	11	9	5	13	7	+	Y	Y	Y	Y	2 02F-01	V
chr6:162,177,023-163,489,668	65	40	9.50E-04	1.92	9 74F-04	33	17	10	11	9	5	13	7	+	Ŷ	Ŷ	Ŷ	Ŷ	2.02E 01 2.02E-01	Ý
chr6:162 804 504-164 033 649	55	35	3.66E-03	1.84	3.63E-03	26	11	9	10	8	4	12	10	+	Ŷ	Ŷ	Ŷ	Ŷ	8 02F-01	Ŷ
chr8:15 817 196-16 045 585	58	33	9.50E-04	2.03	9 74F-04	24	10	17	11	6	3	11	9	+	Ŷ	Ŷ	Ŷ	Ŷ	1 15E-02	Ŷ
chr8:15.817.196-16.092.656	59	33	8.10E-04	2.05	7.45E-04	24	10	18	11	6	3	11	9	+	Ŷ	Ŷ	Ŷ	Ŷ	6.03E-03	Ŷ
						FAI	LED Q	C		Č										
chr1:106,307,942-106,367,506	23	2	1.00E-05	14.71	1.89E-06	0	0	0	0	20	0	3	2	-	Ν	Y	Y	Y	5.61E-21	Ν
chr1:106,327,837-106,371,203	20	0	1.00E-05	Inf	1.66E-07	0	0	0	0	20	0	0	0	-	Ν	Y	Y	Y	1.13E-27	Ν
chr2:57,270,600-57,595,408	7	0	2.82E-03	Inf	2.96E-03	2	0	1	0	2	0	2	0	+	Y	Y	Y	Y	6.86E-01	Ν
chr2:89,141,311-90,403,624	13	1	4.70E-04	16.51	4.25E-04	0	0	0	0	13	1	0	0	?	Ν	Ν	Y	Ν	2.28E-19	Ν
chr4:36,894,737-36,936,789	21	5	7.10E-04	4.74	7.26E-04	0	0	10	1	9	3	2	1	+	Y	Y	Y	Y	3.03E-09	Ν
chr4:6,618,624-6,652,800	25	5	4.70E-04	4.75	4.71E-04	0	0	0	0	25	4	0	1	-	Y	Y	Y	Y	1.93E-38	Ν
chr4:6,627,084-6,687,545	25	5	6.00E-04	4.75	4.71E-04	0	0	0	0	25	4	0	1	-	Y	Y	Y	Y	1.93E-38	Ν
chr4:186,394,634-186,421,724	14	4	5.91E-03	4.27	5.52E-03	0	0	2	2	0	0	12	2	+	Low	Y	Y	Y	1.03E-05	Ν
chr8:14,802,942-14,825,833	5	0	4.15E-02	Inf	4.21E-02	1	0	2	0	1	0	1	0	+	Y	Y	Y	Y	5.34E-01	Ν
chr15:94,779,085-94,829,625	15	6	1.27E-02	3.16	1.29E-02	10	2	1	3	2	1	2	0	+	Y	Y	Y	Y	2.61E-01	Ν
chr17:17,400,972-17,444,638	16	0	2.00E-05	Inf	1.20E-05	16	0	0	0	0	0	0	0	-	Y	Y	Y	Y	3.40E-05	Ν
chr20:14,569,942-15,082,546	84 (83)	66	6.22E-03	1.55	5.84E-03	30	19	13	13	18	13	23	21	+	Y	Ŷ	Ŷ	Ν	4.00E-02	Ν
chr20:14,569,942-15,100,284	84 (83)	67	7.81E-03	1.52	7.80E-03	30	20	13	13	18	13	23	21	+	Y	Ŷ	Y	N	4.88E-02	N
chr20:14,569,942-15,170,143	84 (83)	67	8.28E-03	1.52	7.80E-03	30	20	13	13	18	13	23	21	+	Y	Ŷ	Ŷ	N	4.88E-02	N
chr20:14,569,942-15,107,038	84 (83)	6/	8.50E-03	1.52	7.80E-03	30	20	13	13	18	13	23	21	+	Y	Ŷ	Ŷ	N	4.88E-02	N
CNF2U: 14, / 14, 45 / - 15, 234, / 69	80 (79)	62	6.57E-03	1.57	5.96E-03	30	20	12	12	15	13	23	1/	+	Y	Ŷ	Ŷ	N	1.54E-01	N
CNF2U: 14,837,263-15,254,051	66 (65)	50	8.94E-03	1.62	8.25E-03	28	17		9		10	16	14	+	Ŷ	Ŷ	Ŷ	N	5.3/E-01	N
			K		(contin	nues	on n	ext p)age))										

Zhang et al.

					-	4	-		0											
Region	Comb Case	Comb cont	EMP p-value	CMH OR	CMH p-value	RADIANT case	RADIANT con	GR Affy case	GR Affy cont	GR Illum case	GR Illum cont	Neth case	Neth cont	Plot check	RADIANT cov	Affy cov	GR Illum cov	Rare region	Prop test p-value	VALID
						PASSE	ED QC							7						
chr6:106,549,398-107,026,323	6	0	6.06E-03	Inf	5.93E-03	2	0	1	0	0	0	3	0	+	Y	Y	Y	Y	5.88E-01	Y
chr15:22,652,330-23,309,294	24	7	7.80E-04	3.88	7.58E-04	7	3	2	1	11	0	4	3	+	Υ	Y	Y	Υ	2.32E-03	Y
						FAILE	D QC						1							
chr1:188,993,946-189,828,204	19	7	9.18E-03	2.98	9.33E-03	13	2	0	1	4	3	2	1	-	Y	Y	Y	Y	1.33E-02	Ν
chr1:188,993,946-189,870,893	19	7	9.45E-03	2.98	9.33E-03	13	2	0	1	4	3	2	1	-	Υ	Y	Y	Υ	1.33E-02	Ν
chr4:33,223,075-33,512,554	9	1	5.17E-03	11.08	5.14E-03	9	1	0	0	0	0	0	0	-	Υ	Y	Y	Υ	2.20E-03	Ν
chr6:27,601,587-28,004,982	25	13	9.36E-03	2.38	9.48E-03	1	1	5	5	9	5	10	2	+	Y	Y	Y	Y	2.34E-06	Ν
chr6:27,601,587-27,985,388	25	13	9.49E-03	2.38	9.48E-03	1	1	5	5	9	5	10	2	+	Υ	Y	Y	Υ	2.34E-06	Ν
chr7:6,065,194-6,518,359	2	0	7.13E-02	Inf	7.10E-02	0	0	1	0	1	0	0	0	+	Y	Y	Y	Y	2.10E-01	Ν
chr9:10,412,112-11,645,495	32	18	3.87E-03	2.34	3.78E-03	3	6	27	1	0	10	2	1	-	Υ	Y	Y	Y	1.64E-12	Ν
chr9:10,412,112-11,321,119	31	18	5.81E-03	2.24	6.05E-03	2	6	27	1	0	10	2	1	-	Y	Y	Y	Y	5.18E-13	Ν
chr12:129,153,544-129,581,856	20	11	3.32E-02	2.12	3.48E-02	11	6	-3	3	1	1	5	1	+	Y	Y	Y	Y	3.14E-01	Ν
chr13:114,576,614-115,108,397	35	14	6.80E-04	2.84	5.93E-04	28	12	3	0	2	2	2	0	-	Y	Y	Y	Y	1.13E-07	Ν
chr13:114,610,675-115,108,397	34	10	8.00E-05	3.86	5.58E-05	27	9	3	0	2	1	2	0	-	Υ	Y	Y	Y	6.65E-07	Ν
chr13:114,740,938-115,108,397	34	10	8.00E-05	3.86	5.58E-05	27	9	3	0	2	1	2	0	-	Y	Y	Y	Y	6.65E-07	Ν
chr14:104,478,511-104,640,011	24	3	6.00E-05	7.63	5.24E-05	23	3	0	0	0	0	1	0	+	Υ	Low	Y	Y	1.38E-07	Ν
chr18:50,127,781-50,166,065	4	0	4.84E-02	Inf	4.95E-02	2	0	1	0	1	0	0	0	+	Y	Y	Y	Y	6.33E-01	Ν

D. Duplications in CNV regions.

Shown are the numbers of CNVs in each gene or CNV region for all cohorts combined and also for each cohort with CMH p < 0.01 and permutation p < 0.01 for manual review, separately for deletions and duplications. Value in parentheses is the number of individuals carrying the CNV if it is not the same number as CNVs. All tests were stratified for batch and sex. Emp p-value = empirical (permutation-based) p-values. CMH = Cochrane-Mantel-Haenszel exact tests. OR = odds ratio. Inf = infinite, OR not calculable with 0 CNVs in cases. Prop test p-value = proportion test p-values. In column RADIANT cov, Affy cov, and GR Illum cov, Y = >10 probes on the genotyping platform, N = no probes, Low = Not enough probes. In column Rare region and VALID, Y = yes, N = no. "+" represents passing plot check; "-" failed; "?" unclear.

Table S11. Summary of number of CNV calls.

Cohort	CNV type	Total CNVs	CNVs/subject	Long (>100 kb)	Long CNVs/subject	Short (<100 kb)	Short CNVs/subject
	ALL	217,339	17.5189	53,133	4.2828	164,206	13.2360
	Deletions	155,636	12.5452	24,611	1.9838	131,025	10.5614
Combined	Duplications	61,703	4.9736	28,522	2.2990	33,181	2.6746
cohorts	RARE (<1%)	30,871	2.4884	10,005	0.8065	20,866	1.6819
	Deletions	16,326	1.3160	3,982	0.3210	12,344	0.9950
	Duplications	14,545	1.1724	6,023	0.4855	8,522	0.6869
	ALL	20,402	4.0424	8,239	1.6325	12,163	2.4099
	Deletions	11,095	2.1983	2,914	0.5774	8,181	1.6210
RADIANT	Duplications	9,307	1.8441	5,325	1.0551	3,982	0.7890
cohort	RARE (<1%)	8,293	1.6432	3,906	0.7739	4,387	0.8692
	Deletions	3,721	0.7373	1,455	0.2883	2,266	0.4490
	Duplications	4,572	0.9059	2,451	0.4856	2,121	0.4202
	ALL	88,641	25.4642	21,772	6.2545	66,869	19.2097
	Deletions	65,938	18.9423	9,721	2.7926	56,217	16.1497
NESDA/NTR	Duplications	22,703	6.5220	12,051	3.4619	10,652	3.0600
cohort	RARE (<1%)	10,190	2.9273	2,917	0.8380	7,273	2.0893
	Deletions	5,700	1.6375	1,158	0.3327	4,542	1.3048
	Duplications	4,490	1.2899	1,759	0.5053	2,731	0.7845
	ALL	54,841	24.8712	14,214	6.4463	40,627	18.4249
	Deletions	42,077	19.0825	8,051	3.6512	34,026	15.4313
GenRED	Duplications	12,764	5.7887	6,163	2.7950	6,601	2.9937
cohort	RARE (<1%)	6,074	2.7546	1,705	0.7732	4,369	1.9814
	Deletions	3,471	1.5741	771	0.3497	2,700	1.2245
	Duplications	2,603	1.1805	934	0.4236	1,669	0.7569
	ALL	53,455	31.9516	8,908	5.3246	44,547	26.6270
	Deletions	36,526	21.8326	3,925	2.3461	32,601	19.4866
GenRED-II	Duplications	16,929	10.1189	4,983	2.9785	11,946	7.1405
cohort	RARE (<1%)	6,314	3.7741	1,477	0.8828	4,837	2.8912
	Deletions	3,434	2.0526	598	0.3574	2,836	1.6952
	Duplications	2,880	1.7215	879	0.5254	2,001	1.1961

Zhang et al.

Supplement

Table S12. Logistic regression analyses of global burden of CNVs for each cohort.

								A. Del	etions								
Type of	Type of		RADIA	NT (<1%)		_	GenRE	D II (<1%)		_	GenR	ED (<1%)		-	NESDA/	NTR (<1%))
Dels	CNV	OR	2.50%	97.50%	p value	OR	2.50%	97.50%	p value	OR	2.50%	97.50%	p value	OR	2.50%	97.50%	p value
	All	1.0287	0.9270	1.1415	5.94E-01	1.1880	0.9973	1.4176	5.46E-02	1.0167	0.8726	1.1839	8.31E-01	0.9789	0.8712	1.0993	7.19E-01
Long	Genic	0.9699	0.8473	1.1096	6.57E-01	1.1486	0.9104	1.4510	2.44E-01	1.1131	0.9154	1.3530	2.82E-01	1.1370	0.9732	1.3282	1.05E-01
LUNY (\100kb)	Exonic	0.9371	0.8154	1.0761	3.58E-01	1.0951	0.8558	1.4027	4.71E-01	1.1561	0.9421	1.4182	1.64E-01	1.1660	0.9932	1.3691	6.05E-02
(>100KD)	Intronic	1.5676	0.9374	2.6645	9.00E-02	1.8301	0.8607	4.1014	1.26E-01	0.7676	0.3976	1.4456	4.19E-01	0.7474	0.3688	1.4535	4.00E-01
	Intergenic	1.1201	0.9522	1.3181	1.71E-01	1.2167	0.9451	1.5708	1.30E-01	0.8856	0.6938	1.1266	3.25E-01	0.8033	0.6700	0.9608	1.72E-02
	All	1.0490	0.9659	1.1394	2.56E-01	0.9958	0.9315	1.0646	9.03E-01	1.0871	1.0056	1.1754	3.57E-02	1.0692	1.0130	1.1316	1.83E-02
<u> </u>	Genic	1.1496	1.0281	1.2859	1.46E-02	0.9352	0.8489	1.0289	1.71E-01	1.0646	0.9517	1.1909	2.74E-01	1.0444	0.9716	1.1289	2.52E-01
Snort (<100kb)	Exonic	1.2494	1.0913	1.4317	1.30E-03	0.9253	0.8209	1.0408	1.99E-01	1.1099	0.9632	1.2794	1.50E-01	1.0402	0.9524	1.1442	3.91E-01
((10010))	Intronic	0.9606	0.7893	1.1685	6.88E-01	0.9461	0.7912	1.1308	5.42E-01	0.9934	0.8280	1.1904	9.43E-01	1.0655	0.9266	1.2248	3.73E-01
	Intergenic	0.9367	0.8262	1.0616	3.06E-01	1.0730	0.9663	1.1919	1.88E-01	1.1197	0.9996	1.2543	5.08E-02	1.1050	1.0201	1.1972	1.44E-02

B. Duplications

Type of	Type of		RADIA	NT (<1%)			GenRl	ED II (<1%)			GenR	ED (<1%)			NESDA/	<mark>NTR (<1%)</mark>)
Dups	CNV	OR	2.50%	97.50%	p value	OR	2.50%	97.50%	p value	OR	2.50%	97.50%	p value	OR	2.50%	97.50%	p value
	All	0.9371	0.8710	1.0079	8.12E-02	1.1422	1.0025	1.3028	4.65E-02	1.0229	0.8920	1.1721	7.45E-01	1.0790	1.0089	1.1602	3.22E-02
Lana	Genic	0.8981	0.8267	0.9748	1.05E-02	1.1286	0.9731	1.3101	1.10E-01	1.0764	0.9284	1.2473	3.28E-01	1.0782	1.0054	1.1631	4.19E-02
LONG	Exonic	0.8964	0.8248	0.9733	9.54E-03	1.1139	0.9598	1.2937	1.56E-01	1.0810	0.9318	1.2534	3.03E-01	1.0757	1.0031	1.1603	4.81E-02
(>100kb)	Intronic	1.1570	0.4079	3.3611	7.82E-01	8.2454	1.2159	163.4242	6.17E-02	0.4937	0.0243	3.5696	5.40E-01	2.0466	0.6157	7.8386	2.55E-01
	Intergenic	1.1327	0.9452	1.3585	1.77E-01	1.2350	0.9138	1.6742	1.71E-01	0.7823	0.5530	1.0966	1.59E-01	1.1096	0.8598	1.4309	4.23E-01
	All	1.0024	0.9264	1.0843	9.53E-01	0.9128	0.8439	0.9837	1.93E-02	1.0876	0.9835	1.2025	1.01E-01	0.9919	0.9412	1.0437	7.54E-01
<u>.</u>	Genic	0.9793	0.8916	1.0749	6.60E-01	0.9915	0.8955	1.0967	8.69E-01	1.0420	0.9136	1.1879	5.39E-01	0.9745	0.9086	1.0420	4.56E-01
Short (<100kb)	Exonic	0.9503	0.8580	1.0513	3.25E-01	0.9707	0.8682	1.0833	5.97E-01	0.9800	0.8431	1.1381	7.92E-01	0.9931	0.9198	1.0704	8.57E-01
(<100kb)	Intronic	1.2247	0.9256	1.6247	1.57E-01	1.1558	0.8571	1.5628	3.44E-01	1.3057	0.9821	1.7377	6.65E-02	0.8053	0.6419	1.0042	5.74E-02
	Intergenic	1.0653	0.9163	1.2386	4.10E-01	0.7581	0.6574	0.8695	1.05E-04	1.1601	0.9902	1.3588	6.56E-02	1.0304	0.9246	1.1486	5.86E-01

Supplement

Table S13. Logistic regression analyses of global burden of CNVs.

								A.	Deletion	s								
Tupo of Dol		Tested	-	All	(< 1%)		-	Single	ton CNVs		-	> 500	kb CNVs			> 1 M	b CNVs	
Type of Del	Type of City	effect	OR	2.50%	97.50%	p value	OR	2.50%	97.50%	p value	OR	2.50%	97.50%	p value	OR	2.50%	97.50%	p value
	A II	NSEG	1.0296	0.9658	1.0975	3.71E-01	1.1068	0.9466	1.2940	2.03E-01	1.1369	0.8832	1.4637	3.19E-01	1.4435	0.8839	2.3822	1.45E-01
	All	KB	1.0001	0.9999	1.0003	3.08E-01	1.0001	0.9996	1.0007	6.72E-01	1.0002	0.9999	1.0005	2.08E-01	1.0002	0.9999	1.0006	2.34E-01
	Gene-	NSEG	1.0606	0.9754	1.1531	1.68E-01	1.0987	0.9169	1.3164	3.07E-01	1.1239	0.8586	1.4707	3.94E-01	1.3108	0.7780	2.2253	3.10E-01
1 (100	containing	KB	1.0001	0.9999	1.0004	2.35E-01	1.0002	0.9996	1.0007	5.29E-01	1.0001	0.9999	1.0004	3.20E-01	1.0002	0.9998	1.0005	3.98E-01
Long (> 100	Exon-	NSEG	1.0521	0.9646	1.1475	2.51E-01	1.1105	0.9242	1.3343	2.63E-01	1.1239	0.8586	1.4707	3.94E-01	1.3108	0.7780	2.2253	3.10E-01
longer)	containing	KB	1.0001	0.9999	1.0004	2.69E-01	1.0002	0.9997	1.0008	4.16E-01	1.0001	0.9999	1.0004	3.20E-01	1.0002	0.9998	1.0005	3.98E-01
longery	Intronic	NSEG	1.1672	0.8591	1.5876	3.23E-01	1.2429	0.6541	2.3868	5.07E-01	NA	NA	NA	NA	NA	NA	NA	NA
	Intronic	KB	1.0008	0.9988	1.0028	4.49E-01	1.0002	0.9956	1.0048	9.32E-01	NA	NA	NA	NA	NA	NA	NA	NA
	Intergonic	NSEG	0.9881	0.8956	1.0899	8.11E-01	1.1758	0.9066	1.5248	2.22E-01	1.2482	0.5924	2.6818	5.61E-01	3.1975	0.7163	22.2489	1.62E-01
	Intergenic	KB	1.0000	0.9995	1.0004	9.20E-01	1.0005	0.9992	1.0019	4.67E-01	1.0005	0.9996	1.0015	3.04E-01	1.0009	0.9996	1.0025	1.98E-01
	A II	NSEG	1.0483	1.0139	1.0843	5.92E-03	1.0664	0.9955	1.1473	7.70E-02								
	All	KB	1.0011	1.0004	1.0019	3.93E-03	1.0020	1.0003	1.0037	2.32E-02	_							
	Gene-	NSEG	1.0343	0.9877	1.0842	1.56E-01	1.0224	0.9377	1.1191	6.17E-01								
	containing	KB	1.0010	1.0000	1.0021	4.74E-02	1.0012	0.9993	1.0033	2.41E-01								
Short (<	Exon-	NSEG	1.0552	0.9965	1.1192	6.95E-02	1.0360	0.9382	1.1510	4.90E-01								
100 kb)	containing	KB	1.0013	1.0002	1.0025	2.61E-02	1.0013	0.9992	1.0035	2.52E-01								
	Intronic	NSEG	0.9952	0.9149	1.0825	9.11E-01	0.9425	0.7822	1.1342	5.31E-01								
	Intronic	KB	1.0001	0.9979	1.0022	9.39E-01	0.9998	0.9948	1.0049	9.46E-01								
	Intergonic	NSEG	1.0716	1.0190	1.1270	7.14E-03	1.1574	1.0338	1.2962	1.13E-02								
Ir	intergenit	KB	1.0014	1.0002	1.0026	2.26E-02	1.0032	1.0006	1.0059	1.74E-02								

Zhang et al.

								B. D	uplication	ıs								
Type of	Type of CNV	Tested		All	<mark>(< 1%)</mark>			Singlet	on CNVs			> 500	kb CNVs			> 1 M	lb CNVs	
Dup	Type of Civi	effect	OR	2.50%	97.50%	p value	OR	2.50%	97.50%	p value	OR	2.50%	97.50%	p value	OR	2.50%	97.50%	p value
	A 11	NSEG	1.0268	0.9837	1.0725	2.29E-01	1.1097	0.9876	1.2484	8.13E-02	0.9819	0.8599	1.1207	7.87E-01	0.9906	0.7461	1.3136	9.48E-01
	All	KB	1.0000	0.9999	1.0001	5.29E-01	1.0002	0.9998	1.0006	3.26E-01	1.0000	0.9999	1.0001	9.32E-01	1.0000	0.9999	1.0002	7.75E-01
	Gene-	NSEG	1.0187	0.9723	1.0677	4.37E-01	1.0483	0.9236	1.1908	4.66E-01	0.9708	0.8438	1.1165	6.79E-01	0.9466	0.7075	1.2643	7.11E-01
lang (containing	KB	1.0000	0.9999	1.0001	8.93E-01	1.0000	0.9996	1.0004	9.63E-01	1.0000	0.9998	1.0001	7.10E-01	1.0000	0.9998	1.0001	7.54E-01
LONG (>	Exon-	NSEG	1.0166	0.9702	1.0657	4.89E-01	1.0426	0.9179	1.1850	5.21E-01	0.9708	0.8438	1.1165	6.79E-01	0.9466	0.7075	1.2643	7.11E-01
longer)	containing	KB	1.0000	0.9999	1.0001	9.10E-01	1.0000	0.9996	1.0003	8.54E-01	1.0000	0.9998	1.0001	7.10E-01	1.0000	0.9998	1.0001	7.54E-01
longery	Intropic	NSEG	1.5254	0.7880	3.0095	2.13E-01	1.3693	0.5310	3.6480	5.16E-01	NA	NA	NA	NA	NA	NA	NA	NA
	Intronic	KB	1.0007	0.9981	1.0033	6.11E-01	1.0026	0.9956	1.0100	4.79E-01	NA	NA	NA	NA	NA	NA	NA	NA
	Intergenic	NSEG	1.0912	0.9654	1.2333	1.62E-01	1.1908	0.9304	1.5262	1.66E-01	1.0894	0.7098	1.6726	6.94E-01	2.4597	0.6690	11.6064	1.99E-01
	Intergenic	KB	1.0002	0.9999	1.0005	1.55E-01	1.0006	0.9995	1.0016	3.04E-01	1.0002	0.9999	1.0006	2.34E-01	1.0004	0.9999	1.0010	1.49E-01
	ΔII	NSEG	0.9850	0.9512	1.0194	3.90E-01	0.9925	0.9219	1.0681	8.41E-01	~							
	All	KB	0.9997	0.9990	1.0004	4.69E-01	1.0000	0.9986	1.0015	9.45E-01								
	Gene-	NSEG	0.9845	0.9410	1.0296	4.96E-01	0.9607	0.8716	1.0581	4.17E-01								
	containing	KB	0.9999	0.9990	1.0007	7.73E-01	0.9998	0.9981	1.0015	8.15E-01								
Short (<	Exon-	NSEG	0.9730	0.9253	1.0225	2.83E-01	0.9392	0.8452	1.0426	2.41E-01								
100 kb)	containing	KB	0.9997	0.9989	1.0006	5.72E-01	0.9995	0.9977	1.0013	5.78E-01								
100 KD)	Intropic	NSEG	1.0586	0.9285	1.2066	3.94E-01	0.9088	0.7050	1.1681	4.57E-01								
	Intronic	KB	1.0017	0.9983	1.0051	3.18E-01	0.9983	0.9924	1.0042	5.75E-01								
	Intergonic	NSEG	0.9788	0.9166	1.0449	5.21E-01	1.0510	0.9282	1.1911	4.33E-01								
	intergenic	KB	0.9993	0.9978	1.0007	3.17E-01	1.0009	0.9983	1.0035	4.87E-01								

Shown are results of logistic regression analysis for all kinds of deletions and duplications using batch and sex as covariates.

Zhang et al.

Supplement

Table S14. Meta-analysis of global CNV burden.

						А.	Deletion	S						
Type of	Type	RADIANT	All (<1%)	GR Illum	All (<1%)	GR Affy /	All (<1%)	Neth A	ll (<1%)	Cochran's		Fixed effe	ect model	
Deletion	of CNV	Beta	SE	Beta	SE	Beta	SE	Beta	SE	Q-test p-value	Beta	2.50%	97.50%	p-value
	All	0.0283	0.0531	0.1723	0.0896	0.0166	0.0778	-0.0213	0.0593	0.3475	0.0303	-0.0340	0.0947	0.3551
Long	Genic	-0.0306	0.0688	0.1385	0.1188	0.1071	0.0996	0.1284	0.0793	0.3719	0.0638	-0.0204	0.1480	0.1376
LUIIY	Exonic	-0.0650	0.0707	0.0909	0.1259	0.1450	0.1043	0.1536	0.0818	0.1607	0.0575	-0.0297	0.1448	0.1964
(>100kb)	Intronic	0.4495	0.2652	0.6044	0.3945	-0.2645	0.3271	-0.2912	0.3458	0.1201	0.1399	-0.1765	0.4564	0.3861
	Intergenic	0.1134	0.0829	0.1961	0.1294	-0.1215	0.1235	-0.2190	0.0919	0.0133	-0.0146	-0.1140	0.0847	0.7732
	All	0.0479	0.0421	-0.0042	0.0340	0.0835	0.0398	0.0669	0.0284	0.3086	0.0482	0.0141	0.0823	0.0056
Short	Genic	0.1394	0.0571	-0.0670	0.0489	0.0626	0.0572	0.0434	0.0379	0.0467	0.0371	-0.0101	0.0843	0.1230
31101 t (<100kb)	Exonic	0.2226	0.0692	-0.0777	0.0604	0.1043	0.0724	0.0394	0.0459	0.0103	0.0555	-0.0023	0.1134	0.0598
(<100kb)	Intronic	-0.0402	0.1000	-0.0554	0.0910	-0.0066	0.0925	0.0634	0.0711	0.7219	0.0020	-0.0827	0.0867	0.9635
	Intergenic	-0.0654	0.0639	0.0705	0.0535	0.1130	0.0579	0.0999	0.0408	0.1342	0.0685	0.0178	0.1192	0.0081

B. Duplications

	Type of	RADIANT	All (<1%)	GR Illum	All (<1%)	GR Affy /	All (<1%)	Neth A	ll (<1%)	Cochran's		Fixed effe	ect model	
Duplication	CNV	Beta	SE	Beta	SE	Beta	SE	Beta	SE	Q-test p-value	Beta	2.50%	97.50%	p-value
	All	-0.0649	0.0372	0.1329	0.0668	0.0227	0.0696	0.0760	0.0355	0.0147	0.0246	-0.0198	0.0690	0.2779
long	Genic	-0.1075	0.0420	0.1210	0.0758	0.0736	0.0753	0.0753	0.0370	0.0033	0.0171	-0.0312	0.0653	0.4887
LUNG	Exonic	-0.1094	0.0422	0.1079	0.0761	0.0779	0.0756	0.0730	0.0369	0.0040	0.0149	-0.0335	0.0632	0.5466
(>100KD)	Intronic	0.1458	0.5274	2.1097	1.1290	-0.7059	1.1516	0.7162	0.6287	0.2981	0.4513	-0.2566	1.1593	0.2115
	Intergenic	0.1246	0.0924	0.2111	0.1541	-0.2456	0.1743	0.1040	0.1298	0.2148	0.0858	-0.0378	0.2094	0.1737
	All	0.0024	0.0401	-0.0913	0.0390	0.0839	0.0512	-0.0082	0.0261	0.0505	-0.0123	-0.0474	0.0227	0.4905
Short	Genic	-0.0209	0.0476	-0.0085	0.0516	0.0411	0.0669	-0.0258	0.0346	0.8433	-0.0132	-0.0585	0.0320	0.5671
30011 (~100kb)	Exonic	-0.0510	0.0517	-0.0298	0.0564	-0.0202	0.0765	-0.0069	0.0383	0.9222	-0.0238	-0.0737	0.0262	0.3511
(<100kb)	Intronic	0.2027	0.1433	0.1448	0.1529	0.2667	0.1454	-0.2165	0.1139	0.0266	0.0556	-0.0778	0.1890	0.4144
	Intergenic	0.0633	0.0768	-0.2770	0.0714	0.1485	0.0807	0.0300	0.0551	0.0002	-0.0129	-0.0801	0.0544	0.7078

Shown are results of global burden meta-analysis. Beta and SE are coefficient and its standard error from logistic regression.

Supplement

Table S15. Logistic regression analyses of global burden of short deletions with various sizes.

Dolotion cizo	CNVs/	subject	OD	05% 01	Effort cizo	n valuo
Deletion size	Cases	Control	UK	93% CI	Effect Size	p value
10-20 kb	0.3379	0.3298	1.0447	0.9840-1.1093	0.0438	1.52E-01
20-30 kb	0.1708	0.1702	1.0313	0.9468-1.1233	0.0308	4.80E-01
30-40 kb	0.1265	0.1186	1.0886	0.9825-1.2062	0.0849	1.05E-01
40-50 kb	0.0998	0.1031	0.9843	0.8793-1.1016	-0.0158	7.84E-01
50-60 kb	0.0644	0.0663	0.9675	0.8442-1.1077	-0.0331	6.32E-01
60-70 kb	0.0673	0.0552	1.2465	1.0794-1.4403	0.2204	2.73E-03
70-80 kb	0.0581	0.0521	1.1204	0.9630-1.3041	0.1137	1.41E-01
80-90 kb	0.0505	0.0391	1.2945	1.0933-1.5340	0.2581	2.80E-03
90-100 kb	0.0396	0.0433	0.9134	0.7661-1.0877	-0.0906	3.11E-01
				47		

Table S16. Logistic regression analyses of global burden of all rare deletions and duplications.

			Combine	d cohort	
		OR	2.50%	97.50%	p value
	All	1.0435	1.0134	1.0748	4.56E-03
	Gene-containing	1.0402	0.9990	1.0837	5.77E-02
All rare deletion	Exon-containing	1.0537	1.0048	1.1060	3.25E-02
	Intronic	1.0064	0.9280	1.0913	8.77E-01
	Intergenic	1.0530	1.0071	1.1010	2.30E-02
	All	1.0010	0.9764	1.0261	9.39E-01
	Gene-containing	1.0007	0.9715	1.0306	9.65E-01
All rare duplication	Exon-containing	0.9966	0.9661	1.0279	8.31E-01
	Intronic	1.0730	0.9438	1.2195	2.81E-01
<u> </u>	Intergenic	1.0026	0.9473	1.0610	9.28E-01

Zhang et al.

Table S17. Global burden analyses of rare CNVs after filtering common CNVs within each cohort separately rather than in all cohorts.

						A. I	Deletions							
Type of		- Tested offert	_	All (<1%)		S	Singleton CN	Vs	;	> 500 kb CN\	/s	_	> 1 Mb CNV	S
Del	Type of City	Tested effect	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value
	A 11	CNVs/subj	0.3336	0.3266	1.76E-01	0.0559	0.0501	8.11E-02	0.0216	0.0189	2.06E-01	0.0066	0.0044	9.50E-02
	All	Subjs w CNV	0.2879	0.2774	5.66E-02	0.0547	0.0485	6.50E-02	0.0215	0.0186	1.91E-01	0.0066	0.0044	9.50E-02
	Intorgonia	CNVs/subj	0.1370	0.1402	6.12E-01	0.0206	0.0180	1.07E-01	0.0028	0.0020	3.94E-01	0.0010	0.0003	1.18E-01
	Intergenic	Subjs w CNV	0.1275	0.1319	6.98E-01	0.0204	0.0178	1.14E-01	0.0028	0.0020	3.94E-01	0.0010	0.0003	1.18E-01
		CNVs/subj	0.1965	0.1864	7.46E-02	0.0420	0.0377	1.49E-01	0.0189	0.0169	2.37E-01	0.0055	0.0041	2.03E-01
. ,	Gene-	Subjs w CNV	0.1820	0.1678	1.34E-02	0.0412	0.0371	1.66E-01	0.0189	0.0166	1.99E-01	0.0055	0.0041	2.03E-01
Long (>	containing	Genes/CNV	0.7367	0.7247	3.74E-01	0.1285	0.1422	8.00E-01	0.2097	0.1656	1.09E-01	0.0931	0.0457	4.63E-02
IOD KD OF		Genes/CNV kb	0.0099	0.0099	5.57E-01	0.0120	0.0132	8.91E-01	0.0113	0.0116	3.73E-01	0.0100	0.0079	1.66E-01
ionger)		CNVs/subj	0.1815	0.1742	1.07E-01	0.0410	0.0365	1.24E-01	0.0189	0.0169	2.39E-01	0.0055	0.0041	2.00E-01
	Exon-	Subjs w CNV	0.1682	0.1582	3.60E-02	0.0403	0.0359	1.29E-01	0.0189	0.0166	2.01E-01	0.0055	0.0041	2.00E-01
C	containing	Genes/CNV	3.9980	3.8080	2.69E-01	0.6933	0.7514	7.29E-01	1.3940	1.0450	6.51E-02	0.6121	0.3052	5.52E-02
		Genes/CNV kb	0.0484	0.0479	5.01E-01	0.0588	0.0676	9.20E-01	0.0742	0.0727	2.55E-01	0.0639	0.0525	2.03E-01
	Intropic	CNVs/subj	0.0151	0.0122	2.07E-01	0.0036	0.0027	3.54E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
	Intronic	Subjs w CNV	0.0151	0.0119	1.70E-01	0.0036	0.0027	3.54E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
	A.U.	CNVs/subj	1.0760	1.0200	2.10E-04	0.2154	0.2021	4.90E-02						
	All	Subjs w CNV	0.6040	0.5909	2.54E-03	0.1869	0.1730	8.46E-03						
	Intorgonio	CNVs/subj	0.5564	0.5155	1.60E-04	0.1047	0.0928	1.10E-02						
	intergenic	Subjs w CNV	0.3986	0.3838	5.40E-03	0.0972	0.0872	1.43E-02						
		CNVs/subj	0.5197	0.5045	4.96E-02	0.1178	0.1162	3.34E-01						
	Gene-	Subjs w CNV	0.3844	0.3741	2.30E-02	0.1061	0.1055	3.47E-01						
Short (<	containing	Genes/CNV	0.9059	0.8676	4.28E-02	0.2087	0.1960	2.16E-01						
100 kb)		Genes/CNV kb	0.0264	0.0277	8.22E-01	0.0323	0.0344	7.69E-01						
		CNVs/subj	0.3349	0.3151	2.97E-02	0.0895	0.0859	2.85E-01						
	Exon-	Subjs w CNV	0.2727	0.2563	6.81E-03	0.0810	0.0788	3.40E-01						
	containing	Genes/CNV	2.1480	1.9660	5.34E-02	0.5413	0.5088	3.75E-01						
		Genes/CNV kb	0.0523	0.0513	4.51E-01	0.0667	0.0683	7.92E-01						
	Intropic	CNVs/subj	0.1848	0.1894	4.17E-01	0.0351	0.0388	7.27E-01						
	intronic	Subjs w CNV	0.1666	0.1677	2.54E-01	0.0337	0.0377	7.47E-01						

Zhang et al.

B. Duplications														
Tune of Dun		Tested offeet		All (< 1%))	Si	<mark>ngleton</mark> C	NVs	>	500 kb C	NVs	;	1 Mb CN	IVs
Type of Dup	Type of Civy	Tested effect	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value
	All	CNVs/subj	0.5298	0.5072	8.29E-02	0.0862	0.0746	2.52E-02	0.0735	0.0727	6.10E-01	0.0173	0.0166	5.14E-01
	All	Subjs w CNV	0.3879	0.3824	3.55E-01	0.0777	0.0693	4.70E-02	0.0694	0.0697	6.92E-01	0.0170	0.0163	5.14E-01
	Intorgonic	CNVs/subj	0.0886	0.0818	1.18E-01	0.0225	0.0186	7.92E-02	0.0076	0.0066	4.12E-01	0.0012	0.0005	1.73E-01
	Intergenic	Subjs w CNV	0.0837	0.0771	1.19E-01	0.0218	0.0181	8.31E-02	0.0076	0.0066	4.12E-01	0.0012	0.0005	1.73E-01
		CNVs/subj	0.4412	0.4254	1.46E-01	0.0702	0.0644	1.79E-01	0.0659	0.0661	6.59E-01	0.0161	0.0162	6.28E-01
	Gene-containing	Subjs w CNV	0.3362	0.3319	3.65E-01	0.0633	0.0608	3.63E-01	0.0630	0.0635	6.79E-01	0.0157	0.0159	6.30E-01
l ong (> 100 kb or longer)	Oche-containing	Genes/CNV	2.6420	2.6400	4.79E-01	0.2903	0.2703	3.95E-01	0.8031	0.8648	7.51E-01	0.3465	0.3842	7.08E-01
		Genes/CNV kb	0.0171	0.0181	9.68E-01	0.0162	0.0172	8.43E-01	0.0122	0.0130	6.54E-01	0.0126	0.0133	5.62E-01
		CNVs/subj	0.4375	0.4230	1.69E-01	0.0694	0.0641	2.06E-01	0.0659	0.0661	6.59E-01	0.0161	0.0162	6.26E-01
	Exon-containing	Subjs w CNV	0.3336	0.3308	4.40E-01	0.0628	0.0605	3.76E-01	0.0630	0.0635	6.80E-01	0.0157	0.0159	6.27E-01
	Exon containing	Genes/CNV	15.9500	15.6200	3.68E-01	1.6970	1.6030	4.82E-01	5.5020	5.9640	7.53E-01	2.4240	2.7310	7.18E-01
		Genes/CNV kb	0.0933	0.0946	6.86E-01	0.0894	0.0960	8.84E-01	0.0837	0.0877	5.63E-01	0.0879	0.0953	5.98E-01
	Intronic	CNVs/subj	0.0036	0.0024	1.03E-01	0.0017	0.0012	2.88E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
		Subjs w CNV	0.0036	0.0024	1.03E-01	0.001/	0.0012	2.88E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
	All	CNVs/subj	0.7299	0.7588	7.09E-01	0.1709	0.1778	6.68E-01						
		Subjs w CNV	0.4917	0.4881	1.21E-01	0.1514	0.1476	1.49E-01						
	Intergenic	CNVs/subj	0.2855	0.2932	4.78E-01	0.0706	0.0699	2.52E-01						
	Intergenie	Subjs w CNV	0.2412	0.2410	1.85E-01	0.0677	0.0631	5.87E-02						
		CNVs/subj	0.4445	0.4656	7.81E-01	0.1064	0.1136	8.55E-01						
	Cono containing	Subjs w CNV	0.3407	0.3390	2.49E-01	0.0962	0.0981	5.94E-01						
	Gene-containing	Genes/CNV	0.9993	1.0670	8.87E-01	0.2272	0.2377	7.12E-01						
Short (< 100 kb)		Genes/CNV kb	0.0328	0.0327	6.16E-01	0.0325	0.0337	7.44E-01						
		CNVs/subj	0.3664	0.3873	8.40E-01	0.0895	0.0977	9.12E-01						
		Subis w CNV	0.2901	0.2911	4.12E-01	0.0813	0.0848	7.56E-01						
I	Exon-containing	Genes/CNV	3,7000	3,8390	7.45F-01	0.7990	0.8521	7.72F-01						
		Genes/CNV kb	0.1045	0.0996	2.71F-01	0.0939	0.1026	9.06F-01						
		CNVs/subi	0.0780	0.0783	3 76E-01	0.0190	0.0220	8.33E-01						
	Intronic Cl	Subis w CNIV	0.0746	0.0703	2 28E_01	0.0120	0.0220	8 30F-01						
	S		0.0740	0.0731	2.20L-01	0.0109	0.0217	0.30L-01						

Shown are results of whole genome burden analyses on combined data of CNV calls after filtering common CNVs within each cohort separately.

Zhang et al.

Table S18. Global burden analyses of CNVs called by both QuantiSNP and PennCNV for Illumina dataand by Birdsuite for Affymetrix data.

	A. Deletions													
Type of Del		Tostod offoct		All (<1%)	Si	ngleton C	NVs	>	500 kb Cl	NVs	-	> 1 Mb CN	Vs
Type of Del		Testeu enect	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value
	All	CNVs/subj	0.3163	0.3100	1.51E-01	0.0547	0.0486	6.35E-02	0.0215	0.0187	2.08E-01	0.0064	0.0044	1.11E-01
	All	Subjs w CNV	0.2756	0.2658	5.25E-02	0.0535	0.0469	4.93E-02	0.0213	0.0184	1.92E-01	0.0064	0.0044	1.11E-01
	Intergenic	CNVs/subj	0.1301	0.1357	7.08E-01	0.0202	0.0178	1.11E-01	0.0026	0.0020	4.50E-01	0.0009	0.0003	1.72E-01
	Intergenie	Subjs w CNV	0.1215	0.1283	7.98E-01	0.0201	0.0177	1.18E-01	0.0026	0.0020	4.50E-01	0.0009	0.0003	1.72E-01
		CNVs/subj	0.1862	0.1743	3.66E-02	0.0412	0.0362	1.05E-01	0.0189	0.0168	2.24E-01	0.0055	0.0041	2.00E-01
	Gene-containing	Subjs w CNV	0.1732	0.1586	8.14E-03	0.0403	0.0356	1.16E-01	0.0189	0.0165	1.87E-01	0.0055	0.0041	2.00E-01
Long (> 100 kb or longer)		Genes/CNV	0.6995	0.6357	6.71E-02	0.1270	0.1361	7.23E-01	0.2097	0.1567	7.26E-02	0.0931	0.0457	4.66E-02
		Genes/CNV kb	0.0098	0.0093	1.78E-01	0.0120	0.0127	8.14E-01	0.0114	0.0110	2.68E-01	0.0103	0.0079	1.46E-01
		CNVs/subj	0.1711	0.1621	5.35E-02	0.0401	0.0350	8.32E-02	0.0189	0.0168	2.23E-01	0.0055	0.0041	2.00E-01
	Evon-containing	Subjs w CNV	0.1593	0.1488	2.30E-02	0.0395	0.0344	8.59E-02	0.0189	0.0165	1.87E-01	0.0055	0.0041	2.00E-01
	EXON-CONTAINING	Genes/CNV	3.7430	3.2060	3.38E-02	0.6834	0.7126	6.38E-01	1.3940	0.9834	4.00E-02	0.6121	0.3052	5.57E-02
		Genes/CNV kb	0.0465	0.0427	1.18E-01	0.0581	0.0637	8.39E-01	0.0748	0.0685	1.68E-01	0.0657	0.0525	1.83E-01
	Intronic	CNVs/subj	0.0151	0.0122	2.07E-01	0.0036	0.0027	3.56E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
		Subjs w CNV	0.0151	0.0119	1.71E-01	0.0036	0.0027	3.56E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
	All	CNVs/subj	0.9524	0.9042	6.00E-05	0.2099	0.1890	2.51E-03						
		Subjs w CNV	0.5645	0.5572	5.98E-03	0.1811	0.1637	7.00E-04						
	Intergenic	CNVs/subj	0.4789	0.4491	2.60E-04	0.1022	0.0884	2.22E-03						
	Intergenie	Subjs w CNV	0.3578	0.3471	6.17E-03	0.0952	0.0835	3.16E-03						
		CNVs/subj	0.4735	0.4550	1.09E-02	0.1145	0.1067	6.58E-02						
	Gene-containing	Subjs w CNV	0.3621	0.3518	9.79E-03	0.1031	0.0987	8.18E-02						
Short (< 100 kb)	Conc containing	Genes/CNV	0.8320	0.7822	7.28E-03	0.2066	0.1778	2.16E-02						
511011 (< 100 kb)		Genes/CNV kb	0.0276	0.0279	4.82E-01	0.0326	0.0334	4.62E-01						
		CNVs/subj	0.3042	0.2818	5.26E-03	0.0869	0.0768	3.41E-02						
	Exon-containing	Subjs w CNV	0.2542	0.2386	4.65E-03	0.0787	0.0720	5.05E-02						
	Exon-containing	Genes/CNV	1.9670	1.7550	1.21E-02	0.5441	0.4555	8.59E-02						
		Genes/CNV kb	0.0542	0.0515	2.38E-01	0.0661	0.0635	5.05E-01						
	Intronic	CNVs/subj	0.1694	0.1733	3.46E-01	0.0337	0.0367	6.02E-01						
	Intronic	Subjs w CNV	0.1547	0.1559	2.16E-01	0.0324	0.0358	6.41E-01						

Zhang et al.

	B. Duplications													
Type of		Tostad offeat		All (< 1%)			Singleton CN	Vs	;	> 500 kb CN\	/s		> 1 Mb CNV	S
Dup	туре от стал	Tested effect	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value	Cases	Controls	p value
	A.II	CNVs/subj	0.4282	0.4147	1.19E-01	0.0766	0.0702	1.36E-01	0.0671	0.0644	4.11E-01	0.0145	0.0142	5.86E-01
	All	Subjs w CNV	0.3334	0.3293	3.17E-01	0.0699	0.0667	3.08E-01	0.0638	0.0628	5.48E-01	0.0144	0.0142	6.11E-01
	Intorgonic	CNVs/subj	0.0671	0.0697	6.82E-01	0.0182	0.0168	3.54E-01	0.0061	0.0060	6.21E-01	0.0005	0.0003	4.81E-01
	Intergenic	Subjs w CNV	0.0652	0.0670	6.54E-01	0.0182	0.0163	2.71E-01	0.0061	0.0060	6.21E-01	0.0005	0.0003	4.81E-01
		CNVs/subj	0.3611	0.3450	7.56E-02	0.0649	0.0599	1.96E-01	0.0611	0.0584	3.84E-01	0.0140	0.0139	6.17E-01
Long (>	Gene-	Subjs w CNV	0.2891	0.2819	1.76E-01	0.0587	0.0575	4.84E-01	0.0588	0.0571	4.53E-01	0.0138	0.0139	6.42E-01
100 kb or	containing	Genes/CNV	2.1920	2.0200	9.28E-02	0.2645	0.2483	3.81E-01	0.7280	0.6980	3.51E-01	0.3062	0.3346	6.66E-01
longer)		Genes/CNV kb	0.0173	0.0168	2.71E-01	0.0161	0.0161	5.42E-01	0.0121	0.0114	1.57E-01	0.0133	0.0133	3.76E-01
····g-·,		CNVs/subj	0.3576	0.3426	8.82E-02	0.0640	0.0596	2.25E-01	0.0611	0.0584	3.85E-01	0.0140	0.0139	6.18E-01
	Exon- containing	Subjs w CNV	0.2867	0.2809	2.26E-01	0.0581	0.0572	4.96E-01	0.0588	0.0571	4.55E-01	0.0138	0.0139	6.44E-01
		Genes/CNV	13.3900	12.0900	6.38E-02	1.5240	1.4700	4.61E-01	5.0550	4.8670	3.38E-01	2.1960	2.4320	6.63E-01
		Genes/CNV kb	0.0936	0.0871	1.98E-02	0.0859	0.0884	6.97E-01	0.0843	0.0777	7.59E-02	0.0953	0.0976	4.07E-01
	Intronic	CNVs/subj	0.0035	0.0024	1.25E-01	0.0016	0.0012	3.58E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
		Subjs w CNV	0.0035	0.0024	1.25E-01	0.0016	0.0012	3.58E-01	0.0000	0.0000	1.00E+00	0.0000	0.0000	1.00E+00
	All	CNVs/subj	0.5389	0.5542	3.91E-01	0.1464	0.1542	6.19E-01						
		Subjs w CNV	0.3952	0.3957	1.47E-01	0.1318	0.1310	1.61E-01						
	Intergenic	CNVs/subj	0.2093	0.2129	2.75E-01	0.0614	0.0623	3.40E-01						
	Intergenie	Subjs w CNV	0.1849	0.1832	1.04E-01	0.0597	0.0571	9.88E-02						
		CNVs/subj	0.3296	0.3412	5.24E-01	0.0903	0.0966	7.39E-01						
	Gene-	Subjs w CNV	0.2675	0.2695	2.93E-01	0.0824	0.0854	5.59E-01						
Short (<	containing	Genes/CNV	0.7211	0.7701	8.13E-01	0.1919	0.2006	6.05E-01						
100 kb)		Genes/CNV kb	0.0316	0.0334	9.57E-01	0.0304	0.0331	8.92E-01						
		CNVs/subj	0.2689	0.2781	5.58E-01	0.0773	0.0810	6.42E-01						
	Exon-	Subjs w CNV	0.2244	0.2274	4.20E-01	0.0706	0.0723	5.06E-01						
	containing	Genes/CNV	2.7030	2.6270	2.47E-01	0.6865	0.6951	5.56E-01						
	2	Genes/CNV kb	0.0999	0.0966	4.29E-01	0.0908	0.0951	8.16E-01						
		CNVs/subj	0.0607	0.0631	4.38E-01	0.0152	0.0204	9.61E-01						
	Intronic	Subjs w CNV	0.0581	0.0590	3.08E-01	0.0151	0.0201	9.61E-01						

Shown are results of whole genome burden analyses on combined data of only CNV calls reported by both QuantiSNP and PennCNV from Illumina data and Birdsuite calls from Affymetrix data.

Table S19. Global burden analyses of CNVs after excluding nominally significant CNV regions that failed manual checks.

CNIV typo	CNVs/	subject	OP	05% CI	n valuo						
Ciav type	Cases	Cont	UK	95% CI	p value						
		D	eletions								
>100kb — All	0.324	0.318	1.0296	0.9658-1.0975	3.71E-01						
Intergenic	0.134	0.138	0.9881	0.8956-1.0899	8.11E-01						
Genic	0.191	0.181	1.0606	0.9754-1.1531	1.68E-01						
Exonic	0.175	0.168	1.0521	0.9646-1.1475	2.51E-01						
Intronic	0.015	0.012	1.1672	0.8591-1.5876	3.23E-01						
<100kb — All	1.014	0.977	1.0481	1.0137-1.0841	6.13E-03						
Intergenic	0.506	0.483	1.0711	1.0185-1.1265	7.51E-03						
Genic	0.508	0.494	1.0343	0.9877-1.0842	1.56E-01						
Exonic	0.329	0.310	1.0539	0.9953-1.1178	7.61E-02						
Intronic	0.178	0.184	0.9978	0.9172-1.0855	9.60E-01						
Duplications											
>100kb — All	0.496	0.476	1.0262	0.9830-1.0718	2.40E-01						
Intergenic	0.087	0.079	1.0912	0.9654-1.2333	1.62E-01						
Genic	0.409	0.397	1.0179	0.9716-1.0669	4.56E-01						
Exonic	0.405	0.395	1.0159	0.9695-1.0649	5.10E-01						
Intronic	0.004	0.002	1.5254	0.7880-3.0095	2.13E-01						
<100kb — All	0.668	0.701	0.9831	0.9493-1.0175	3.33E-01						
Intergenic	0.250	0.265	0.9736	0.9116-1.0395	4.23E-01						
Genic	0.417	0.436	0.9838	0.9402-1.0288	4.76E-01						
Exonic	0.344	0.364	0.9729	0.9251-1.0224	2.80E-01						
Intronic	0.073	0.072	1.0532	0.9237-1.2006	4.38E-01						

Supplement

Table S20. DNA sample sources of the subjects included in this dataset.

Cohort	# Cases	# Controls	Total	Source
RADIANT	2,460	2,587	5,047	Blood
NESDA/NTR	1,568	1,913	3,481	Blood
GenRED II	811	862	1,673	Blood (137 cases & 862 controls); LCL (674 cases)
GenRED	941	1,264	2,205	Blood (7 controls); LCL (941 cases & 1257 controls)

Table S21. CNV burden comparison between blood vs. LCL case DNAs in cohort GenRED II.

		CNVs/s	subject	Pormutation n value	Logistic Regression					
Type of City	Type of city	Blood	LCL		OR	2.50%	97.50%	p value		
	All	0.2920	0.3991	0.9815	0.7078	0.4923	0.9908	5.21E-02		
	Genic	0.1679	0.2211	0.9243	0.7343	0.4513	1.1443	1.91E-01		
Long deletion (>100kb)	Exonic	0.1606	0.1929	0.8290	0.8158	0.4948	1.2868	4.01E-01		
	Intronic	0.0073	0.0282	0.9768	0.2527	0.0140	1.2340	1.82E-01		
	Intergenic	0.1241	0.1780	0.9401	0.6943	0.4011	1.1241	1.63E-01		
	All	1.6060	1.7200	0.8107	0.9439	0.8237	1.0747	3.94E-01		
	Genic	0.7883	0.8442	0.7501	0.9373	0.7633	1.1394	5.25E-01		
Short deletion (<100kb)	Exonic	0.4818	0.5549	0.8678	0.8710	0.6657	1.1193	2.96E-01		
	Intronic	0.3066	0.2893	0.3909	1.0616	0.7467	1.4735	7.29E-01		
	Intergenic	0.8175	0.8754	0.7488	0.9407	0.7720	1.1331	5.31E-01		
	All	0.5839	0.5623	0.4026	1.0348	0.8164	1.2943	7.71E-01		
	Genic	0.4745	0.4451	0.3477	1.0594	0.8138	1.3579	6.58E-01		
Long duplication (>100kb)	Exonic	0.4599	0.4407	0.4075	1.0389	0.7956	1.3345	7.72E-01		
	Intronic	0.0146	0.0045	0.1994	3.3495	0.4369	20.4738	1.89E-01		
	Intergenic	0.1095	0.1172	0.6413	0.9321	0.5123	1.5852	8.06E-01		
	All	1.1610	1.0820	0.2409	1.0589	0.9042	1.2298	4.64E-01		
Short duplication (<100kb)	Genic	0.8029	0.6988	0.1121	1.1387	0.9277	1.3859	2.03E-01		
	Exonic	0.6861	0.5816	0.0919	1.1696	0.9348	1.4501	1.60E-01		
	Intronic	0.1168	0.1172	0.5465	0.9964	0.5647	1.6434	9.89E-01		
	Intergenic	0.3577	0.3828	0.6667	0.9472	0.7081	1.2311	6.99E-01		

Table S22. Logistic regression analyses of global burden of CNVs for RADIANT cases vs. screened controls and for RADIANT cases vs. unscreened NBS samples.

Type of Deletion	Type of CNV	R/ sc	ADIANT cas creened con	es vs itrols			RADIAN unscreened	IT cases vs I NBS contro	ols
	-	OR	2.50%	97.50%	p value	OR	2.50%	97.50%	p value
	All	1.0562	0.8677	1.2989	5.95E-01	1.0237	0.9185	1.1412	6.72E-01
	Gene-containing	1.1273	0.8654	1.4975	3.91E-01	0.9480	0.8241	1.0903	4.54E-01
Long (>100kb)	Exon-containing	1.1201	0.8527	1.5036	4.32E-01	0.9115	0.7892	1.0522	2.06E-01
	Intronic	1.1757	0.5023	3.4380	7.36E-01	1.6856	0.9747	2.9992	6.70E-02
	Intergenic	0.9742	0.7336	1.3201	8.61E-01	1.1473	0.9673	1.3625	1.16E-01
	All	1.2721	1.0750	1.5182	6.23E-03	1.0155	0.9321	1.1064	7.26E-01
	Gene-containing	1.2706	1.0205	1.6042	3.77E-02	1.1333	1.0085	1.2745	3.61E-02
Short (<100kb)	Exon-containing	1.4719	1.1164	1.9870	8.44E-03	1.2161	1.0566	1.4018	6.64E-03
	Intronic	0.9559	0.6774	1.3953	8.06E-01	0.9684	0.7883	1.1903	7.60E-01
	Intergenic	1.2856	0.9898	1.7026	6.89E-02	0.8885	0.7810	1.0107	7.21E-02
				T	Y				

Type of Duplication	Type of CNV		RADIANT cas screened con	es vs trols	-	RADIAN unscreened	IT cases vs d NBS contro	ols	
		OR	2.50%	97.50%	p value	OR	2.50%	<mark>97.50%</mark>	p value
	All	0.9264	0.8153	1.0606	2.53E-01	0.9382	0.8696	1.0119	9.85E-02
Long (>100kb)	Gene-containing	0.9502	0.8180	1.1151	5.17E-01	0.8884	0.8156	0.9671	6.43E-03
	Exon-containing	0.9431	0.8118	1.1070	4.58E-01	0.8876	0.8146	0.9666	6.29E-03
	Intronic	Inf	NA	NA	NA	0.9660	0.3394	2.8165	9.48E-01
	Intergenic	0.8162	0.6137	1.1100	1.77E-01	1.2185	1.0047	1.4819	4.59E-02
	All	1.0419	0.8939	1.2257	6.10E-01	0.9938	0.9157	1.0784	8.81E-01
	Gene-containing	1.0559	0.8753	1.2920	5.83E-01	0.9648	0.8756	1.0625	4.67E-01
Short (<100kb)	Exon-containing	1.0521	0.8571	1.3119	6.40E-01	0.9325	0.8392	1.0350	1.91E-01
	Intronic	1.0921	0.6661	1.9180	7.42E-01	1.2533	0.9319	1.6942	1.38E-01
	Intergenic	1.0158	0.7778	1.3541	9.12E-01	1.0751	0.9183	1.2596	3.68E-01

Supplement

Tionuo	E	nhancer re	gions	Non	-enhancer	regions	
lissues	AFF	UNAFF	LR p-value	AFF	UNAFF	LR p-value	
K562 Leukemia Cells	0.0701	0.0607	0.0146	0.4362	0.4224	0.0502	
All tissues combined	0.4254	0.4093	0.0240	0.0808	0.0738	0.1015	
Foreskin Keratinocyte Primary Cells skin03	0.1519	0.1401	0.0262	0.3543	0.3430	0.0751	
Primary B cells from peripheral blood	0.0514	0.0444	0.0398	0.4548	0.4387	0.0295	
hESC Derived CD56+ Mesoderm Cultured Cells	0.1166	0.1065	0.0477	0.3896	0.3765	0.0455	
Adipose Derived Mesenchymal Stem Cell Cultured Cells	0.1427	0.1328	0.0496	0.3635	0.3503	0.0514	
CUR							

38

Zhang et al.

Supplement

Table S24. Regional tests on known regions associated with psychiatric disorders.

Regions (hg19)	Chr	Start	End	# Deletions in cases	# Deletions in controls	EMP1 of deletions	# Duplications in cases	# Duplications in controls	EMP1 of duplication
1q21.1	1	145,934,643	147,709,376	2	2	0.638	2	5	1.000
NRXN1	2	50,147,488	51,259,674	25	17	0.077	2	2	0.637
3q29	3	195,745,603	197,355,603	2	3	1.000	7	12	1.000
7q11.21	7	64,838,768	64,865,998	0	0	1.000	0	0	1.000
7q11.23	7	72,742,064	74,142,064	1	1	0.669		2	1.000
7p36.3	7	158,453,198	158,972,237	1	0	0.562	4	5	1.000
8q22.2	8	100,025,494	100,889,808	0	2	1.000	2	0	0.147
9p24.3	9	841,690	969,090	1	2	1.000	2	0	0.107
13q12.11	13	20,411,593	20,437,773	0	0	1.000	0	1	1.000
15q11.2	15	22,798,636	23,088,559	13	15	1.000	15	9	0.090
AS/PWS	15	24,820,000	28,430,000	9	6	0.149	3	1	0.243
15q13.3	15	31,132,708	32,482,708	3	6	1.000	38	34	0.270
16p13.11	16	15,510,000	16,300,000	11	19	1.000	14	18	1.000
16p11.2 distal	16	28,822,499	29,052,499	0	2	1.000	1	3	1.000
16p11.2 proximal	16	29,652,499	30,202,499	3	4	1.000	6	3	0.305
17p12	17	14,160,000	15,430,000	4	1	0.255	1	1	0.772
17q12	17	34,810,000	36,200,000	1	0	0.475	1	1	0.600
22q11.2	22	19,020,000	21,420,000	15	16	0.487	17	17	0.517

AS/PWS, Angelman/Prader–Willi syndrome

K CER

Zhang et al.

Table S25. Regional tests on known regions associated with developmental delay.

Regions (hg19)	# Deletions in cases	# Deletions in contro	Is EMP1 of deletions #	Duplications in cases	# Duplications in controls	EMP1 of duplication
chr1:710,137-9,977,413	34	38	0.566	62	93	1.000
chr1:860,137-3,660,140	9	19	1.000	42	67	1.000
chr1:145,338,643-147,883,376	7	8	0.641	28	25	0.326
chr1:171,733,377-172,333,377	0	0	1.000	0	0	1.000
chr1:242,433,377-246,733,377	9	8	0.415	9	14	1.000
chr1:245,033,377-248,833,377	17	24	1.000	19	29	1.000
chr2:110,000-1,720,993	7	11	1.000	5	19	1.000
chr2:3,270,993-3,470,993	0	0	1.000	0	0	1.000
chr2:45,346,496-46,046,496	2	2	0.694	6	2	0.148
chr2:111,333,937-113,133,529	1	5	1.000	3	4	1.000
chr2:111,333,937-113,233,529	1	5	1.000	3	4	1.000
chr2:165,691,754-166,391,754	0	2	1.000	0	1	1.000
chr2:235,735,261-243,102,476	11	4	0.032	49	40	0.120
chr3:125,000-925,000	8	8	0.389	7	8	0.569
chr3:825,000-1,425,000	6	3	0.165	10	7	0.405
chr3:2,125,000-9,825,000	129	106	0.005	17	14	0.368
chr3:195,715,603-197,415,603	2	3	1.000	7	12	1.000
chr4:110,000-7,049,099	50	35	0.031	42	51	1.000
chr4:360,000-3,913,620	10	9	0.327	37	45	1.000
chr4:9,840,902-10,841,902	5	7	1.000	0	7	1.000
chr4:81,730,976-83,130,976	0	0	1.000	0	4	1.000
chr4:184,013,006-184,513,006	0	0	1.000	0	1	1.000
chr4:187,263,006-187,963,006	0	3	1.000	2	1	0.452
chr5:47,000-1,447,000	6	8	1.000	44	40	0.192
chr5:3,697,000-4,397,000	0	0	1.000	3	1	0.216
chr5:175,517,394-177,517,394	25	18	0.093	3	5	1.000
chr5:180,117,394-180,817,394	1	1	0.818	27	26	0.389
chr6:155,000-5,855,001	24	34	1.000	18	33	1.000
chr6:20,742,021-21,142,021	2	0	0.150	1	0	0.584
chr6:165,330,010-170,908,075	9	6	0.213	11	23	1.000
chr7:10,239-3,833,474	27	36	1.000	23	27	1.000
chr7:5,733,474-6,233,475	2	1	0.276	6	2	0.179
chr7:72,662,064-74,262,064	1	1	0.670	1	2	1.000
chr8:160,000-11,912,591	180	191	0.196	84	104	1.000
chr8:360,000-1,062,593	3	5	1.000	5	3	0.207
chr8:2,362,593-4,362,592	39	30	0.050	5	6	1.000
chr8:8,212,590-11,912,591	17	36	1.000	10	12	1.000
chr8:53,287,447-53,887,447	0	0	1.000	6	19	1.000
chr8:143,252,093-145,979,195	26	15	0.055	34	60	1.000
chr9:160,000-1,660,000	32	41	1.000	46	54	1.000
chr9:160,000-6,760,000	74	83	0.452	66	77	1.000
chr9:131,060,179-141,080,179	13	13	0.503	47	60	1.000

Zhang	et	al.
-------	----	-----

Supplement

Regions (hg19)	# Deletions in cases	s # Deletions in controls	EMP1 of deletions	# Duplications in cases	# Duplications in controls	EMP1 of duplication
chr10:2,610,000-3,210,000	0	3	1.000	2	5	1.000
chr10:81,610,020-88,910,020	16	21	1.000	31	24	0.072
chr10:127,760,010-135,400,010	7	11	1.000	20	28	1.000
chr11:310,000-3,443,424	7	7	0.509	9	14	1.000
chr11:128,044,790-134,844,790	14	21	1.000	72	77	0.313
chr12:229,739-3,629,739	15	13	0.330	20	24	1.000
chr12:279,739-779,739	5	4	0.441	3	2	0.585
chr12:8,158,733-8,358,733	0	1	1.000	0	0	1.000
chr13:19,402,000-20,302,000	0	1	1.000	6	6	0.504
chr14:36,430,249-37,230,249	0	0	1.000	3	0	0.122
chr14:104,480,247-106,378,955	15	3	0.004	44	20	0.002
chr15:22,648,636-28,626,405	49	50	0.145	46	38	0.082
chr15:22,648,636-31,912,708	59	63	0.200	61	53	0.112
chr15:30,862,708-32,962,708	10	10	0.489	38	35	0.316
chr15:85,098,996-85,798,996	9	3	0.063	4	2	0.294
chr15:100,382,477-102,382,477	12	16	1.000	55	54	0.355
chr15:101,032,477-101,732,477	5	1	0.093	3	1	0.299
chr16:160,000-5,209,999	15	24	1.000	41	34	0.093
chr16:709,999-2,509,999	6	0	0.009	13	10	0.208
chr16:3,709,999-5,209,999	7	20	1.000	1	2	1.000
chr16:14,892,499-16,912,499	24	32	1.000	35	42	1.000
chr16:14,892,499-18,292,499	24	32	1.000	37	44	1.000
chr16:21,892,499-22,492,499	5	4	0.458	2	6	1.000
chr16:28,442,499-30,342,499	5	6	1.000	9	8	0.511
chr16:83,792,499-90,222,499	35	30	0.218	18	24	1.000
chr16:87,742,499-90,172,499	8	11	1.000	14	11	0.240
chr17:100,000-4,153,251	16	27	1.000	21	29	1.000
chr17:703,250-1,603,250	4	3	0.527	17	14	0.275
chr17:16,659,275-25,475,873	40	24	0.008	23	40	1.000
chr17:16,709,275-20,309,408	24	- 11	0.010	6	8	1.000
chr17:29,025,874-29,825,880	0	4	1.000	4	0	0.087
chr17:34,725,887-36,295,000	1	0	0.473	2	2	0.581
chr17:34,775,887-36,275,614	1	0	0.473	2	2	0.581
chr17:43,644,217-44,144,178	0	0	1.000	3	2	0.497
chr17:72,088,405-81,060,000	7	10	1.000	46	53	1.000
chr18:110,000-5,310,000	61	57	0.137	10	17	1.000
chr18:6,760,000-7,360,000	0 🗸	1	1.000	2	2	0.638
chr18:70,949,020-77,899,009	9	16	1.000	27	15	0.025
chr19:199,000-5,899,000	5	9	1.000	41	34	0.060
chr19:199,000-8,789,000	19	27	1.000	75	82	0.344
chr19:54,858,188-59,058,188	10	18	1.000	20	38	1.000
chr20:152,000-1,162,000	2	1	0.507	6	7	1.000
chr21:21,028,129-21,328,129	20	14	0.060	1	0	0.563
chr21:42,478,130-47,975,572	7	11	1.000	20	24	1.000

Zhang et al.

Supplement



Figure S1. Statistical power to detect single CNV loci associated with MDD. Different colors represent different power intervals over the genotypic relative risk (y axis) and the risk allele frequency in the population (x axis). Calculations were based on 5780 cases, 6626 controls, a dominant model, lifetime risk of MDD of 10% and at three levels of α (0.05, 7.06E-04, 3.53E-05).

Average number of short deletions per subject



Figure S2. Average number of short deletions of various sizes per subject.



Figure S3. Odds ratios and 95% confidence intervals of short deletions of various sizes. The size of the square is proportional to precision.



Zhang et al.

Figure S4. The forest plot of odds ratio (OR) estimates and 95% confidence intervals for each burden test by cohort.
Figure S5. Plots of 15q11.2 dups, 6q21 dups, 8p22 dels, and 6q26 dels

Shown below are plots of CNVs in the four independent regions listed in Table 3, for both case and control carriers. All CNVs in the dataset are shown for 15q11.2 duplications, 6q21 duplications. For the more frequent CNVs, 15 CNVs were randomly selected from among the 92 8p22 deletions and 15 from among the 105 6q26 deletions. Plots of all CNVs in these regions, and for randomly selected negative controls, are available on request.

In each plot, the copy number and the position of the CNV boundaries are shown in the top, as called by Birdsuite for Affymetrix data or QuantiSNP for Illumina data. The physical positions of CNVs in the *GenRED-II* cohort are based on hg19 while the positions for all the other cohorts are based on hg18 (although for statistical analyses in this paper, all hg18 coordinates were lifted over to hg19).

X-axis values are bp locations. Y-axis values are Log R Ratio [LRR] (upper panels) and B Allele Frequency [BAF] (lower panels). Blue vertical lines represent the CNV boundaries reported by Birdsuite for Affymetrix data or QuantiSNP for Illumina data. The red dots are the point-by-point copy number estimates made by an alternative algorithm (Lai et al., 2008).

Lai TL, Xing H, Zhang N (2008): Stochastic segmentation models for array-based comparative genomic hybridization data analysis. Biostatistics. 9:290-307.

(A) All the duplications in chromosome 15q11.2

























Codes for the analysis pipeline: PLINK command and R scripts used in the analyses

```
# Exonic deletions
plink --noweb \
--cfile Filter_Rare_CNV \
--cnv-del \
--cnv-kb 100 \
--cnv-indiv-perm \
--mperm 100000 --within Sex_Batch_cluster.txt \
--cnv-count hg19_Exons.txt \
--out Del_100kb_exon_count
```

```
plink --noweb \

--cfile Filter_Rare_CNV \

--cnv-del \

--cnv-kb 100 \

--cnv-freq-exclude-above 1 \

--cnv-indiv-perm \

--mperm 100000 --within Sex_Batch_cluster.txt \

--cnv-count hg19_Exons.txt \

--out Del_100kb_singleton_exon_count
```

```
plink --noweb \

--cfile Filter_Rare_CNV \

--cnv-del \

--cnv-kb 500 \

--cnv-indiv-perm \

--mperm 100000 --within Sex_Batch_cluster.txt \

--cnv-count hg19_Exons.txt \

--out Del_500kb_exon_count
```

```
plink --noweb \

--cfile Filter_Rare_CNV \

--cnv-del \

--cnv-kb 1000 \

--cnv-indiv-perm \

--mperm 100000 --within Sex_Batch_cluster.txt \

--cnv-count hg19_Exons.txt \

--out Del_1000kb_exon_count
```

```
plink --noweb \

--cfile Filter_Rare_CNV \

--cnv-del \

--cnv-kb 9 \

--cnv-max-kb 100 \

--cnv-indiv-perm \

--mperm 100000 --within Sex_Batch_cluster.txt \
```

--cnv-count hg19_Exons.txt \ --out Del_small_exon_count

plink --noweb \ --cfile Filter_Rare_CNV \ --cnv-del \ --cnv-kb 9 \ --cnv-max-kb 100 \ --cnv-freq-exclude-above 1 \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --cnv-count hg19_Exons.txt \ --out Del_small_singleton_exon_count

plink --noweb \ --cfile Filter_Rare_CNV \ --cnv-del \ --cnv-kb 100 \ --cnv-intersect hg19_Exons.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Del_100_exon_intersect

```
plink --noweb \

--cfile Filter_Rare_CNV \

--cnv-del \

--cnv-kb 100 \

--cnv-freq-exclude-above 1 \

--cnv-intersect hg19_Exons.txt \

--cnv-indiv-perm \

--mperm 100000 --within Sex_Batch_cluster.txt \

--out Del_100_singleton_exon_intersect
```

plink --noweb \ --cfile Filter_Rare_CNV \ --cnv-del \ --cnv-kb 500 \ --cnv-intersect hg19_Exons.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Del_500_exon_intersect

plink --noweb \ --cfile Filter_Rare_CNV \ --cnv-del \ --cnv-kb 1000 \ --cnv-intersect hg19_Exons.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Del_1000_exon_intersect

plink --noweb \setminus

```
Zhang et al.
```

ACCEPTED MANUSCRIPT

Supplement

```
--cfile Filter_Rare_CNV \setminus
--cnv-del \
--cnv-kb 9
--cnv-max-kb 100 \
--cnv-intersect hg19_Exons.txt \setminus
--cnv-indiv-perm \
--mperm 100000 --within Sex_Batch_cluster.txt \
--out Del small exon intersect
plink --noweb \setminus
--cfile Filter_Rare_CNV \setminus
--cnv-del \
--cnv-kb 9
--cnv-max-kb 100 \
--cnv-freq-exclude-above 1 \setminus
--cnv-intersect hg19_Exons.txt \setminus
--cnv-indiv-perm \
--mperm 100000 --within Sex_Batch_cluster.txt \
--out Del_small_singleton_exon_intersect
# Genic deletions
plink --noweb \setminus
--cfile Filter Rare CNV \setminus
--cnv-del \
--cnv-kb 100 \
--cnv-indiv-perm \
--mperm 100000 --within Sex_Batch_cluster.txt \
--cnv-count hg19_RefGenes.txt \
--out Del 100kb gene count
plink --noweb \setminus
--cfile Filter_Rare_CNV \setminus
--cnv-del \
--cnv-kb 100 \
--cnv-freq-exclude-above 1 \setminus
--cnv-indiv-perm \
--mperm 100000 --within Sex Batch cluster.txt \
--cnv-count hg19_RefGenes.txt \
--out Del_100kb_singleton_gene_count
plink --noweb \setminus
--cfile Filter_Rare_CNV
--cnv-del \
--cnv-kb 500 \
--cnv-indiv-perm \
--mperm 100000 --within Sex_Batch_cluster.txt \
--cnv-count hg19_RefGenes.txt \
--out Del_500kb_gene_count
plink --noweb \setminus
--cfile Filter Rare CNV \
```

--cnv-del \setminus

ACCEPTED MANUSCRIPT

Zhang et al.

Supplement

--cnv-kb 1000 \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --cnv-count hg19_RefGenes.txt \ --out Del_1000kb_gene_count

plink --noweb \ --cfile Filter_Rare_CNV \ --cnv-del \ --cnv-kb 9 \ --cnv-max-kb 100 \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --cnv-count hg19_RefGenes.txt \ --out Del_small_gene_count

```
plink --noweb \

--cfile Filter_Rare_CNV \

--cnv-del \

--cnv-kb 9 \

--cnv-max-kb 100 \

--cnv-freq-exclude-above 1 \

--cnv-indiv-perm \

--mperm 100000 --within Sex_Batch_cluster.txt \

--cnv-count hg19_RefGenes.txt \

--out Del_small_singleton_gene_count
```

```
plink --noweb \

--cfile Filter_Rare_CNV \

--cnv-del \

--cnv-kb 100 \

--cnv-intersect hg19_RefGenes.txt \

--cnv-indiv-perm \

--mperm 100000 --within Sex_Batch_cluster.txt \

--out Del_100_gene_intersect
```

```
plink --noweb \

--cfile Filter_Rare_CNV \

--cnv-del \

--cnv-kb 100 \

--cnv-freq-exclude-above 1 \

--cnv-intersect hg19_RefGenes.txt \

--cnv-indiv-perm \

--mperm 100000 --within Sex_Batch_cluster.txt \

--out Del_100_singleton_gene_intersect
```

```
plink --noweb \
--cfile Filter_Rare_CNV \
--cnv-del \
--cnv-kb 500 \
--cnv-intersect hg19_RefGenes.txt \
--cnv-indiv-perm \
```

Supplement

--mperm 100000 --within Sex_Batch_cluster.txt \ --out Del_500_gene_intersect plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-del \ --cnv-kb 1000 \ --cnv-intersect hg19_RefGenes.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Del_1000_gene_intersect plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-del \setminus --cnv-kb 9--cnv-max-kb 100 \ --cnv-intersect hg19_RefGenes.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Del small gene intersect plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-del \ --cnv-kb 9--cnv-max-kb 100 \ --cnv-freq-exclude-above $1 \setminus$ --cnv-intersect hg19 RefGenes.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex Batch cluster.txt --out Del_small_singleton_gene_intersect # Exonic duplications plink --noweb \ --cfile Filter_Rare_CNV \ --cnv-dup \setminus --cnv-kb 100 \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --cnv-count hg19 Exons.txt \ --out Dup_100kb_exon_count plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-dup \setminus --cnv-kb 100 \ --cnv-freq-exclude-above $1 \setminus$ --cnv-indiv-perm \

--mperm 100000 --within Sex_Batch_cluster.txt \

--cnv-count hg19 Exons.txt \setminus

--out Dup_100kb_singleton_exon_count

Supplement

plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-dup \setminus --cnv-kb 500 \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --cnv-count hg19 Exons.txt \setminus --out Dup_500kb_exon_count plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-dup \setminus --cnv-kb 1000 \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --cnv-count hg19_Exons.txt \setminus --out Dup_1000kb_exon_count plink --noweb \setminus --cfile Filter Rare CNV \ --cnv-dup \setminus --cnv-kb $9 \$ --cnv-max-kb 100 \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --cnv-count hg19_Exons.txt \setminus --out Dup_small_exon_count plink --noweb \setminus --cfile Filter Rare $CNV \setminus$ --cnv-dup \setminus --cnv-kb $9 \$ --cnv-max-kb 100 \ --cnv-freq-exclude-above $1 \setminus$ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --cnv-count hg19_Exons.txt \ --out Dup_small_singleton_exon_count plink --noweb \setminus --cfile Filter_Rare_CNV --cnv-dup \setminus --cnv-kb 100 \ --cnv-intersect hg19_Exons.txt \setminus --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_100_exon_intersect plink --noweb \setminus --cfile Filter Rare CNV \

```
--cnv-dup \
```

--cnv-kb 100 \ --cnv-freq-exclude-above 1 \ --cnv-intersect hg19_Exons.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_100_singleton_exon_intersect

plink --noweb \ --cfile Filter_Rare_CNV \ --cnv-dup \ --cnv-kb 500 \ --cnv-intersect hg19_Exons.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_500_exon_intersect

```
plink --noweb \

--cfile Filter_Rare_CNV \

--cnv-dup \

--cnv-kb 1000 \

--cnv-intersect hg19_Exons.txt \

--cnv-indiv-perm \

--mperm 100000 --within Sex_Batch_cluster.txt \

--out Dup_1000_exon_intersect
```

plink --noweb \ --cfile Filter_Rare_CNV \ --cnv-dup \ --cnv-kb 9 \ --cnv-max-kb 100 \ --cnv-intersect hg19_Exons.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_small_exon_intersect

```
plink --noweb \

--cfile Filter_Rare_CNV \

--cnv-dup \

--cnv-kb 9 \

--cnv-max-kb 100 \

--cnv-freq-exclude-above 1 \

--cnv-intersect hg19_Exons.txt \

--cnv-indiv-perm \

--mperm 100000 --within Sex_Batch_cluster.txt \

--out Dup_small_singleton_exon_intersect
```

Genic duplications
plink --noweb \
--cfile Filter_Rare_CNV \
--cnv-dup \
--cnv-kb 100 \
--cnv-indiv-perm \

Supplement

--mperm 100000 --within Sex_Batch_cluster.txt \ --cnv-count hg19_RefGenes.txt \ --out Dup_100kb_gene_count plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-dup \setminus --cnv-kb 100 \ --cnv-freq-exclude-above $1 \setminus$ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --cnv-count hg19_RefGenes.txt \ --out Dup_100kb_singleton_gene_count plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-dup \setminus --cnv-kb 500 \ --cnv-indiv-perm \setminus --mperm 100000 --within Sex_Batch_cluster.txt \ --cnv-count hg19 RefGenes.txt \ --out Dup_500kb_gene_count plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-dup \setminus --cnv-kb 1000 \ --cnv-indiv-perm \ --mperm 100000 --within Sex Batch cluster.txt --cnv-count hg19_RefGenes.txt \ --out Dup 1000kb gene count plink --noweb \setminus --cfile Filter_Rare_CNV \setminus $--cnv-dup \setminus$ --cnv-kb 9--cnv-max-kb 100 \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --cnv-count hg19_RefGenes.txt \ --out Dup small gene count plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-dup \setminus --cnv-kb 9--cnv-max-kb 100 \ --cnv-freq-exclude-above $1 \setminus$ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --cnv-count hg19 RefGenes.txt \

--out Dup_small_singleton_gene_count

Supplement

plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-dup \setminus --cnv-kb 100 \ --cnv-intersect hg19 RefGenes.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_100_gene_intersect plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-dup \setminus --cnv-kb 100 \ --cnv-freq-exclude-above $1 \setminus$ --cnv-intersect hg19_RefGenes.txt \setminus --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_100_singleton_gene_intersect plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-dup \setminus --cnv-kb 500 \ --cnv-intersect hg19_RefGenes.txt \setminus --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_500_gene_intersect plink --noweb \setminus --cfile Filter Rare $CNV \setminus$ --cnv-dup \setminus --cnv-kb 1000 \ --cnv-intersect hg19_RefGenes.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_1000_gene_intersect plink --noweb \setminus --cfile Filter_Rare_CNV --cnv-dup \setminus --cnv-kb 9--cnv-max-kb 100 \ --cnv-intersect hg19_RefGenes.txt \setminus --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_small_gene_intersect plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-dup \setminus --cnv-kb 9

--cnv-max-kb 100 \ --cnv-freq-exclude-above 1 \ --cnv-intersect hg19_RefGenes.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_small_singleton_gene_intersect

Intergenic duplications
plink --noweb \
--cfile Filter_Rare_CNV \
--cnv-dup \
--cnv-kb 100 \
--cnv-exclude hg19_RefGenes.txt \
--cnv-indiv-perm \
--mperm 100000 --within Sex_Batch_cluster.txt \
--out Dup_100_intergenic

plink --noweb \ --cfile Filter_Rare_CNV \ --cnv-dup \ --cnv-kb 100 \ --cnv-freq-exclude-above 1 \ --cnv-exclude hg19_RefGenes.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_100_singleton_intergenic

```
plink --noweb \

--cfile Filter_Rare_CNV \

--cnv-dup \

--cnv-kb 500 \

--cnv-exclude hg19_RefGenes.txt \

--cnv-indiv-perm \

--mperm 100000 --within Sex_Batch_cluster.txt \

--out Dup_500_intergenic
```

plink --noweb \ --cfile Filter_Rare_CNV \ --cnv-dup \ --cnv-kb 1000 \ --cnv-exclude hg19_RefGenes.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_1000_intergenic

```
plink --noweb \
--cfile Filter_Rare_CNV \
--cnv-dup \
--cnv-kb 9 \
--cnv-max-kb 100 \
--cnv-exclude hg19_RefGenes.txt \
--cnv-indiv-perm \
```

--mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_small_intergenic

plink --noweb \
--cfile Filter_Rare_CNV \
--cnv-dup \
--cnv-kb 9 \
--cnv-max-kb 100 \
--cnv-freq-exclude-above 1 \
--cnv-exclude hg19_RefGenes.txt \
--cnv-indiv-perm \
--mperm 100000 --within Sex_Batch_cluster.txt \
--out Dup small singleton intergenic

Intergenic deletions
plink --noweb \
--cfile Filter_Rare_CNV \
--cnv-del \
--cnv-kb 100 \
--cnv-exclude hg19_RefGenes.txt \
--cnv-indiv-perm \
--mperm 100000 --within Sex_Batch_cluster.txt \
--out Del_100_intergenic

plink --noweb \ --cfile Filter_Rare_CNV \ --cnv-del \ --cnv-kb 100 \ --cnv-freq-exclude-above 1 \ --cnv-exclude hg19_RefGenes.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Del_100_singleton_intergenic

plink --noweb \ --cfile Filter_Rare_CNV \ --cnv-del \ --cnv-kb 500 \ --cnv-exclude hg19_RefGenes.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Del_500_intergenic

plink --noweb \ --cfile Filter_Rare_CNV \ --cnv-del \ --cnv-kb 1000 \ --cnv-exclude hg19_RefGenes.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Del_1000_intergenic

ACCEPTED MANUSCRIPT

Supplement

Zhang et al. plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-del \ --cnv-kb 9--cnv-max-kb 100 \ --cnv-exclude hg19_RefGenes.txt \setminus --cnv-indiv-perm \ --mperm 100000 --within Sex Batch cluster.txt \ --out Del_small_intergenic plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-del \ --cnv-kb $9 \$ --cnv-max-kb 100 \ --cnv-freq-exclude-above $1 \setminus$ --cnv-exclude hg19_RefGenes.txt \setminus --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Del_small_singleton_intergenic ######## Intronic deletions #### For large deletions plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-del \ --cnv-kb 100 \ --cnv-intersect hg19_RefGenes.txt \ --cnv-write \setminus --out Del_100_genic ## Make map file plink --noweb \ --cnv-list Del_100_genic.cnv --cnv-make-map --out Del_100_genic plink --noweb \setminus --cfile Del 100 genic \setminus --cnv-exclude hg19_Exons.txt \setminus --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Del 100 intronic plink --noweb \setminus --cfile Del_100_genic \setminus --cnv-del \ --cnv-kb 100 \ --cnv-freq-exclude-above $1 \setminus$ --cnv-exclude hg19_Exons.txt \setminus --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Del 100 singleton intronic

ACCEPTED MANUSCRIPT

Supplement

plink --noweb \ --cfile Del_100_genic \ --cnv-del \ --cnv-kb 500 \ --cnv-exclude hg19_Exons.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Del_500_intronic

plink --noweb \ --cfile Del_100_genic \ --cnv-del \ --cnv-kb 1000 \ --cnv-exclude hg19_Exons.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Del_1000_intronic

For small deletions
plink --noweb \
--cfile Filter_Rare_CNV \
--cnv-del \
--cnv-kb 9 \
--cnv-max-kb 100 \
--cnv-intersect hg19_RefGenes.txt \
--cnv-write \
--out Del_small_genic

Make map file
plink --noweb \
--cnv-list Del_small_genic.cnv --cnv-make-map --out Del_small_genic

plink --noweb \ --cfile Del_small_genic \ --cnv-exclude hg19_Exons.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Del_small_intronic

plink --noweb \ --cfile Del_small_genic \ --cnv-del \ --cnv-kb 9 \ --cnv-max-kb 100 \ --cnv-freq-exclude-above 1 \ --cnv-exclude hg19_Exons.txt \ --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Del_small_singleton_intronic

######## Intronic duplications
For large duplications

Supplement

plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-dup \setminus --cnv-kb 100 \ --cnv-intersect hg19_RefGenes.txt \setminus --cnv-write \setminus --out Dup_100_genic ## Make map file plink --noweb \ --cnv-list Dup_100_genic.cnv --cnv-make-map --out Dup_100_genic plink --noweb \setminus --cfile Dup_100_genic \ --cnv-exclude hg19_Exons.txt \setminus --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_100_intronic plink --noweb \setminus --cfile Dup 100 genic \setminus --cnv-dup \setminus --cnv-kb 100 \ --cnv-freq-exclude-above $1 \setminus$ --cnv-exclude hg19_Exons.txt \setminus --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_100_singleton_intronic plink --noweb \setminus --cfile Dup 100 genic \setminus --cnv-dup \setminus --cnv-kb 500 \ --cnv-exclude hg19_Exons.txt \setminus --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_500_intronic plink --noweb \setminus --cfile Dup_100_genic \ --cnv-dup \setminus --cnv-kb 1000 \ --cnv-exclude hg19_Exons.txt \setminus --cnv-indiv-perm \ --mperm 100000 --within Sex_Batch_cluster.txt \ --out Dup_1000_intronic #### For small duplications plink --noweb \setminus --cfile Filter_Rare_CNV \setminus --cnv-dup \setminus --cnv-kb 9

--cnv-max-kb 100 \ --cnv-intersect hg19_RefGenes.txt \ --cnv-write \ --out Dup_small_genic

Make map file
plink --noweb \
--cnv-list Dup_small_genic.cnv --cnv-make-map --out Dup_small_genic

```
plink --noweb \
--cfile Dup_small_genic \
--cnv-exclude hg19_Exons.txt \
--cnv-indiv-perm \
--mperm 100000 --within Sex_Batch_cluster.txt \
--out Dup_small_intronic
```

```
plink --noweb \

--cfile Dup_small_genic \

--cnv-dup \

--cnv-kb 9 \

--cnv-max-kb 100 \

--cnv-freq-exclude-above 1 \

--cnv-exclude hg19_Exons.txt \

--cnv-indiv-perm \

--mperm 100000 --within Sex_Batch_cluster.txt \

--out Dup_small_singleton_intronic
```

}

ACCEPTED MANUSCRIPT

print(metagen(beta_m[i,],std_m[i,],method.tau="HE"))
}

plink --noweb \ --cnv-list Gene_Exonic_CNV.cnv \ --cnv-make-map \ --out Gene_Exonic_CNV

```
plink --noweb \
--cfile Gene_Exonic_CNV \
--cnv-del \
--cnv-intersect Gene_region.txt \
--cnv-test-region \
--mperm 100000 \
--within Sex_Batch_cluster.txt \
--out All_del
```

plink --noweb \ --cfile Gene_Exonic_CNV \ --cnv-dup \ --cnv-intersect Gene_region.txt \ --cnv-test-region \ --mperm 100000 \ --within Sex_Batch_cluster.txt \ --out All_dup

 $\label{eq:conv_count} try <-c(cnv_count$V9[i], cnv_count$V8[i], 724-cnv_count$V9[i], 1240-cnv_count$V8[i], cnv_count$V11[i], cnv_count$V10[i], 1736-cnv_count$V11[i], 1347-cnv_count$V10[i], not count$V10[i], not count$V11[i], not count$V10[i], n$

ACCEPTED MANUSCRIPT

```
cnv_count$V13[i],cnv_count$V12[i],139-cnv_count$V13[i],384-cnv_count$V12[i],
cnv count$V15[i],cnv count$V14[i],672-cnv count$V15[i],478-cnv count$V14[i],
cnv count$V17[i],cnv count$V16[i],271-cnv count$V17[i],743-cnv count$V16[i],
cnv count$V19[i],cnv count$V18[i],670-cnv count$V19[i],521-cnv count$V18[i],
cnv_count$V21[i],cnv_count$V20[i],488-cnv_count$V21[i],719-cnv_count$V20[i],
cnv count$V23[i],cnv count$V22[i],1080-cnv count$V23[i],1194-cnv count$V22[i])
 \dim(try) < -c(2,2,8)
 dimnames(try) = list(Phenotype = c("Case", "Control"), cnv = c("Yes", "No"),Array =
c("RADIANT_Illumina_male","RADIANT_Illumina_female",
"GenRED_II_male", "GenRED_II_female", "GenRED_male",
"GenRED_female","NESDA_NTR_male","NESDA_NTR_female"))
 CMH output<-mantelhaen.test(try.exact=TRUE.alternative="greater")
write(paste(cnv count$V1[i],cnv count$V2[i],cnv count$V3[i],cnv count$V4[i],cnv count$V6[i],cnv count$
V7[i],cnv_count$V5[i],CMH_output[["estimate"]][["common odds
ratio"]],CMH output[["p.value"]],cnv count$V8[i],cnv count$V9[i],cnv count$V10[i],cnv count$V11[i],cnv
_count$V12[i],cnv_count$V13[i],cnv_count$V14[i],cnv_count$V15[i],cnv_count$V16[i],cnv_count$V17[i],cn
v_count$V18[i],cnv_count$V19[i],cnv_count$V20[i],cnv_count$V21[i],cnv_count$V22[i],cnv_count$V23[i],s
ep="\t"),"CMH-test.txt", append=TRUE)
 rm(try)
 rm(CMH output)
}
Permutation test on segment groups
plink --noweb \setminus
--cfile Filtered_rare_deletions \
--segment-group \
--out Del_groups
plink --noweb \
--cfile Filtered_rare_duplications
--segment-group \
--out Dup groups
plink --noweb \setminus
--cfile Del_all \
--cnv-intersect Deletion segment-group region.txt \
--cnv-test-region \setminus
--mperm 100000 \
--within Sex Batch cluster.txt \
--out Del_segment_test
plink --noweb \
--cfile Dup_all \
--cnv-intersect Duplication segment-group region.txt \
--cnv-test-region \
--mperm 100000 \
--within Sex_Batch_cluster.txt \
```

--out Dup_segment_test

R scripts for CMH test on segment groups cnv_count<-read.table("Breakdown_count.txt",header=FALSE) write(paste("Test","Chr","Start","End","Combined Control","Combined Case","EMP1","CMH Odds_ratio","CMH p.value", "RADIANT_control_male","RADIANT_case_male","RADIANT_control_female","RADIANT_case_female", "GenRED II control male", "GenRED II case male", "GenRED II control female", "GenRED II case femal e", "GenRED_control_male", "GenRED_case_male", "GenRED_control_female", "GenRED_case_female", "NES DA_NTR_control_male","NESDA_NTR_case_male","NESDA_NTR_control_female","NESDA_NTR_case_f emale", sep="\t"), "CMH-test.txt", append=TRUE) for(i in 1:length(cnv_count\$V1)){ try<-c(cnv count\$V9[i],cnv count\$V8[i],724-cnv count\$V9[i],1240-cnv count\$V8[i], cnv_count\$V11[i],cnv_count\$V10[i],1736-cnv_count\$V11[i],1347-cnv_count\$V10[i], cnv count\$V13[i],cnv count\$V12[i],139-cnv count\$V13[i],384-cnv count\$V12[i], cnv_count\$V15[i],cnv_count\$V14[i],672-cnv_count\$V15[i],478-cnv_count\$V14[i], cnv_count\$V17[i],cnv_count\$V16[i],271-cnv_count\$V17[i],743-cnv_count\$V16[i], cnv_count\$V19[i],cnv_count\$V18[i],670-cnv_count\$V19[i],521-cnv_count\$V18[i], cnv_count\$V21[i],cnv_count\$V20[i],488-cnv_count\$V21[i],719-cnv_count\$V20[i], cnv count\$V23[i],cnv count\$V22[i],1080-cnv count\$V23[i],1194-cnv count\$V22[i]) $\dim(try) < -c(2,2,8)$ dimnames(try) = list(Phenotype = c("Case", "Control"), cnv = c("Yes", "No"),Array = c("RADIANT_Illumina_male","RADIANT_Illumina_female", "GenRED_II_male", "GenRED_II_female", "GenRED_male", "GenRED_female","NESDA_NTR_Affy_male","NESDA_NTR_Affy_female")) CHM_output<-mantelhaen.test(try,exact=TRUE,alternative="greater") write(paste(cnv count\$V1[i],cnv count\$V2[i],cnv count\$V3[i],cnv count\$V4[i],cnv count\$V6[i],cnv count\$ V7[i],cnv_count\$V5[i],CHM_output[["estimate"]][["common odds

ratio"]],CHM_output[["p.value"]],cnv_count\$V8[i],cnv_count\$V9[i],cnv_count\$V10[i],cnv_count\$V11[i],cnv_count\$V12[i],cnv_count\$V13[i],cnv_count\$V14[i],cnv_count\$V15[i],cnv_count\$V16[i],cnv_count\$V16[i],cnv_count\$V17[i],cnv_count\$V18[i],cnv_count\$V19[i],cnv_count\$V20[i],cnv_count\$V21[i],cnv_count\$V22[i],cnv_count\$V23[i],s ep="\t"),"CMH-test.txt", append=TRUE)

```
rm(try)
```

rm(CHM_output)

}